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Abstract: Identifizierung von synthetisch-letalen genetischen Interaktionen mit REV3 in Lungenkreb-
szellen Polymerase ￿ (Zeta) ist die einzige bekannte Transläsionspolymerase, deren Knockout embry-
onale Letalität bei Mäusen bewirkt. Diese Tatsache legt nahe, dass sie, abgesehen von ihrer Funk-
tion in der postreplikativen DNA Reparatur, eine besondere, noch unbekannte Rolle in der Entwick-
lung von Säugetieren spielt. Es ist bekannt, dass die Hemmung von REV3, der katalytischen Untere-
inheit der Transläsionspolymerase ￿, die Resistenzbildung gegen Cisplatin reduziert und die Empfind-
lichkeit der menschlichen Zellen dagegen erhöht. Neueste Erkenntnisse aus unserem Labor zeigten, dass
die Hemmung von REV3 per se das Zellwachstum von Mesotheliom-, Lungenkrebs- und Brustkreb-
szellen reduziert, während normalen Zellen weniger betroffen sind. Das Ziel meiner Doktorarbeit war
es, Gene zu identifizieren, deren Hemmung das Wachstum von REV3 -defizitären Krebszellen nicht nur
reduzieren sondern vollständig stoppen kann, d.h. synthetisch-letale Interaktionen mit REV3 in men-
schlichen Lungenkrebszellen zu identifizieren. Dieses wurde getan, um krebsspezifische Änderungen zu
erkennen, die für die beobachtete differenzielle Wirkung von REV3 per se verantwortlich sein könnten.
Darüber hinaus könnte die Entdeckung solcher Gene die Grundlage für eine neue Kombinationstherapie
bieten. Schliesslich erwarteten wir von den Ergebnissen auch neue Einblicke in die zelluläre Funktion von
REV3. Mit einer Gesamtgenom-siRNA-Bibliothek haben wir wiederholt globale Screens durchgeführt,
um Ziele zu identifizieren, deren Hemmung vorzugsweise die Lebensfähigkeit von REV3-defizitären A549-
Lungenkrebszellen reduziert. Einer der Top-Hits, welcher in unabhängigen Experimenten bestätigt wurde,
war RRM1, die grosse Untereinheit der Ribonucleotidreduktase (RNR), eines kritischen Enzyms des de
novo-Nukleotidsynthesewegs. Die Behandlung mit dem RNR-Inhibitor Hydroxurea (HU) erhöhte syner-
gistisch den Anteil der REV3-defizitären Zellen, welche Einzelstrang-DNA (ssDNA) enthalten, was mit
Hilfe der Durchflusszytometrie als erhöhte Immunfluoreszenzfärbung von Replikationsprotein A (RPA)
erkennbar war. Dieser Anstieg war jedoch nicht von einer Akkumulation des DNA-Schadenmarkers
￿H2AX begleitet, was darauf hindeutet, dass REV3 nicht nur eine Funktion in der DNA Reparatur
sondern auch in der Toleranz gegen Replikationsstress (RS) hat. Weiter beschränkte sich die erhöhte
RPA-Färbung auf Zellen in der S-Phase des Zellzyklus was im Einklang mit einer Rolle von REV3
während der DNA Replikation ist. Zusätzlich haben wir festgestellt, dass Gene, welche mit RS assozi-
iert sind, unter den Top-Hits des Screens signifikant angereichert waren, was die Bedeutung von REV3
für die Replikation unter RS Bedingungen weiter bekräftigt. Zusammengefasst implizieren diese Daten
eine neue Funktion von REV3 in der Toleranz von RS, welche sowohl die krebsspezifische Wirkung der
REV3-Hemmung auf molekularer Ebene erklären als auch die Unentbehrlichkeit von REV3 während der
embryonalen Entwicklung in Säugetieren begründen würde. Identification of Synthetic Lethal Gene In-
teractions with REV3 in Lung Cancer Cells Polymerase ￿ (zeta) is the only known translesion synthesis
polymerase, of which the knockout causes embryonic lethality in mice. This fact suggests that apart from
its function in post-replication repair it plays a special, yet to be identified, role in mammalian develop-
ment. It is known that inhibition of REV3, the catalytic subunit of the translesion polymerase ￿, reduces
the formation of resistance and increases the sensitivity of human cells to cisplatin. Surprisingly, recent
findings of our laboratory revealed that inhibition of REV3 per se reduces cell growth of mesothelioma,
lung- and breast cancer cells whereas normal cells are less affected. The purpose of my PhD thesis was to
identify genes whose inhibition will not only reduce but completely abolish cancer cell growth in a REV3-
deficient background, i.e. to investigate synthetic lethal interactions with REV3 in human lung cancer
cells. This was done to identify cancer-specific alterations that might be responsible for the observed
differential REV3 per se effect. Additionally, the discovery of such genes could provide a rationale for
a new combinational therapy. Finally, these results could also give us insights into the cellular function
of REV3. Using a whole-genome siRNA library we performed sets of global screens to identify targets
whose inhibition preferentially affects viability of REV3-deficient A549 cells. The top confirmed hit was
RRM1, the large subunit of ribonucleotide reductase (RNR), a critical enzyme of de novo nucleotide
synthesis. Treatment with the RNR-inhibitor hydroxyurea (HU) synergistically increased the fraction
of REV3- deficient cells containing single stranded DNA (ssDNA) as indicated by increased staining of
replication protein A (RPA). However, this increase was not accompanied by accumulation of the DNA
damage marker ￿H2AX suggesting a role of REV3 in tolerance of replication stress (RS). Consistent with
a role of REV3 in DNA replication, increased RPA staining was confined to S-phase cells. Additionally,
we found genes related to RS to be significantly enriched among the top hits of the synthetic lethality
screen further corroborating the importance of REV3 for replication under conditions of RS. These data
outline a novel function of mammalian REV3 that could serve as a molecular basis of the observed REV3
cancer-specific per se effect as well as its indispensability during embryonic development.
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1. Summary 
Polymerase ζ (zeta) is the only known translesion synthesis polymerase, of which the 
knockout causes embryonic lethality in mice. This fact suggests that apart from its 
function in post-replication repair it plays a special, yet to be identified, role in 
mammalian development. 
It is known that inhibition of REV3, the catalytic subunit of the translesion polymerase ζ, 
reduces the formation of resistance and increases the sensitivity of human cells to 
cisplatin. Surprisingly, recent findings of our laboratory revealed that inhibition of REV3 
per se reduces cell growth of mesothelioma, lung- and breast cancer cells whereas 
normal cells are less affected. 
The purpose of my PhD thesis was to identify genes whose inhibition will not only 
reduce but completely abolish cancer cell growth in a REV3-deficient background, i.e. to 
investigate synthetic lethal interactions with REV3 in human lung cancer cells. This was 
done to identify cancer-specific alterations that might be responsible for the observed 
differential REV3 per se effect. Additionally, the discovery of such genes could provide a 
rationale for a new combinational therapy. Finally, these results could also give us 
insights into the cellular function of REV3. 
Using a whole-genome siRNA library we performed sets of global screens to identify 
targets whose inhibition preferentially affects viability of REV3-deficient A549 cells. The 
top confirmed hit was RRM1, the large subunit of ribonucleotide reductase (RNR), a 
critical enzyme of de novo nucleotide synthesis. 
Treatment with the RNR-inhibitor hydroxyurea (HU) synergistically increased the fraction 
of REV3-deficient cells containing single stranded DNA (ssDNA) as indicated by 
increased staining of replication protein A (RPA). However, this increase was not 
accompanied by accumulation of the DNA damage marker γH2AX suggesting a role of 
REV3 in tolerance of replication stress (RS). Consistent with a role of REV3 in DNA 
replication, increased RPA staining was confined to S-phase cells. Additionally, we 
found genes related to RS to be significantly enriched among the top hits of the synthetic 
lethality screen further corroborating the importance of REV3 for replication under 
conditions of RS. These data outline a novel function of mammalian REV3 that could 
serve as a molecular basis of the observed REV3 cancer-specific per se effect as well 
as its indispensability during embryonic development.  
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2. Introduction 
2.1. Translesion synthesis 
Translesion DNA synthesis (TLS) is a specialized process of copying damaged DNA 
template that allows avoiding replication fork breakdown and subsequent chromosomal 
instability. This process doesn’t repair the DNA damage but rather allows tolerating it, 
very often leading to occurrence of mutations. TLS is carried out by translesion 
polymerases that include 7 polymerases from four families – X, Y, A and B families [1]. X 
family of polymerases consists of three polymerases - DNA polymerase beta (Polβ, 
POLB), TLS polymerase lambda (Polλ, POLL) and TLS polymerase mu (Polμ, POLM). 
All four polymerases in the Y family are translesion polymerases including REV1 
(REV1L), polymerase Eta (Polη, POLH), polymerase Iota (Polι, POLI) and polymerase 
Kappa (Polκ, POLK) [2]. Translesion polymerases of the A family are represented by 
polymerase theta (Polθ, POLQ) and polymerase nu (Polν, POLN). The only member of 
the B-family that is involved in TLS is polymerase zeta (Polζ), which consists of two 
subunits – catalytic subunit REV3 (REV3L) and structural subunit REV7 (MAD2L2, 
MAD2B). The choice of polymerases recruited for TLS is heavily dependent on the 
nature of DNA damage and is briefly discussed below [1]. 
Activation of DNA damage tolerance mechanisms is commonly thought to be mediated 
by PCNA modifications [3, 4]. Monoubiquitination of PCNA is carried out by RAD6-
RAD18 complex and initiates TLS. The polymerases of Y-family can start the DNA 
damage bypass by binding to monoubiquitinated PCNA via ubiquitin-interacting domains 
such as the UBM, the UBZ and the PCNA interacting peptide box (PIP) [5, 6]. 
Alternatively, Fanconi anemia FA-ID complex [7-9] and Rad9-Rad1-Hus1 (9-1-1) 
complex can play a role in exchange of replicative polymerases by TLS polymerases 
[10]. 
In yeast RAD5/Ubc13/Mms2 can polyubiquitinate monoubiquitinated PCNA. PCNA 
polyubiquitination can trigger template switching and recombination-assisted error-free 
DNA damage bypass [11, 12]. Rad5 has two homologues in human, HLTF and SHPRH, 
both of which can polyubiqutinate PCNA in vitro [13, 14]. The potentially mutagenic 
switch to TLS appears to be controlled by deubiquitinating enzyme USP1 and the 
protein Elg1 (ATAD5) [15] [16, 17]. 
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Although initially proposed to function in S-phase [18], the growing body of evidence 
supports a role of TLS polymerases in post-replicative repair (PRR) outside of S-phase. 
Thus, depletion of REV3 in mouse embryonic fibroblasts (MEFs) didn’t affect replication-
dependent TLS across UV-adducts, but completely abolished post-replicative repair of 
[6-4] photoproducts [19]. Additionally, expression of both subunits of polymerase zeta – 
REV3 and REV7 is the highest during G2/M phase suggesting a function of TLS in this 
cell cycle phase [20]. REV1 that interacts with several TLS polymerases appears to be 
important for bypass of blocking lesions during replication, while PCNA is required for 
the post-replicative gap filling in chicken DT40 cells, indicating differential role of REV1 
and PCNA in replicative and post-replicative TLS. 
TLS can be performed using one and two translesion polymerases. Some types of 
lesions can be bypassed by a single TLS polymerase. For example, UV-induced cis-syn 
cyclobutane pyrimidine dimers (CPDs) are bypassed by Polη in an error-free way in vivo 
[21]. Similarly, it was shown that several TLS polymerases are capable of replicating 
over abasic sites [22]. But for efficient TLS-mediated bypass of other lesions the so-
called two-polymerase mechanism is employed. In this process, the first TLS 
polymerase inserts a nucleotide opposite the lesion and the second one efficiently 
extends from it. The choice of the first polymerase is dictated by the type of the DNA 
damage that has to be bypassed. Due to its unique ability to extend from the nucleotides 
inserted opposite the lesions, DNA Polζ very often functions as the second polymerase 
in the two polymerase mechanism and therefore plays a very important role in TLS 
across a wide variety of DNA lesions in mammalian cells [23]. Main types of DNA 
lesions and the polymerases that are known to be employed for their bypass are 
summarized in the Table 1. 
Replication of undamaged template by TLS polymerases is error-prone with the error 
rate ranging from 10-1 to 10-3 [24]. For comparison the error rate of the conventional 
replicative polymerases from the A, B and C families is between 10-6 and 10-8 which is 
further decreased by accessory proteins like PCNA and RPA and mismatch repair 
(MMR) down to 10-8-10-10 [25]. The low fidelity of TLS polymerases is the result of 
lacking exonuclease activity and a more open and less constrained catalytic site that 
allows accommodation of DNA lesions and unconventional base pairs [26]. Therefore, 
even in the absence of DNA damage, excessive activity of TLS polymerases leads to 
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mutagenesis and can lead to occurrence of cancer [27]. The same is true for the TLS 
bypassing of DNA lesions, which can be carried out in error-free manner in vitro, but 
results of in vivo experiments show that this process is very often the main source of 
mutability. This makes TLS, and especially REV3 as an essential member of it, highly 
relevant for tumorigenesis and cancer treatment [1]. 
REV3L was found to be overexpressed in human gliomas and its expression level was 
reversely correlated with their sensitivity to cisplatin [28]. Conversely, human REV3L 
gene is located at the chromosome 6q21 within the FRA6F CFS that was reported to be 
frequently deleted in human tumors [29]. Moreover, REV3 is less expressed in colon 
carcinomas compared to the normal adjacent tissues and was proposed to play a tumor-
suppressor role [30].  
Besides tumorigenesis, TLS synthesis is also associated with the outcome of cancer 
therapy including sensitivity to chemotherapeutic agents and occurrence of resistance. 
TLS allows bypass of various lesions that are formed as a result of DNA modification by 
chemotherapeutic drugs thus decreasing sensitivity of the tumor. For instance, REV3L 
suppression sensitized both chemosensitive lymphoma and chemoresistant non-small-
cell lung cancer to cisplatin treatment [31]. On the other hand, TLS due to its error-
prone, mutagenic nature facilitates acquirement of tumor chemoresistance [32] thereby 
deteriorating response to treatment. Taken together, these two arguments strongly 
support the rationale for complementing traditional chemotherapy with REV3 targeting. 
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Table 1.1. TLS opposite DNA lesions by mammalian one and two-polymerase 
mechanism. Reproduced from [1] 
 
DNA lesion Insertion Extension Outcome 
Apurinic/ apyrimidinic (AP) site TLS Pol κ TLS Pol κ Mutagenic   
 
TLS Pol θ  TLS Pol θ  Mutagenic   
 
TLS Pol η  TLS Pol η  Mutagenic    
 
TLS Pol λ  TLS Pol λ  Unknown     
 
TLS Pol µ  Unknown Mutagenic    
 
TLS Pol ι Unknown Mutagenic    
 
REV1 Unknown Accurate      
7, 8-dihydro-8-oxoguanine (8-oxo-G) TLS Pol ι TLS Pol ι Mutagenic    
 
TLS Pol µ N/A Mutagenic   
 
TLS Pol λ N/A Accurate (+PCNA and RPA)      
 
TLS Pol η  N/A Mutagenic (+PCNA and RPA)    
Thymine glycol (Tg)  TLS Pol θ 
 
Mutagenic    
 
TLS Pol ν TLS Pol ν Accurate (5S-Tg); Mutagenic (5R-Tg)    
 
TLS Pol λ TLS Pol λ Mutagenic 
 
TLS Pol κ TLS Pol ζ Accurate 
(6-4) photoproduct TLS Pol ι TLS Pol θ Mutagenic   
 
TLS Pol ι Unknown Mutagenic    
 
TLS Pol η Unknown  Mutagenic    
 
TLS Pol µ Unknown Accurate      
 
Unknown TLS Pol ζ Accurate      
Cyclobutane pyrimidine dimer (CPD) TLS Pol µ TLS Pol µ Mutagenic   
 
TLS Pol η TLS Pol η Accurate      
 
TLS Pol ι TLS Pol ζ Mutagenic    
 
TLS Pol κ TLS Pol ζ Mutagenic    
 
Unknown TLS Pol ζ Mutagenic    
Benzo[α]pyrene-guanine (BP-G) TLS Pol η TLS Pol ζ Accurate      
 
TLS Pol κ TLS Pol ζ Mutagenic    
CDDP Intrastrand-crosslinks  Pol β  Pol β Unknown     
 
TLS Pol η TLS Pol η Mutagenic    
 
TLS Pol κ TLS Pol ζ Mutagenic    
 
TLS Pol η TLS Pol ζ Accurate      
CDDP Interstrand-crosslink (ICL)  
Recombination independent ICL repair including 
NER, REV1 and TLS Pol ζ Mutagenic    
 
Recombination dependent ICL repair including 
NER, REV1 and TLS Pol ζ Mutagenic    
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2.2. Synthetic lethality 
The idea about existence of synthetic lethal gene interaction originated in the field of 
Drosophila genetics and is almost a century old [33], However, the precise term 
“synthetic lethal” was introduced only two decades later [34]. Synthetic lethality is a type 
of genetic interaction where the co-occurrence of two genetic events results in 
organismal or cellular death [35, 36]. In other words, two genes are synthetic lethal when 
the single mutants are viable but simultaneous disruption of both genes results in killing 
of the cell. Similarly, when the double gene knockout doesn’t cause cell death but 
impairs cellular fitness the gene interaction is called synthetic sickness. Synthetic 
sickness is often considered together with the synthetic lethality under the common term 
synthetic sickness/lethality (SSL). This type of interaction can be viewed as a particular 
case of gene buffering. Within the course of evolution, living organisms developed 
several ways to perform the same function in order to maintain homeostasis in the face 
of diverse genetic and environmental challenges. This functional redundancy allows 
cells to tolerate disruption of certain genes making thereby SSL a feature of genetic 
robustness [36, 37]. 
Simplicity of gene knockdown in yeast allowed the genome-wide scale quantitative 
mapping of genetic interactions [38]. Resulting networks can be used for functional gene 
annotation, because the genes that are connected with SSL interaction, i.e. buffering 
each other, very often act in the same pathway and tend to cluster together in the 
network [35, 39]. SSL are significantly evolutionary conserved. Thus, the data of genetic 
interactions for two yeast species S. cerevisiae and S. pombe indicate that this 
organisms share approximately 30% of their genetic interactions [40, 41]. Although 
several studies found that as few as 1% of interactions are conserved between yeast 
and C. elegans, questioning the general conservation of synthetic lethality between 
evolutionary distant organisms [42, 43]. Similarly, the few studies that used yeast 
genetic interactions to predict interactions in mammalian cells suggest that conservation 
is rather limited [36, 44, 45]. This also implies the difficulty of direct transfer of the SSL 
interactions from model organisms to mammalian and human cells and supports the 
need of direct investigation of genetic interactions in these cells.  
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Discovery of RNA interference (RNAi) made it possible to perform efficient silencing of 
target genes in mammalian cells. Even though overexpression of genes can also result 
in SSL, wide spreading of loss-of-function genetic screens was facilitated by the rapid 
development of RNAi technology [36, 46]. Another advantage of loss-of-function screens 
is their ability to be translated to medical practice since the absolute majority (if not all) of 
the drugs used in the clinic are inhibitors of a certain function. 
Cancer cells harbor multiple mutations in their genome, many of which affect DDR and 
lead to genomic instability but can be tolerated because of the redundant function of 
some of the DNA repair pathways [47]. Targeting the genes that carry out the function of 
the gene disturbed by a mutation is an attractive approach to cancer therapy [48]. The 
idea of using SSL for targeting tumors is based on the assumption that there are 
pathways, disruption of which by itself can be tolerated but become lethal when 
combined with cancer-specific mutations, i.e. a synthetic lethal interaction [1,49]. 
Cancer cells are often adapted to oncogene overexpression/activation or tumor 
suppressor deletion/inactivation which makes them more vulnerable to some stimuli than 
normal cells. This phenomenon is often defined as oncogene addiction and denotes the 
genetic changes that are directly associated with oncogenic transformation. A major 
problem in tumor therapy is that most oncogenes and tumor suppressors are not 
druggable meaning that they are difficult to target by a small molecule. The new genetic 
network of cancer cells should also carry some changes not directly caused by the 
oncogene but occurred as a result of genetic rewiring. In contrast to oncogene addiction, 
these changes lead to so called non-oncogene addiction that represent promising 
approach to the cancer therapy [50]. 
Currently the biggest success of the synthetic lethality concept for cancer treatment is 
the SSL interaction between BRCA1/2 and PARP1. Upon PARP inhibition, spontaneous 
single-strand breaks are not repaired and subsequently result in collapsed replication 
forks, triggering HR-dependent repair as evidenced by gamma-H2AX and RAD51 foci 
formation. It was shown that BRCA2-deficient cells, as a result of their deficiency in HR, 
are strongly dependent on PARP1 function and therefore are sensitive to PARP 
inhibitors. BRCA1 and BRCA1 are often mutated in breast cancer making these tumors 
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ideal target of therapy with PARP-inhibitors [51, 52]. In a clinical trial, the PARP inhibitor 
olaparib had few of the adverse effects of conventional chemotherapy and demonstrated 
antitumor activity in cancers associated with the BRCA1 or BRCA2 mutation [53]. 
SSL interactions among DDR genes seem to be quite common. Thus, following the 
example of BRCA1/2 and PARP1, deficiencies in mismatch repair proteins were found 
to be SSL with DNA polymerases: MSH2 with DNA polymerase β (POLB) and MLH1 
with polymerase γ (POLG). Both SSL resulted in the accumulation of 8-oxoG oxidative 
DNA lesions and appeared to be caused by formation of DNA breaks [54].  
A recent study gives another example of synthetic lethality between the genes related to 
replication and repair. Silencing of DNA pol λ (POLL) induced replication fork stress and 
slowed down S phase progression in different human cancer cell lines. Moreover, the 
absence of DNA pol λ is specifically lethal in the cells with non-functional S-phase 
checkpoint suggesting a SSL interaction between pol λ and Chk1. Mechanistically, this 
synthetic lethal interaction indicates that DNA pol λ not only protects cells from oxidative 
DNA damage, but also functions in rescuing stalled replication forks [55]. 
Besides targeting DDR genes, an intriguing approach for selective killing of cancer cells 
based on SSL is to target common oncogenes. Lately there were several publications in 
which RNA interference technology was successfully used to identify vulnerabilities of 
cancers driven by RAS oncogene. One study found many processes involved in the 
buffering of RAS-induced transformation. Most notably, RAS mutant cells were 
hypersensitive to inhibition of polo-like kinase 1 (PLK1) [56]. In a similar effort, a screen 
in isogenic colorectal carcinoma cell line HCT116 identified the transcription factor 
SNAIL2 to be SSL with RAS [57]. Another two bigger screens determined SSL of RAS 
with STK33 [58] and TBK1 [59]. The latter kinase was known to activate NF-κB pathway, 
which in turn was shown to be essential for RAS transformed cells [60, 61]. Confirming 
the screen results, NF-κB signaling was required for progression of RAS-driven lung 
adenocarcinoma in a mouse model [62]. 
Oncogenes that are known to induce excessive RS, e.g. Myc and Cyclin E, are 
supposed to be SSL with the genes that allow the cell to cope with RS [63]. Examples of 
such genes are Chk1 and ATR that were demonstrated to be essential in tumors with 
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high levels of RS [64]. Since RS is a rather common phenomenon, genes with a SSL 
interaction with RS are considered a promising target for cancer therapy and 
identification of such gene interactions will be an interesting direction for future research.  
 
 
 
 
Figure 1.1. Concept of synthetic lethality applied to cancer cells deficient for DNA 
damage. Loss-off-function RNAi screen (siARRAY) can be used to identify SSL 
interactions with the targeted DDR gene (REV3). 
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2.3. Nucleotide synthesis 
The ability to replicate itself is a fundamental property of the living cell. Cells require four 
deoxyribonucleotides to replicate and repair its DNA. As replication progresses, 
nucleotide pools have to be constantly replenished, i.e. nucleotides have to be 
synthesized from glucose and aminoacids. Deoxynucleotides synthesis can be divided 
in two main pathways: de novo and salvage synthesis. In the de novo pathway 
ribonucleotides are first synthesized from other metabolites that are subsequently 
reduced to deoxyribonucleotides (dNs). The last transformation is performed by the 
enzyme ribonucleotide reductase (RNR) and is thought to be limiting for the whole de 
novo synthesis pathway. During this process, the four ribonucleotides ADP, CDP, GDP 
and UDP are reduced to form their deoxy-counterparts three of which dADP, dCDP, 
dGDP after phosphorylation by nucleoside diphosphate kinase can be directly used for 
DNA synthesis. Another substrate of DNA replication, dTTP cannot be obtained in this 
way, but has to be synthesized from reduced forms of dCDP or dUTP, making dTTP 
synthesis also strongly dependent on the function of RNR. The central role of this 
enzyme in the de novo pathway allows fine regulation and balancing of the different 
nucleotide pools but at the same time requires tight control of its function. This is 
accomplished by many mechanisms such as regulation of mRNA expression, 
posttranslational modifications of the protein and allosteric regulation of its catalytic 
activity that will be described later in a more detail [65]. 
As an alternative to the de novo pathway, cells can obtain nucleotides by 
phosphorylation of nucleosides catalyzed by specialized kinases. Such transformation is 
often called salvage synthesis and the corresponding enzymes – salvage kinases, 
because activity of this pathway is not necessary for the survival of mammalian cells in 
culture. This pathway is intended to recycle the nucleosides obtained in the process of 
DNA degradation and nucleosides that enter the cell by a process of facilitated diffusion. 
The extracellular deoxyribonucleosides (dNs) originate from liver biosynthesis [66], 
degradation of DNA in apoptotic cells [67] and food digestion. Deoxycytidine kinase 
(dCK) and thymidine kinase 1 (TK1) are the salvage kinases that are rate limiting for the 
metabolic flux of the pathway. dCK phosphorylates dC to produce deoxycytidine 
monophosphate (dCMP), a precursor of dCTP and dTTP pools. Although with the lower 
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efficacy dCK can also phosphorylate dA and dG [68]. TK1 phosphorylates thymidine to 
produce dTMP that can be used for synthesis of dTTP required for DNA replication [67]. 
Even though the salvage pathway is not essential for the cell, it seems to play an 
important role in cancer and in certain tissues. Thus, it was shown that purine salvage 
enzyme activities were higher in human intestinal and breast carcinomas than compared 
to that of normal tissues [69].  
Besides, this pathway is particularly important in hematopoietic tissue because it 
contributes both to induction and to prevention of replication stress (RS) during 
development. dCK-/- mice have severe developmental abnormalities affecting T cell, B 
cell and erythroid lineage [70]. TK1 knockout leads to slightly abnormal lymphoid 
structures and elevated levels of micronucleated erythrocytes [71]. Intriguingly, dCTP 
pool depletion, RS and hematopoietic defects induced by dCK inactivation are almost 
completely reversed by a concomitant TK1 knockout. In this case endogenous thymidine 
has a novel biological activity of RS inducer through TK1-mediated dCTP pool depletion 
[72]. 
The dominant role of RNR in regulation of dNTP pool sizes and composition has long 
been recognized [81]. The mammalian RNR consists of two homodimeric subunits, i.e. 
large subunit R1 and small subunit R2. The R1 subunit (RRM1, 90 kDa) carries the 
active site, whereas the small R2 protein (RRM2, 45 kDa) contains an iron center 
generating a tyrosyl free radical that is essential for catalysis [65, 73]. An additional 
mammalian RNR protein, p53R2, was identified in 2000 [73, 74]. Like the homologous 
R2 protein, p53R2 contains a tyrosyl free radical and forms an active RNR complex with 
R1 protein. The tyrosyl free radical of both the R2 and the p53R2 proteins is specifically 
destroyed by RNR inhibitor hydroxyurea [73, 75]. Expression of p53R2 is controlled by 
the tumor suppressor p53 and strongly increases after DNA damage allowing a 
moderate (less than two fold) expansion of nucleotide pools in G0/G1 cell phases, where 
the pools are about 5% that of the size of the pools in S-phase [73]. 
Reduction of NDPs by mammalian RNR is strongly regulated by nucleoside triphosphate 
allosteric effectors. There are three types of allosteric sites present on the large subunit 
– activity, substrate specificity and hexamerization sites. The activity site changes 
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overall activity of the enzyme by binding ATP or dATP (activity correspondingly 
increases and decreases). In addition to controlling activity, the allosteric mechanism 
also regulates the substrate specificity and ensures the enzyme produces an equal 
amount of each dNTP for DNA synthesis. Binding of ATP or dATP to the allosteric site 
induces reduction of CDP and UDP; dGTP induces reduction of ADP; and dTTP induces 
reduction of GDP[76]. Interestingly, upon allosteric regulation not only catalytic 
properties of the enzyme change but it also undergoes multistep oligomerization. 
According to a model, nucleotide binding to the specificity site (s-site) drives formation of 
an active R12R22 dimer, ATP or dATP binding to the adenine site (a-site) drives 
formation of a tetramer, mR14a, which isomerizes to an inactive form, mR14b, and ATP 
binding to the hexamerization site (h-site) drives formation of an active R16R26 hexamer 
[77, 78]. Later X-ray structural studies confirmed formation of the hexamer in the 
presence of physiological dATP concentrations [79]. Mutations affecting allosteric control 
sites lead to both unbalanced dNTP pools and increased mutation rates [76]. 
RNR activity varies greatly during the cell cycle. It is highest in S-phase contributing to 
nucleotide pool expansion in this cell phase and barely detectable in resting G0 cells. 
The regulation is mainly mediated by targeting the small subunit of RNR. Whereas R1 
levels remain relatively constant and high through the mammalian cell cycle, R2 
fluctuates cyclically and is controlled by both protein synthesis and degradation [81]. The 
transcription of R2 is mainly regulated by the E2F transcription factor. As a number of 
other genes, R2 transcription is repressed by E2F in a cycle-specific manner. In the 
beginning of S-phase the repression is released by activating the region upstream of the 
R2 gene [80]. Upon exit from S-phase the R2 levels are reduced by selective protein 
degradation. In detail, cell cycle regulator Cdh1 is phosphorylated late in S phase 
leading to its release from anaphase-promoting complex (APC), a cell cycle dependent 
ubiquitin ligase. APC in turn recognizes a specific peptide sequence on the R2 protein 
leading to its ubiquitination and subsequent proteosomal degradation. The depletion of 
the R2 protein stops the nucleotide synthesis in G2, but residual dNTP remain as shown 
in studies with synchronized cells [81]. Apart from RNR, APC also controls other 
nucleotide synthesis enzymes. Thymidylate kinase and thymidine kinase are recognized 
and targeted for degradation by APC during the transition from mitosis to the early G1 
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phase and after mitotic exit, respectively, showing that that down-regulation of dTTP 
pool size by the APC pathway during mitosis and the G1 phase is an essential means to 
maintain a balanced dNTP pool and to avoid genetic instability [82]. A recent publication 
uncovers another universal mechanism of RNR regulation by cyclin F. During G2, 
following CDK-mediated phosphorylation of Thr33, RRM2 is degraded via cyclin F. After 
DNA damage, cyclin F is downregulated in an ATR-dependent manner to allow 
accumulation of RRM2 [83]. 
Because of the low levels of nucleotide pools outside of S phase of the cell cycle the 
importance of dNTP pool expansion after DNA damage has long been speculated and 
thought to be mediated by p53R2 [74]. Although, unlike in yeast where nucleotide pools 
raise by some 6- to 8-fold as a result of DNA-damaging events [84], mammalian cells 
don’t respond to DNA damage induction with a major dNTP pool expansion suggesting 
existence of other mechanism supporting nucleotide supply to the sites of DNA damage. 
Indeed, compartmentalization of RNR was shown to play major role in this process and 
is dependent on a histone acetyl transferase Tip60. RRM1 was shown to physically 
interact and being recruited to sites of DNA damage by Tip60. Disruption of Tip60-RRM1 
interaction leads to hypersensitivity to DNA damage which supports the role of Tip60 in 
nucleotide supplementation to the sites of DNA repair during G1 phase [85]. 
Nucleotide concentrations are critical for the fidelity of normal replication process. 
Increased or decreased nucleotide concentrations as well as nucleotide pool imbalances 
lead to increased replication error rate and mutagenesis. The likelihood of a mismatched 
nucleotide to force a replication error, whether through misinsertion or a next-nucleotide 
effect, was shown to be strongly dependent on the concentrations of correct and 
incorrect nucleotides [81, 86]. Asymmetry of dNTP pools are naturally occurring in most 
of the living organisms and therefore can be an important factor contributing to 
replication mutagenesis. For deoxynucleosides-triphosphate (dNTP), the concentrations 
in dividing mammalian cells are: dATP, 24 +/- 22 µM; dGTP, 5.2 +/- 4.5 µM; dCTP, 29 
+/- 19 µM and dTTP 37 +/- 30 µM [87]. For synchronized S-phase HeLa cells this 
concentration are estimated to be: dATP 60 µM, dTTP 60 µM, dCTP 30 µM, dGTP 10 
µM [88]. According to this data, dGTP seems to be always underrepresented in dNTP 
pools constituting only 6% of the total. In vitro replication experiments showed that 
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change from equimolar to in vivo dNTP concentrations didn’t cause increase in 
replication error rate [89], suggesting that natural dNTP pool asymmetries are not 
strongly mutagenic [81]. In contrast, strong dNTP pool imbalances caused by different 
amino acid substitutions in yeast R1 increased substitution and insertion-deletion rates 
by 10- to 300-fold. But the locations of the mutations in the CAN1 gene in a strain with 
elevated dTTP and dCTP concentrations were completely different from those in a strain 
with elevated dATP and dCTP concentrations [90]. Therefore imbalanced dNTP pools 
reduce genome stability in a manner that is highly dependent on the nature and degree 
of the imbalance. 
The increased mutagenesis due to increased concentrations of four dNTPs found in cell-
free extracts [89] can be relevant for cancer cells because an elevated rate on 
nucleotide synthesis in tumors has long been recognized. Change of nucleotide 
metabolism by oncogenes has been best demonstrated for Myc and it was shown that 
nucleotide metabolic genes are enriched among c-Myc targets [91]. c-MYC depletion in 
melanoma cells resulted in the repression of several genes encoding enzymes rate-
limiting for dNTP metabolism including thymidylate synthase (TS), inosine 
monophosphate dehydrogenase 2 (IMPDH2) and phosphoribosyl pyrophosphate 
synthetase 2 (PRPS2). This repression resulted in reduction in the amounts of 
deoxyribonucleoside triphosphates (dNTPs) and inhibition of proliferation. On the other 
hand, overexpression of C-MYC in normal melanocytes enhanced expression of the 
above enzymes and increased individual dNTP pools [92]. Similarly, up-regulation of 
RRM2 expression mediated by another oncogene KRAS is essential for the proliferation 
of colorectal cancer cell lines [93]. This phenomenon appear to be rather common in 
cancer cells, since a study including a large samples size found that concentrations of 
the 4 dNTPs in tumor cells are on average 6-11 fold over normal cells, and for the 4 
NTPs, tumor cells also have concentrations 1.2-5 fold over the normal cells [87]. 
If an oncogene increases replication rate but doesn’t activate the nucleotide synthesis to 
a sufficient extent this can cause RS and subsequent genomic instability. Thus, aberrant 
activation of Rb-E2F pathway by HPV-16 E6/E7 or cyclin E oncogenes significantly 
decreased the cellular concentrations of dNTPs. Exogenously supplied nucleosides 
rescued the RS and DNA damage and dramatically decreased oncogene-induced 
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transformation. And expression of c-myc increased transcription of nucleotide 
biosynthesis genes, alleviated nucleotide deficiency and also rescued the replication-
induced DNA damage [94]. This study provides a model of oncogene-induced genomic 
instability in the early stages of cancer development. 
A recent finding provides a link between nucleotide synthesis and oncogene-induced 
senescence. It shows that oncogene-induced repression of RRM2 leads to decreased 
dNTP concentrations and subsequent senescence-associated cell-cycle exit. 
Consistently, RRM2 downregulation is both necessary and sufficient for senescence 
[95]. It was shown that anchorage-independent growth of cells transformed with v-fms, 
v-src, A-raf, v-fes, c-myc, and ornithine decarboxylase was markedly enhanced when 
RRM2 was overexpressed. Therefore, RRM2 cooperates with a variety of activated 
oncogenes to support the transformation and its overexpression increases the malignant 
potential of cells [96, 97]. Altogether these data indicate that overexpression of RRM2 
observed in many tumors can serve as a tool to overcome the barrier of oncogene-
induced senescence in early tumorigenesis. 
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Figure 1.2. De novo pathway of deoxyribonucleotide synthesis. Allosterically regulated 
enzymes:(1) ribonucleotide reductase, (2) dCMP deaminase. Not regulated: (3) dTMP 
synthase, (4) (d)CMP kinase, (5) thymidylate kinase, (6) nucleoside diphosphate kinase, 
(7) dUTPase. Abbreviations used: THF, tetrahydrofolate; DHF, dihydrofolate. Adapted 
from [65]. 
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2.4. Replication stress 
DNA replication stress (RS) is defined as inefficient DNA replication that causes DNA 
replication forks to progress slowly or stall [98]. Even though not fully understood, RS 
and RS-induced DNA damage are thought to be caused by multiple factors. These 
include dNTP pools imbalances and altered frequency of origin initiation, DNA damage 
lesions that block replication fork and inhibition of DNA replication by drugs. Also the 
difficult-to-replicate regions are especially prone to RS due to their secondary structure, 
chromatin organization or their intrinsic topological complexity that makes them difficult 
to unwind. Some replication proteins bound to DNA are able to pause the replication 
thus causing RS [99]. 
There are many proteins that participate in stabilization and restart of stalled replication 
forks as well as restart of collapsed forks. Most of these proteins are known by their well-
defined functions in homologous recombination (HR) repair and/or DNA damage 
checkpoint signaling. In this introduction I will only shortly introduce some major players 
of the RS response [100]. 
The cell response to RS is mainly orchestrated by ATR even though ATM seems to play 
a certain role. Thus, thymidine that induces RS by depleting cellular dCTP pools induces 
DNA damage response that depends on both ATM and ATR, ATM playing a role in 
HRR-mediated rescue of replication forks impaired by thymidine treatment [101].  
Several types of DNA damage and replication interference such as DNA breaks, 
adducts, crosslinks and inhibition of DNA polymerases activate ATR-ATRIP kinase 
signaling [102]. It is widely accepted nowadays that ATR activation is triggered by 
single-stranded DNA (ssDNA), which is commonly formed during DNA replication and 
repair. When generated, ssDNA is immediately coated by replication protein A (RPA) 
complex. ATRIP is mediating ATR recruitment by binding RPA-ssDNA complex and 
allowing the ATRIP-ATR complex to be localized to the sites of DNA damage and stalled 
replication forks [102, 103]. 
RPA not only recruits ATR but is also a target of ATR-mediated phosphorylation. It was 
shown that RPA2 is phosphorylated by ATR primarily in the late S and G2 phases. Cells 
carrying mutations in RPA2, a target of ATR-mediated phosphorylation, had low rate of 
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DNA synthesis and higher levels of ssDNA upon RS. After mitosis these cells also had a 
broader DNA distribution and were prone to apoptosis [104]. Apart from ATR-Chk1 
pathway, DNA-dependent protein kinase (DNA-PK) appears to be indispensable for RS 
response signaling. DNA-PKcs mutant cells fail to arrest replication following stress, and 
mutations in RPA32 phosphorylation sites targeted by DNA-PK catalytic subunit 
increase the proportion of cells in mitosis, impair ATR signaling to Chk1 and confer a 
G2/M arrest defect [105]. These data corroborate an important role of RPA 
phosphorylation by ATR and DNA-PK in response to RS. 
In addition to ssDNA, double-stranded DNA (dsDNA) adjacent to ssDNA is required for 
ATR activation [106]. The two main regulators of ATR are the Rad17-RFC complex and 
the Rad9-Rad1-Hus1 (9-1-1) complex. Rad17-RFC complex functions to recruit the 
clamp-shaped 9-1-1 complex onto DNA in the presence of ssDNA-dsDNA junctions 
[102, 107]. The recruitment of Rad17-RFC and 9-1-1 complexes is largely independent 
from recruitment of ATR-ATRIP by RPA-ssDNA [108]. In human cells, besides RPA, 
Rad17-RFC and 9-1-1, full activation of ATR also requires topoisomerase II binding 
protein 1 (TOPBP1). TOPBP1 functions in both the initiation of DNA replication and 
activation of the checkpoint, but how it is regulated upon DNA damage is not fully 
understood [102]. ATR phosphorylates RAD17, which recruits Claspin to be 
phosphorylated by ATR. Phosphorylated RAD17-Claspin (along with TIM and Tipin) 
promotes ATR phosphorylation/activation of Chk1 [100]. In yeast, expression of a 
mutant allele of MEC1 leads to destabilization of DNA polymerases at stalled forks [109]. 
These activation mechanisms constitute the intra-S checkpoint that is activated upon 
induction of RS [110]. 
Chk1 is a critical G2/M checkpoint protein transducing the signal upon induction of DNA 
strand breaks but is also required for normal proliferation [111, 122]. Chk1 appears to 
have two distinct functions in two phases of the unperturbed cell cycle: S phase and 
mitosis [122]. During unperturbed S phase, Chk1 controls the progress of DNA 
replication. Inhibition of Chk1 activity leads to increased replication-associated DNA 
strand breaks [112], impaired replication fork progression, and increased fork stalling 
[113, 114, 122]. An important function of the ATR–Chk1 pathway is also associated with 
common fragile sites (CFS) where several proteins involved in the Chk1 signaling, 
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including TOPBP1, BRCA1, CLASPIN and CHK1, are required for preventing fork 
collapse [102, 115]. 
Several studies in yeast support the critical role of ATR-Chk1 pathway in RS response 
and protection of replication forks at speciﬁc loci in the genome during unperturbed S 
phase [102]. Thus, Chk1 homologue Rad53 was shown to be indispensable for 
stabilization of stalled forks induced by nucleotide depletion [116]. In the absence of 
Rad53, Exo1 exonuclease is recruited to stalled forks counteracting reversed fork 
accumulation by generating ssDNA intermediates [117]. Consistently, deletion of Exo1 
rescues the fork instability induced by RAD53 mutation [118]. The yeast ATR homolog 
Rad3 phosphorylates histone H2A during S phase at natural replication fork barriers, 
ribosomal DNA (rDNA) repeats and heterochromatin in centromeres and telomeres [102, 
119]. Besides that, ATR-Chk1 signaling regulates licensing of replication origins, that are 
available in excess provided sufficient amount of Mcm2-7 complexes [120]. Thus, ATR 
and Chk1 suppress origin firing in response to replication blocks and during normal S 
phase by inhibiting the cyclin-dependent kinase Cdk2 [113, 121]. 
Chk1 knockout mice are not viable [111], but the essential function seems to be related 
to mitosis and not associated with DNA damage checkpoint and replication control. 
Unlike mice with a targeted Chk1 mutation of S345, S317 mutants are viable, but had 
deficient G2/M checkpoint activation, impaired efficient progression of DNA replication 
forks, and increased fork stalling [122]. S345 phosphorylation initiated at the centrosome 
during unperturbed mitosis is independent of codon 317 status and mechanistically 
distinct from the ordered and sequential phosphorylation of serine residues on Chk1 
induced by DNA damage [122]. 
The physiological importance of ATR is highlighted by the fact that ATR knockout is 
lethal in mice [123, 124]. However, there is a hypomorphic mutation in humans that 
causes Seckel syndrome. Homozygous mutation introduces a splicing defect that 
reduces the abundance of ATR to almost undetectable, yet the remaining protein is 
sufficient for viability. Viable ATR-Seckel mice show high levels of RS during 
embryogenesis, which is reduced in postnatal life. In spite of this decrease, adult Seckel 
mice show accelerated aging, which is further aggravated in the absence of p53. This 
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study suggests that RS contributes to the onset of aging in postnatal life, and this is 
balanced by the replicative stress–limiting role of the checkpoint proteins ATR and p53 
[125]. 
Mutations in many DNA repair and cell cycle associated genes cause age-related 
diseases. Werner syndrome, Cockayne syndrome, trichothiodystrophy, dyskeratosis 
congenital and ataxia-telangiectasia are examples of such diseases [126]. RS was 
suggested to play an important role in aging based on the premature aging phenotypes 
observed in eukaryotes harboring mutations in RecQ helicases [98]. Mutations in RecQ 
helicases WRN, BLM and RECQL4 all cause genome instability and the premature 
aging syndromes called Werner, Bloom Rothmund–Thomson syndromes respectively 
[127, 128]. Moreover, RS induced by reduced Mcm2 expression results in severe 
stem/progenitor cell deficiency, premature aging and cancer [129]. Since premature 
aging phenotype can be a result of stem and progenitor cells attrition, it was speculated 
that stem cells might be particularly vulnerable to RS [130]. 
Homologous recombination (HR) pathway plays a major role in restarting stalled and 
collapsed forks and therefore is essential for RS tolerance [100, 131]. Apart from the 
core HR proteins (RAD51, RAD54, BRCA1/2, BLM), PARP-1 mediated recruitment of 
MRN complex (MRE11, RAD50 and NBS1) appears to be important for RS-induced HR 
[132]. Interestingly, PARP activity is also required for effective fork reversal that limits 
DSB formation upon RS induced by the topoisomerase I poison camptothecin [133]. 
At stalled forks, HR carries our template switching of a blocked replicating strand to the 
undamaged sister chromatid where DNA synthesis and a second template switch result 
in the bypass of the blocking lesion. At collapsed forks, when the one-ended double 
stranded break is formed, process called break-induced repair (BIR) takes place. In BIR, 
HR mediates strand invasion of the 3’-end of when the one-ended double stranded 
break into sister chromatids that is used as a new template [100]. Apart from their role in 
the fork restart, recent studies identify repair-independent function of HR and Fanconi 
anemia proteins BRCA2, BRCA1 and FANCD2 in direct stabilization of stalled 
replication forks by protecting them from degradation by MRE11 [134, 135]. 
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The growing body of evidence suggests that many oncogenes induce RS playing an 
important role in cancer development and progression. First, DNA damage response 
(DDR) markers such as phosphorylated kinases ATM and Chk2, and phosphorylated 
histone H2AX, p53 and 53bp foci were found in multiple tumor samples. This DDR 
appeared to be associated with oncogene-induced RS, to occur early stages in 
tumorigenesis and to represent an anti-cancer barrier [136, 137]. Further, oncogene-
induced senescence was identified to be associated with signs of RS including 
prematurely terminated DNA replication forks and DNA double-strand breaks and could 
be suppressed by inhibiting the DNA double-strand break response kinase ataxia 
telangiectasia mutated (ATM) [138, 139]. 
The molecular basis of RS still remains largely under-investigated, although there are 
several reports addressing this issue. One study [94] found that transformation by HPV-
16 E6/E7 or cyclin E oncogenes significantly slowed down replication fork progression 
but also decreased cellular nucleotide levels. Interestingly, exogenous supplementation 
of nucleosides rescued the RS and DNA damage induced by these oncogenes, 
suggesting that nucleotide deficiency represents an important factor contributing to 
oncogene-induced RS and genomic instability. In another study [140], Cyclin E 
overexpression caused increased firing of replication origins, impaired replication fork 
progression and DNA damage that activated RAD51-mediated recombination. 
Additionally, inhibition of transcription completely abolished induction of RAD51 foci by 
Cyclin E and reduced numbers of Cyclin E-induced 53BP1 foci indicating that 
interference between replication and transcription underlies the activation of HR upon 
oncogene-induced RS. A very recent study investigated structural basis of RS induced 
by Cyclin E and Cdc25A [141]. Overexpression of these oncogenes slowed down 
replication forks and induced fork reversal, but was not associated with chromosomal 
breakage or DDR activation unless arrested in G2/M or undergo premature mitotic entry.  
The genomic instability of cancers is widely acknowledged [142] and RS is increasingly 
seen as one of the factors contributing to its development [143, 144]. Already in the early 
studies, it was hypothesized that genomic instability arising from DDR induced by RS 
can facilitate later transformation events such as loss of p53 [136, 137]. Later it was 
found that common fragile sites are preferentially targeted by oncogene-induced RS, 
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supporting the idea that RS is especially harmful for the regions that are intrinsically 
difficult for replication [145]. In these regions the forks stall and break more often than 
anywhere else in genome, potentially leading to highly mutagenic DSBs.  Consistently 
with this hypothesis, RS was shown to induce γH2AX-positive micronuclei comprising of 
aggregated DSBs [146]. 
An established mediator of DSB repair 53bp1 was known to form distinct nuclear bodies 
in normally proliferating mammalian cells. A role of 53bp1 in shielding chromosomal 
fragile sites from RS-induced breakage was identified recently [147]. 53bp1 nuclear 
bodies represent therefore under-replicated chromosomal lesions that are transferred to 
the daughter cells through mitosis. 53bp1 was shown to protect DNA ends from 
excessive resection in G1, and thereby favors repair by nonhomologous end-joining 
(NHEJ) as opposed to homologous recombination (HR). But during S phase, BRCA1 
antagonizes 53bp1 to promote HR [148]. Conversely, fragile site loci are often linked 
with BLM-associated DNA ultra-fine bridges even as cells traverse mitosis. These loci 
are often induced after partial inhibition of DNA replication, i.e. after RS, and are covered 
with by Fanconi anaemia proteins FANCD2 and FANCI [149], suggesting that sister-
chromatid homology is used to facilitate replication of fragile sites. These data indicate 
that fragile sites cannot be replicated in time by conventional machinery and 
subsequently rescued either by HR or NHEJ. 
Until recently there was no direct evidence that chromosomal instability can be directly 
caused by RS. But in 2011 a publication came out that investigated this issue and 
showed that sites of chromosome breakage correlate with replication fork locations. 
Moreover, ssDNA can be detected prior to chromosome breakage, suggesting that 
ssDNA accumulation is the common precursor to DSB at collapsed replication forks 
[150]. Following this line, it was demonstrated that DNA lesions induced by RS can 
trigger mitotic aberration, chromosomal missegregation and tetraploidy development 
[151]. The most recent study aimed to identify the genes suppressing chromosomal 
instability by searching for the DNA regions for which copy-number variation negatively 
correlates to the ploidy of the tumors. It found three genes on chromosome 18q, 
silencing of which lead to RS, chromosome abnormalities and chromosome 
missegregation [152]. 
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Frequently induced in tumors, RS is increasingly considered as an attractive target for 
cancer therapy. It was proposed that ATR and Chk1 inhibitors can be employed for 
selective killing of tumors with high levels of RS [63]. There were several studies 
investigating this possibility. Thus, it was demonstrated that the reduced level of ATR 
expression in the mice carrying ATR-Seckel mutation completely prevented the 
development of Myc-induced pancreatic tumors and lymphomas, both of which have 
high levels of RS. Moreover, Chk1 inhibitors were highly efficient in killing Myc-driven 
lymphomas, but not pancreatic adenocarcinomas initiated by K-Ras mutation showing 
no detectable evidence of RS response [64]. Similarly, ATR inhibition was particularly 
toxic for the cells overexpressing cyclin E [153]. Investigation of sensitivity of melanoma 
cell lines to Chk1 inhibition revealed that it was correlated to the level of endogenous 
DNA damage indicating level of RS [154]. These data support the model of the dual role 
of ATR-Chk1 signaling in the cancer progression: suppressive in the early lesions and 
necessary for the survival of full malignancies with the high levels of RS [155]. 
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Figure 1.3. Key proteins and pathways in the replication stress response network. Black 
arrows/bars indicate activation/suppression pathways or interactions between proteins; 
red arrows indicate some of the known phosphorylation events by indicated kinases. 
Note that several proteins, such as RPA and ATR, have roles in more than one pathway 
in this network. Adapted from [100]. 
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Inhibition of REV3 Expression
Induces Persistent DNA
Damage and Growth Arrest
in Cancer Cells1,2
Philip A. Knobel, Ilya N. Kotov,
Emanuela Felley-Bosco, Rolf A. Stahel
and Thomas M. Marti
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Oncology, University Hospital Zurich, Zurich, Switzerland
Abstract
REV3 is the catalytic subunit of DNA translesion synthesis polymerase ζ. Inhibition of REV3 expression increases
the sensitivity of human cells to a variety of DNA-damaging agents and reduces the formation of resistant cells.
Surprisingly, we found that short hairpin RNA–mediated depletion of REV3 per se suppresses colony formation of
lung (A549, Calu-3), breast (MCF-7, MDA-MB-231), mesothelioma (IL45 and ZL55), and colon (HCT116 +/−p53)
tumor cell lines, whereas control cell lines (AD293, LP9-hTERT) and the normal mesothelial primary culture
(SDM104) are less affected. Inhibition of REV3 expression in cancer cells leads to an accumulation of persistent
DNA damage as indicated by an increase in phospho-ATM, 53BP1, and phospho-H2AX foci formation, subse-
quently leading to the activation of the ATM-dependent DNA damage response cascade. REV3 depletion in
p53-proficient cancer cell lines results in a G1 arrest and induction of senescence as indicated by the accumulation
of p21 and an increase in senescence-associated β-galactosidase activity. In contrast, inhibition of REV3 expres-
sion in p53-deficient cells results in growth inhibition and a G2/M arrest. A small fraction of the p53-deficient can-
cer cells can overcome the G2/M arrest, which results in mitotic slippage and aneuploidy. Our findings reveal that
REV3 depletion per se suppresses growth of cancer cell lines from different origin, whereas control cell lines and a
mesothelial primary culture were less affected. Thus, our findings indicate that depletion of REV3 not only can
amend cisplatin-based cancer therapy but also can be applied for susceptible cancers as a potential monotherapy.
Neoplasia (2011) 13, 961–970
Introduction
Screening in Saccharomyces cerevisiae for mutants defective in UV-
induced mutagenesis revealed the so-called reversionless phenotype
(REV), which is characterized by a diminished frequency of muta-
tions reverting a specific marker gene deficiency [1]. Two genes that
confer this phenotype when absent are Rev3 and Rev7, the catalytic
and the structural subunits of the DNA translesion synthesis (TLS)
polymerase ζ (Pol ζ), respectively [2,3]. The mammalian REV3L
gene (hereafter REV3) encodes a ∼350-kDa protein (REV3) consist-
ing of a large C-terminal DNA polymerase subunit, which misses the
characteristic proofreading activity present in other B-family DNA
polymerases (reviewed in Waters et al. [4]). REV3 interacts through
a specific binding domain with REV7, but no additional protein-
protein interaction sites were identified. Deletion of REV3 is embry-
onically lethal around midgestation [5–8], whereas overexpression of
REV3 leads to increased spontaneous mutation rates [9], confirming
that REV3 expression has to be tightly regulated to maintain genomic
integrity. Conversely, one study found that REV3 expression was
downregulated in colon carcinomas compared with that in adjacent
normal tissue [10], whereas another study found that REV3 expression
was elevated in human glioma tissues resected before therapy com-
pared with that in normal brain tissues [11].
Abbreviations: TLS, DNA translesion synthesis; Pol ζ, DNA translesion synthesis poly-
merase ζ; REV3, the mammalian REV3L gene; MEF, mouse embryonic fibroblast; DDR,
DNA damage response; DSBs, DNA double-strand breaks; ATM, ataxia-telangiectasia
mutated; γH2AX, phosphorylated H2AX; P-Chk2, phosphorylated Chk2; AN, aneu-
ploid nondividing; AD, aneuploid dividing
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Pol ζ belongs to the functional group of TLS DNA polymerases,
which are characterized by a less-stringent active site and a lower pro-
cessivity compared with the high-fidelity replicative DNA polymerases
(reviewed in Waters et al. [4]). TLS polymerases contribute to the
maintenance of the genomic integrity by allowing DNA replication
to continue in the presence of DNA adducts, which otherwise could
lead to DNA replication fork breakdown and subsequent gross chro-
mosomal instability. Pol ζ is the major extender from mismatches
formed when incorrect nucleotides are inserted opposite DNA ad-
ducts, thereby contributing to mutation formation on the nucleotide
level. Recently, it was shown that REV3 is involved not only in DNA
damage tolerance but also in DNA repair mechanisms, for example, in-
terstrand cross-link repair [12–14], homologous recombination [15],
and nonhomologous end-joining as indicated by the deficiency of
REV3-deleted B cells in class switching of immunoglobulin genes [16].
The unique function of REV3 is highlighted by the fact that theREV3
depletion increases sensitivity and decreases mutagenesis induced by UV
light, cisplatin, and other mutagens in human and mouse fibroblasts
[15,17,18]. In addition, depletion of REV3 sensitizes mouse B-cell lym-
phomas and lung adenocarcinomas to cisplatin [19,20]. Although dis-
ruption of mouse REV3 leads to embryonic lethality, it is possible to
generate REV3-deleted mouse embryonic fibroblasts (MEFs) in a p53-
deficient background [21]. Spontaneous chromosomal instability was
observed inREV3-deletedMEFs andREV3-deleted cell lines [16,22,23].
DNA damage induction results in the activation of an evolution-
arily conserved signal cascade known as DNA damage response
(DDR) (reviewed in d’Adda di Fagagna [24]). Induction of DNA
double-strand breaks (DSBs) results in recruitment and activation
of ataxia-telangiectasia mutated (ATM). Activated ATM phosphory-
lates the histone variant H2AX at serine 139 (γH2AX) near DNA
DSBs, subsequently leading to an accumulation of DDR proteins
at DSBs, which can be visualized by immunofluorescence microscopy
as distinct foci. Once ATM activation reaches a certain threshold,
checkpoint kinase Chk2 is phosphorylated, resulting in the accumula-
tion of p53, leading to the accumulation of the cyclin-dependent kinase
inhibitor p21. Prolonged activation of p21 after DNA damage is asso-
ciated with a terminal proliferation arrest, i.e., senescence.
While investigating how inhibition of REV3 expression affects
cisplatin-induced mutagenesis, we observed that depletion of REV3
per se reduces cancer cell growth, whereas growth of control cells is
less affected. Suppression of REV3 expression in cancer cells leads to
the accumulation of persistent DNA damage independent of the p53
status. In p53-proficient cancer cells, inhibition of REV3 expression
results in the activation of the ATM-dependent DDR cascade, lead-
ing to senescence induction. In p53-deficient cancer cells, depletion
of REV3 results in a G2/M arrest and increases the fraction of aneu-
ploid cells. In contrast, inhibition of REV3 expression in control cell
lines and a mesothelial primary culture neither reduces colony forma-
tion nor activates the DDR cascade.
Materials and Methods
Cell Lines and Culture
All cell lines used in this study were authenticated by DNA finger-
printing (Microsynth, Balgach, Switzerland). SDM104 was maintained
as described previously [25]. All other cell lines weremaintained in high-
glucose Dulbecco modified Eagle medium (DMEM; Sigma-Aldrich,
St Louis, MO) supplemented with 2 mM L-glutamine, 1 mM sodium
pyruvate, 10% fetal calf serum, and 1% (wt/vol) penicillin/streptomycin.
All cells were grown at 37°C in a humidified atmosphere containing
5% CO2. Additional details can be found in Supplemental Materials
and Methods.
Vector Production and Transduction
Replication-deficient lentiviral particles were produced, titrated,
and used for transduction as described previously [26,27]. Additional
details can be found in Supplemental Materials and Methods.
Plasmid Transfection
Cells were transfected using Lipofectamine 2000 (Invitrogen,
Carlsbad, CA) according to the manufacturer’s instructions with
pSuperior.puro containing either scrambled control short hairpin
RNA (shSCR) or three distinct short hairpin RNA (shRNA) se-
quences targeting the REV3 messenger RNA (shREV3). Additional
details can be found in Supplemental Materials and Methods.
Colony Formation Assay
Crystal violet staining was performed after colonies were visible by
eye and, the number of colonies was determined by eye, applying the
same threshold for colony size to all transduced cell lines. The num-
ber of colonies obtained by mock treatment was set to 100%.
Quantitative Real-time Polymerase Chain Reaction
RNA from samples was isolated using RNeasy Mini kit (Qiagen,
Germantown, MD), and reverse transcription was performed on
300 ng of RNA (QuantiTect Reverse Transcription Protocol; Qiagen).
The quantitative expression of REV3 mRNA was measured by SYBR
Green polymerase chain reaction (PCR) assay (PE Applied Biosystems,
Foster City, CA) on a Prism 5700 detection system (SDS; PE Applied
Biosystems). Additional details can be found in Supplemental Mate-
rials and Methods.
Immunofluorescence Microscopy
Immunofluorescence microscopy was essentially performed as
described [28]. Details can be found in Supplemental Materials
and Methods.
Flow Cytometry
Detection of bromodeoxyuridine (BrdU) incorporation in DNA-
synthesizing cells was carried out using the anti-BrdU antibody (no.
555627; BD Biosciences, San Jose, CA) according to the manufac-
turer’s instructions. Additional details can be found in Supplemental
Materials and Methods.
Senescence-Associated β-Galactosidase Assay
The expression of senescence-associated (SA) β-galactosidase was
determined by SA-β-galactosidase staining as described [29].
Western Analysis
Protein extracts (30 μg) were separated by 4% to 20% SDS-PAGE
and transferred onto polyvinylidene fluoride membranes. Immuno-
blot analysis was performed as described [30]. Details can be found
in Supplemental Materials and Methods.
Enzyme-Linked Immunosorbent Assay
Cells were washed three times with phosphate-buffered saline (PBS)
and serum-free DMEMwas added for 24 hours. Conditionedmedium
was filtered, and cell number was determined in every experiment by
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hemocytometer. Enzyme-linked immunosorbent assay (ELISA) was
performed using human interleukin 6 (IL-6) Quantikine ELISA Kit
(no. D6050; R&D Systems, Minneapolis, MN). Data were normal-
ized to the cell number and reported as fold difference compared with
mock-treated control.
Statistical Analysis
P values were calculated using the two-tailed Student’s t test; *P <
.05 and **P < .01.
Results
Depletion of REV3 Per Se Suppresses Colony Formation
of Cancer Cells
To study the effect of REV3 depletion on cisplatin-induced muta-
genesis, we established a lentiviral-based system, which allowed us to
significantly inhibit REV3 expression in all cell lines and the primary
culture used in this study (Figure W1, A and B). Inhibition of REV3
expression did not significantly reduce colony formation of the con-
trol cell line AD293 (99% remaining colonies compared with mock-
treated control), the primary mesothelial culture SDM104 (81%),
and the hTERT-immortalized derivative of the mesothelial primary
culture LP9 (LP9-hTERT, 98%; Figures 1A and W2A). Surprisingly,
REV3 depletion per se significantly suppressed colony formation of
the p53-proficient adenocarcinoma cell line A549 (30%), the p53-
deficient adenocarcinoma cell line Calu-3 (57%), the p53-deficient
breast cancer cell line MDA-MB-231 (47%), the p53-proficient breast
cancer cell line MCF-7 (32%), the human mesothelioma cell line
ZL55 (27%), and the rat mesothelioma cell line IL45 (4%) compared
with the mock-treated control (Figures 1A and W2A).
In the isogenic p53-proficient and -deficient HCT116 colorectal
carcinoma cell lines, there was no significant difference in the reduc-
tion of REV3 expression levels after transduction with a multiplic-
ity of infection (MOI) of 170, as used for the cell lines described
previously, or an MOI of 800 (Figure W1B). However, only the
high-titer transduction significantly suppressed colony formation of
p53-proficient (49%) and -deficient HCT116 (54%) compared with
the mock control (Figures 1B and W2B). REV3 depletion by high-
titer transduction did not significantly reduce colony formation of
the control cell line AD293 (74%) compared with the mock control
(Figures 1B and W2B).
Inhibition of REV3 expression by transduction with three plas-
mids, one encoding the same small interfering RNA (siRNA) as
the lentiviral-based particles plus two plasmids encoding siRNA tar-
geting alternative sites of the REV3 mRNA (named REV3-5 and
REV3-6), significantly reduced colony formation in the mesothe-
lioma cell line IL45, whereas the control cell line AD293 was not
affected (Figure W3). Therefore, we conclude that the observed re-
duction in colony formation is due to the inhibition of REV3 expres-
sion and not due to an unspecific off-target effect of the REV3-4
siRNA. Thus, REV3 depletion per se significantly suppresses colony
formation in cancer cell lines, whereas colony formation of control
cell lines and a primary mesothelial culture is less affected.
Cancer Cells Accumulate Persistent DNA DSBs after
REV3 Depletion
53BP1 and γH2AX foci formation is regarded as a maker for
DSBs [28], and a recent study showed that their numbers were
increased after persistent DNA damage induction [31]. Seven days
after transduction, REV3 depletion in A549 cells increased the
Figure 1. Inhibition of REV3 expression specifically reduces colony formation of cancer cell lines. Cells were mock treated or transduced
with lentiviral-based particles containing either shSCR or shREV3. (A and B) Cells were stained by crystal violet, and total colonies were
counted after 2 to 4 weeks. Colonies were counted from at least three independent experiments for all cell lines. Colony numbers of
mock-treated cells were set as 100%. *P < .05. **P < .01. Shown are means ± standard deviation (SD).
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average number of P-ATM and γH2AX foci per cell by a factor
of 3.8 and 2.3, respectively, compared with the mock control
(Figure 2A). Inhibition of REV3 expression increased the fraction
of A549 cells containing more than two 53BP1 foci to 34% com-
pared with mock (2%) and scrambled (16%) control (Figure 2A).
Similarly, REV3 depletion in MCF-7 breast cancer cells increased
the average number of γH2AX and 53BP1 foci per cell by a factor
of 3.2 and 2.5, respectively, compared with the mock control
(Figure W4). P-ATM foci formation was also elevated in both
p53-proficient and -deficient HCT116 cells after REV3 depletion
by a factor of 2.3 and 2.5, respectively, compared with the scrambled
control (Figure 2B). In contrast, inhibition of REV3 expression in the
control cell line AD293 did not significantly increase P-ATM,
53BP1, or γH2AX foci formation compared with the scrambled
control (Figure 2A).
DSBs, which are not repaired either due to complex DNA mod-
ifications or to deficiencies in molecular mechanisms result in the
formation of persistent DSBs (reviewed in d’Adda di Fagagna [24]).
P-ATM foci at persistent DSBs are significantly larger than the initial
foci detectable immediately after damage initiation [32]. Microscopic
analysis revealed that the DDR foci induced in REV3-depleted cells
7 days after transduction were larger compared with the background
DDR foci present in the mock controls (Figure 2A).
Gross chromosomal instability indicated by an elevated number of
micronuclei were observed in MEFs with REV3 deletion [21]. Sim-
ilarly, the number of micronuclei increased in A549 cells by a factor
of 9 after inhibition of REV3 expression compared with the mock
control (Figure 2C ). Micronuclei formation was not significantly
elevated after inhibition of REV3 expression in AD293 cells (Fig-
ure 2C ). Thus, inhibition of REV3 expression induces the formation
of persistent DSBs and accumulation of gross chromosomal instabil-
ity in cancer cell lines, whereas the control cell line AD293 is signif-
icantly less affected (P < .05 for γH2AX, P-ATM, and 53BP1 foci
and micronuclei per cell for both A549 and MCF-7 vs AD293;
numbers of P-ATM foci per cell were not determined in MCF-7
cells). In addition, our results indicate that persistent DDR foci for-
mation after REV3 depletion is not dependent on the p53 status.
Inhibition of REV3 Expression Suppresses Proliferation
of Cancer Cells
Because persistent DNA adducts block DNA replication and acti-
vate the DDR pathway, we investigated whether inhibition of REV3
expression results in reduced cellular proliferation. Labeling of newly
synthesized DNA with BrdU is an established method for the assess-
ment of cellular proliferation (reviewed in Quinn and Wright [33]).
Figure 2. REV3 depletion induces persistent DNA damage and genomic instability specifically in cancer cells. Cells were mock treated or
transduced with lentiviral-based particles containing either shSCR or shREV3 and analyzed after 1 week. (A) Cells were stained for
P-ATM, γH2AX, or BrdU (all green) and 53BP1 (red) and quantified by immunofluorescence microscopy. Cells containing more than
two 53BP1 foci per cell were considered as 53BP1 positive. (B) Cells were stained for P-ATM, and foci per cell were quantified by
immunofluorescence microscopy. (C) Cells were stained for γH2AX (green) and nuclear DNA was labeled with DAPI (blue). Micronuclei
formation was identified by immunofluorescence microscopy–based analysis of DAPI staining. At least three independent experiments
were analyzed. *P < .05. **P < .01. Shown are means ± SD.
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Quantitative analysis of BrdU incorporation revealed that cellular
proliferation of A549 cells was reduced by REV3 depletion to 21%
compared with 37% and 38% in mock and scrambled controls, re-
spectively (Figure 3, see also Figure 2A). Inhibition of REV3 expres-
sion reduced the proliferation of p53-proficient HCT116 cells to
25% and that of p53-deficient HCT116 cells, to a lesser extent, to
33% compared with 41% and 45% in their corresponding scram-
bled controls, respectively (Figure 3). Similarly, REV3 depletion also
reduced the proliferation of MCF-7 breast cancer cells to 9.2% com-
pared with 17% and 19% in mock and scrambled controls, respec-
tively (Figure W4). In contrast, the percentage of replicating cells in
the control cell line AD293 and the primary cell culture SDM104
was not diminished by the inhibition of REV3 expression (Figure 3).
Thus, REV3 depletion suppresses cellular proliferation of the analyzed
cancer cells, whereas proliferation of control cells is not affected.
REV3 Depletion Activates the DNA Damage Response
Pathway in Cancer Cells
We investigated whether the observed accumulation of persistent
DSBs in cancer cells results in the activation of the canonical ATM-
kinase–mediated DDR pathway, which is induced by DSBs (re-
viewed in d’Adda di Fagagna [24]). As described here, the number
of phospho-ATM foci per cell increased after the inhibition of REV3
expression compared with mock and scrambled controls in A549 and
p53-proficient and -deficient HCT116 cells, whereas no significant
increase occurred in AD293 control cells (Figure 2, A and B). In
A549 cells, REV3 depletion resulted in increased phosphorylation
of the checkpoint kinase Chk2 (P-Chk2) and the accumulation of
p53 and the senescence mediator p21 (Figure 4A), which was also
observed in MCF-7 breast cancer cells but not in the normal meso-
thelial primary culture SDM104 (Figure W5). In p53-proficient
HCT116 cancer cells, inhibition of REV3 expression also resulted
in an accumulation of p21, which was absent in the p53-deficient
isogenic cell line (Figure 4A). Thus, in the analyzed p53-proficient
cancer cells, inhibition of REV3 expression results in the activation
of the canonical ATM-dependent DDR pathway.
REV3 Depletion Induces a G1 Arrest in p53-Proficient
Cancer Cells
We tested whether the activation of the DDR pathway and the
reduction in BrdU incorporation due to REV3 depletion change
the cell cycle distribution of cancer cells. Depletion of the S phase
after REV3 depletion, as mentioned here, was accompanied by a sig-
nificant increase in the fraction of A549 cells in the G1 phase of the
Figure 3. REV3 depletion changes cell cycle distribution of cancer cell lines. Cells were mock treated or transduced with lentiviral-based
particles containing either shSCR or shREV3 and/or lentiviral-based particles containing shP53. After 1 week, cell cycle distribution was
measured by BrdU/propidium iodide staining and subsequent FACS analysis. The averages of three independent experiments are given
for A549, A549 shP53, p53-proficient HCT116, and p53-deficient HCT116 cells, whereas representative experiments are shown for
SDM104 and AD293 cells. *P < .05. **P < .01. Shown are means ± SD.
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cell cycle to 62% compared with 53% and 51% in the mock and
scrambled controls, respectively (Figure 3). Similarly, the fraction
of p53-proficient HCT116 cells in the G1 phase increased to 38%
after inhibition of REV3 expression compared with 26% in scrambled
control, respectively (Figure 3). In the control cell line AD293 and
the primary cell culture SDM104, neither the fraction of cells in the
S phase was decreased nor was the fraction of cells in the G1 phase
increased after inhibition of REV3 expression compared with mock
and scrambled controls (Figure 3). A small but significant increase
in the fraction of cells in the G2 phase was observed in p53-proficient
HCT116 cells after REV3 depletion (23%) compared with mock
(17%) and scrambled controls (19%). In addition, protein levels of
cyclin E, which accumulate during the G1 phase and are required
for the transition from the G1 phase to the S phase, increased after
inhibition of REV3 expression in p53-proficient but not in p53-
deficient HCT116 cancer cells (Figure 4A). Thus, inhibition of
REV3 expression in the investigated p53-proficient cancer cell lines
induces a G1 arrest, respectively, S-phase depletion, whereas the cell
cycle distribution of the investigated control cell line and the primary
mesothelial culture was not affected.
Inhibition of REV3 Expression Induces Senescence in
p53-Proficient Cancer Cells
Although inhibition of REV3 expression slightly increased the frac-
tion of sub-G1 cells in p53-proficient A549 and HCT116 cells, no
significant induction of apoptosis as indicated by an increased fraction
of sub-G1 cells (Figure 3) or poly(ADP-ribose) polymerase (PARP)
cleavage (Figure 4A) was observed in the remaining control and cancer
cell lines tested in this study.
Because senescence can be induced by persistent DNA damage
[31], we investigated whether cells are senescent after REV3 deple-
tion. Induction of senescence cannot be identified by a single marker
but is associated with a variety of distinct cellular and molecular
changes (reviewed in Collado and Serrano [34]). Microscopic analysis
after crystal violet staining revealed that the morphology of control
AD293 cells was not changed 7 days after inhibition of REV3 ex-
pression compared with mock and scrambled controls (Figure W6).
In the p53-proficient cancer cell lines included in this study, most
colonies were smaller after REV3 depletion, and the cells of these
colonies displayed morphologic changes that are associated with se-
nescence, namely, increased cell size and flattened shape, whereas
cell morphology was not affected in mock and scrambled controls
(Figure W6). SA-β-galactosidase staining revealed increased SA-β-
galactosidase activity in IL45, A549, and HCT116 p53-proficient
cells after inhibition of REV3 expression (Figure W6 and Table 1).
No increase in SA-β-galactosidase staining after inhibition of REV3
expression was detectable in the control cells AD293 or in the p53-
deficient MDA-MB-231 and HCT116 cancer cell lines. As men-
tioned previously, G1 arrest, respectively, S-phase depletion and p21
accumulation were observed in A549 and p53-proficient HCT116
cells after REV3 depletion (Figures 3 and 4A).
An increase in persistent DNA damage indicated by residual 53BP1/
γH2AX foci is associated in human foreskin fibroblasts with a senescence-
associated secretory phenotype including cytokine secretion such as
IL-6 [31]. Twelve days after transduction, IL-6 secretion was increased
in A549 cell after inhibition of REV3 expression compared with mock
and scrambled controls (Figure 4B). In contrast, REV3 depletion in p53-
deficient HCT116 cells did not result in a G1 accumulation nor did
it increase p21 levels or increase SA-β-galactosidase staining (Figures 3,
4A, and W6 and Table 1). Similarly, G1 accumulation and SA-β-
galactosidase staining were abolished in A549 by p53 inhibition (Fig-
ure 3 and Table 1). Thus, among the analyzed cancer cell lines, REV3
depletion per se induces senescence in p53-proficient cancer cells only.
REV3 Depletion Induces a G2 /M Arrest and Aneuploidy in
p53-Deficient Cancer Cells
No G1 arrest was detectable in p53-deficient HCT116 cell after
inhibition of REV3 expression (Figure 3). Instead, REV3 depletion
Figure 4. REV3 depletion induces DDR pathway in cancer cells.
Cells were cisplatin or mock treated or transduced with lentiviral-
based particles containing either shSCR or shREV3. (A) After 1 week,
whole-cell lysates were analyzed by Western analysis. (B) After
24 hours, IL-6 secretion in serum-free DMEM was assessed by
ELISA, normalized to the cell number and reported as fold increase
compared with mock-treated control. The averages of at least three
independent experiments are given. Shown are means ± SD.
Table 1. Induction of Senescence after REV3 Inhibition Is Dependent on p53 Level.
p53 Cell Line Mock shSCR shREV3 t test shSCR/shREV3
+ IL45 2.3 ± 0.7 2.8 ± 1.0 44.2 ± 4.0 *
+ A549 5.8 ± 0.7 6.0 ± 1.4 16.1 ± 2.3 *
− A549 shP53 1.0 ± 0.3 0.9 ± 0.3 0.9 ± 0.3 NS
− MDA-MB-231 0 0 0 N/A
+ AD293 (normal) 0 0 0 N/A
Three independent experiments were analyzed for all cell lines. Shown are means (%) of senescent
cells ± SEM.
N/A indicates not applicable; NS, not significant.
*P < .01%.
966 REV3 Depletion Per Se Reduces Cancer Cell Growth Knobel et al. Neoplasia Vol. 13, No. 10, 2011
in the p53-deficient HCT116 cell line significantly increased the
fraction of cells in the G2/M phase to 26% compared with 17%
and 18% in the mock and scrambled controls, respectively (Figure 3).
In addition, inhibition of REV3 expression also increased the frac-
tion of aneuploid cells, which did not incorporate BrdU (AN, aneu-
ploid nondividing) to 7% compared with 3% and 4% in the mock
and scrambled controls (Figure 3). The fraction of aneuploid cells,
which were still incorporating BrdU (AD, aneuploid dividing), was
not increased after REV3 depletion in p53-deficient HCT116 cells
compared with mock and scrambled controls (Figure 3). Thus, inhi-
bition of REV3 expression in the investigated p53-deficient cancer
cells results in the accumulation of G2/M arrested and AN cells.
In an effort to provide proof-of-principle, we inhibited p53 expres-
sion in p53-proficient A549 cancer cells (Figure W1C ). Inhibition of
p53 expression in A549 cells resulted in a significant increase of the
cells in the G2 phase (22%) and in aneuploidy (total 14%) compared
with p53-proficient A549 cells (7.5% and 1.8%, respectively; Fig-
ure 3), which is in agreement with the dominant role of p53 in
the induction of the G1 arrest [35]. The dominant role of p53 in
protection from aneuploidy is highlighted by the finding that addi-
tional inhibition of REV3 expression in combination with p53 inhi-
bition did not further increase aneuploidy in A549 cancer cells.
Discussion
During our study on the involvement of REV3 in chemotherapy re-
sponse, we found that lentiviral-based inhibition of REV3 expression
was as efficient in the analyzed cancer cell lines as in the primary meso-
thelial culture and the control cell lines, but surprisingly, colony forma-
tion was reduced in the cancer cell lines only. Therefore, we conclude
that reduction in colony formation does not simply mirror the degree
of REV3 expression inhibition relative to the scrambled control.
We found that colony formation was not significantly reduced in
the control cell lines AD293 and LP9-hTERT and the primary meso-
thelial culture SDM104 and after inhibition of REV3 expression.
This is consistent with previous studies where no deficiency in cell
growth/survival was mentioned after antisense-based inhibition of
REV3 expression in human nontumor cell lines [17,36]. In contrast,
it was shown by different groups that REV3 knockout reduced cell
growth of MEFs [21,37]. Thus, additional studies will be necessary
to clarify how normal cells adapt their DDR to tolerate the loss of
REV3 function. At this point, it is worth mentioning that investiga-
tions of cancer-specific pathways are usually performed using so-
called normal cells as control. However, normal cells have a limited
life span [38], which also applies to the primary mesothelial culture
SDM104. In contrast, the control cell lines AD293 and LP9-hTERT
are virally transformed or immortalized by transfection with human
telomerase, respectively, to achieve unlimited proliferation in cell cul-
ture. Thus, AD293 and LP9-hTERT might not fully represent nor-
mal cells, although they have been widely used as normal controls
[39,40] and their response to REV3 depletion was consistent with
the reaction of the primary mesothelial cell culture SDM104.
Studies have shown controversial results on the effect of REV3
depletion on cancer cell growth. On one hand, no deficiency in
cell growth/survival was mentioned after si/shRNA–based inhibi-
tion of REV3 expression in HCT116, U2OS, and HeLa cancer cells
[10,14,41]. Conversely, it was shown that knockout of REV3 re-
sulted in a pronounced growth retardation in Burkitt lymphoma cells
[42]. We found that inhibition of REV3 expression per se reduced
colony formation in lung, breast, mesothelioma, and colon tumor
cell lines. There are two possible explanations for these apparently
controversial observations on the effects of REV3 depletion in cancer
cells. First, the absence of cell growth inhibition in stable cancer cell
lines depleted of REV3 might be due to the genetic modifications
acquired during clonal selection, namely, rewiring of cell cycle check-
point pathways [43]. Thus, it would be interesting to identify if the
clones isolated in the studies mentioned acquired genetic modifi-
cations compared with their parental cell lines. Second, when in-
vestigated, it was found that inhibition of REV3 expression per se
increased DNA damage levels in cancer cells even when no effect
on cell growth/survival was mentioned [10,14,42]. Thus, it is pos-
sible that the DNA damage level necessary for DDR activation is
different in the tested cell lines, explaining the presence or absence
of growth arrest (reviewed in Al-Ejeh et al. [44]).
The second possibility is illustrated by the fact that only inhibition
of REV3 expression by high-titer transduction resulted in a reduction
of colony formation in MMR-deficient HCT116 cells, although REV3
expression was not further reduced. It was shown before that activa-
tion of the DDR is impaired in MMR-deficient HCT116 cells [45].
Thus, a higher level of cellular stress in form of additional DSBs due
to more viral integration events after high-titer transduction might
be required in HCT116 cells for the induction of a DDR resulting
in the reduced colony formation after inhibition of REV3 expression.
In addition, the p53 status influences cell fate after REV3 deple-
tion. The p53 status did not affect the accumulation of persistent
DSBs indicated by P-ATM foci after inhibition of REV3 expression
in HCT116 cells. Similarly, a recent study showed that DNA dam-
age accumulation after prolonged activation of the mitotic check-
point is also independent of the p53 status [46]. Thus, p53 does
not protect cancer cells from damage accumulation due to REV3 de-
pletion, although the subsequent cellular outcome, as discussed be-
low, is dependent on the p53 status.
Previously, accumulation of H2AX phosphorylation in U2OS hu-
man osteosarcoma cells was observed after REV3 depletion [10]. Mi-
croscopic analysis revealed that inhibition of REV3 expression in
cancer cells resulted in the accumulation of persistent DNA damage
foci, which was also observed after exposure to high-dose ionizing
radiation [31], suggesting the accumulation of irreparable DSBs.
Similarly, the accumulation of large 53BP1 foci was also observed
after the induction of mild replication stress or the genetic ablation
of the BLM helicase [47]. Interestingly, a very recent publication
showed that large 53BP1 foci mark sites of replication stress, which
is passed onto daughter cells [48], giving rise to the possibility that
the large 53BP1 foci detected after REV3 depletion mark sites of
incomplete DNA synthesis rather than DSBs due to replication
fork breakdown.
Cellular senescence limits the proliferation of damaged cells that
are at risk for neoplastic transformation (reviewed in Collado and
Serrano [34]). Our data indicate that, at least in p53-proficient can-
cer cells, senescence induction after REV3 depletion might prevent
further transformation of cancer cells by establishing an essentially
irreversible growth arrest. It is also proposed that the senescence-
associated secretory phenotype, which we observed after inhibition
of REV3 expression indicated by increased IL-6 secretion, might
stimulate the immune system to clear senescent cells (reviewed in
Collado and Serrano [34]). However, if senescent cells are not cleared
by the immune system, they remain in a “dormant” state represent-
ing a dangerous potential for tumor relapse.
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A recent study showed that nocodazole (a microtubule polymeri-
zation inhibitor) treatment of p53-deficient HCT116 cells leads to
prolonged mitosis and subsequent return of the mitotically arrested
cells to interphase without cell division resulted in aneuploidy [46], a
process known as mitotic slippage. We observed that REV3 depletion
in the p53-deficient HCT116 cell line and in combination with p53
inhibition in the A549 cell line leads to an accumulation of G2/M
arrested cells and an increase in the frequency of aneuploid cells,
which was also described in p53-deficient REV3-null MEFs [37].
On the basis of these results, we propose a model (Figure 5) in
which inhibition of REV3 expression can be tolerated in normal cells
but results in the accumulation of persistent DNA damage in cancer
cells harboring cancer-specific alterations. Accumulation of persistent
DNA damage leads in p53-proficient cancer cells to senescence,
whereas REV3 depletion in p53-deficient cells results in growth in-
hibition and a G2/M arrest. A small fraction of the p53-deficient
cancer cells can overcome the G2/M arrest, which results in mitotic
slippage and aneuploidy.
The concept of “synthetic lethality,” where defects in two path-
ways alone can be tolerated but become lethal when combined,
has been originally described in Drosophila and yeast genetic studies
[49,50]. This concept has been extended by the idea of “synthetic
sickness,” whereas the combined loss/mutation of function of two
genes does not kill cells but significantly impairs cellular fitness [51].
A recent study showed that inhibiting specific DNA repair poly-
merases induces synthetic sickness/lethality specifically in MMR-
deficient cells [52]. In analogy, we found that REV3 depletion induces
synthetic sickness/lethality in the investigated cancer cells. It will be
interesting to identify the underlying cancer-specific alteration(s),
which render the investigated cancer cell lines prone to growth inhibi-
tion due to REV3 depletion. In this context it was shown that DNA
repair and/or cell cycle checkpoint mechanisms are frequently abro-
gated in cancer cells [53], and the concentration of endogenous
DNA damage is higher in human tumoral tissue compared with the
corresponding adjacent normal tissue (reviewed in Croteau and Bohr
[54]). Therefore, differences in repair capacity or DNA damage levels
between normal and cancer cells might be the underlying cause for
the observed increased sensitivity of cancer cells to REV3 depletion.
Alternatively, replication stress due to the activation of oncogenes
might sensitize cancer cells to the inhibition of REV3 expression. A
recent study showed that overexpression of Sch9, the S. cerevisiae
homolog of the mammalian proto-oncogenes Akt and S6, increases
superoxide-dependent DNA damage, which subsequently leads to
the REV3-dependent formation of point mutations to avoid gross
chromosomal rearrangements [55]. However, we cannot exclude that
the specific genetic or epigenetic alterations underlying the observed
synthetic sickness/lethality after REV3 depletion might differ between
the tested cancer cell lines. Indeed, a recent study showed that REV3
deletion in a S. cerevisiae strain containing a particular additional chro-
mosome resulted in decreased colony formation [56].
Cancer cells can be addicted not only to oncogenes but also to
nononcogenes (reviewed in Luo et al. [57]). “Nononcogene addic-
tion” genes are also required for maintenance of the tumorigenic state
but are in contrast to oncogenes not functionally altered or mutated.
The most prominent example of a “nononcogene addiction” gene
is PARP, which is essential in BRCA-deficient breast cancer cells.
Thus, based on the results of our study, we propose that REV3
functions as a “nononcogene addiction” gene, whose depletion in-
duces synthetic sickness/lethality specifically in the investigated can-
cer cell lines. Along those lines, we are performing a genome-wide
screen to identify essential molecular pathways in cancer cells whose
inhibition will further enhance cell killing in combination with
REV3 inhibition.
It will be interesting to determine whether 1) DNA damage tol-
erance by REV3-dependent TLS, 2) REV3-dependent DNA repair,
or 3) a yet-to-be-identified function of REV3 is essential for cancer
Figure 5. Model: REV3 depletion induces persistent DNA damage specifically in cancer cells, which subsequently results in the induc-
tion of senescence in p53-proficient cancer cells and G2/M arrest in p53-deficient cancer cells. See text for details.
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cell growth. Indeed, the size of mammalian REV3 is approximately
double the size of the yeast homolog, giving rise to the possibility
that the nonconserved region of REV3 harbors a yet-to-be-identified
functional domain, necessary only in higher organisms.
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Supplemental Materials and Methods
Cell Lines
The human MPM cell line ZL55 and the primary cell culture
SDM104 were generated in our laboratory [25,30]. The rat MPM
cell line IL45 was generated elsewhere (Craighead et al., Am J Pathol.
1987;129:448–462). The breast cancer cell lines MDA-MB-231 and
MCF-7, the adenocarcinoma Calu-3, the squamous non–small cell
lung cancer cell line A549 and the HEK 293T were purchased from
American Type Culture Corporation (Manassas, VA). The AD293 cell
line, a HEK 293 derivative with improved cell adherence, was pur-
chased from Stratagene (La Jolla, CA). The colorectal carcinoma cell
lines HCT116 40.16 (p53+/+) and HCT116 379.2 (p53−/−) were
kindly provided by Dr Bert Vogelstein ( Johns Hopkins University,
Baltimore, MD).
Reagents
When indicated, 20 μM cisplatin (Ebewe Pharma, Cham,
Switzerland) was added for 24 hours.
To clone the short hairpin constructs into the plasmid pSuperior.puro,
the following DNA oligonucleotides were ordered from Microsynth:
shREV3-4:
5′-GATCCCCCAAAGATGCTGCTACATTATTCAAGA-
GATAATGTAGCAGCATCTTTGTTTTTA-3′
5′-AGCTTAAAAACAAAGATGCTGCTACATTATCTCTT-
GAATAATGTAGCAGCATCTTTGGGG-3′
shREV3-5:
5′-GATCCCCGATATTCCATCTGTTACAATTCAAGA-
GATTGTAACAGATGGAATATCTTTTTA-3′
5′-AGCTTAAAAAGATATTCCATCTGTTACAATCTCTT-
GAATTGTAACAGATGGAATATCGGG-3′
shREV3-6:
5′-GATCCCCTAGTCAGACTTTTCAGCCTTTCAAGA-
GAAGGCTGAAAAGTCTGACTATTTTTA-3′
5′-AGCTTAAAAATAGTCAGACTTTTCAGCCTTCTCTT-
GAAAGGCTGAAAAGTCTGACTAGGG-3′
shSCR:
5′-GATCCCCATTCTAGGTGAAAGCTAATTTCAAGA-
GATAAGATCCACTTTCGATTATTTTTA-3′
5′-AGCTTAAAAATAATCGAAAGTGGATCTTATCTCTT-
GAAATTAGCTTTCACCTAGAATGGG-3′
shP53:
5′-GATCCCCGACTCCAGTGGTAATCTACTTCAAGA-
GAGTAGATTACCACTGGAGTCTTTTTA-3′
5′-AGCTTAAAAAGACTCCAGTGGTAATCTACTCT-
CTTGAAGTAGATTACCACTGGAGTCGGG-3′
To quantitatively measure the expression of REV3 mRNA by
real-time PCR, the following DNA oligonucleotides were ordered
from Microsynth:
REV3:
Forward 5′-TGAGTTCAAATTTGGCTGTACCT-3′
REV3:
Reverse 5′-TCTAGTCTTCAAAATTTCTTCAAGCA-3′
Histone H3:
Forward 5′-TAAAGCACCCAGGAAACAACTGGC-3′
Reverse 5′-ACCAGGCCTGTAACGATGAGGTTT-3′
P53:
Forward 5′-GCTTTGAGGTTCGTGTTTGTGCCT-3′
Reverse 5′-GCCCACGGATCTTAAGGGTGAAAT-3′
For Western analysis, the following primary antibodies were diluted
at 1:1000: PARP (no. 9542; Cell Signaling, Beverly, MA), P-Chk2
(no. AF1626; R&D Systems), p53 (no. 9282; Cell Signaling), p21
(no. sc-756; Santa Cruz, Santa Cruz, CA), cyclin E (no. sc-247; Santa
Cruz), and MAD2B/Rev7 (no. 612266; BD Biosciences). The pri-
mary antibody β-actin (no. 691001; MP Biomedicals, Solon, OH)
was incubated 1:10,000 for 1 hour at room temperature. The secondary
polyclonal antibodies coupled to horseradish peroxidase were diluted
at 1:10,000.
For immunofluorescence microscopy, the following primary anti-
bodies were used: P-ATM 1:1000 (no. sc-4526; Cell Signaling),
γH2AX 1:1000 (no. 05-636; Upstate Biotechnology, Lake Placid,
NY), 53BP1 1:500 (no. 4937; Cell Signaling), and BrdU 1:1000
(no. 555627; BD Biosciences).
Vector Production and Transduction
Short hairpin REV3-4 and scrambled (shSCR) oligos were ligated
into pSuperior.puro as described by the manufacturer (OligoEngine,
Seattle, WA). The shRNA and H1 promoter fragments were subse-
quently ligated into the constitutive expressing lentiviral vector
pLVTHM (Addgene, Cambridge, MA). Replication-deficient lentiviral
particles were produced and titrated as described previously [26,27].
Cells were seeded in six-well plates (colony formation, immuno-
fluorescence, and SA-β-galactosidase assay: 500 cells/well [SDM104:
1000 cells/well]; FACS andWestern analysis: 2500 cells/well [SDM104:
5000 cells/well]; real-time PCR and ELISA: 5000 cells/well) in 2 ml
of medium. After 6 hours, the medium was removed, and lentivirus
suspension was added for 30 minutes in 300 μl (immunofluorescence,
FACS, and real-time PCR: MOI = 100; Western analysis and colony
formation: MOI = 170). All transductions of HCT116 and the
corresponding control AD293 cells were performed with an MOI of
800 and were incubated for 1 hour. Subsequently, medium was added
to final volume of 1.5 ml. For mock treatment, 0.5-μm filtered condi-
tionedmedium from a HEK 293T culture was added. After 7 days, cells
were further processed for distinct experiment as described below except
for colony formation, which were incubated longer as described below.
Quantitative Real-time PCR
Real-time PCR cycle conditions were as follows: one cycle of 95°C
for 10 minutes, 40 cycles of 95°C for 15 seconds and 60°C for 1 min-
ute, and one cycle of 95°C for 15 seconds and from 60°C slowly
elevating to 95°C for several minutes for dissociation curve analysis.
Histone H3 expression was used to standardize the total amount of
complementary DNA, and the specificity of the PCR was confirmed
by analysis of the melting curve.
Immunofluorescence Microscopy
Immunofluorescence microscopy was performed essentially as de-
scribed before [28]. In detail, for BrdU staining, cells were incubated
with 10 μM BrdU for 1 hour. Fixation and permeabilization were
done with 100% methanol at −20°C and acetone-methanol (50:50)
at −20°C for 20 minutes at room temperature, respectively. Cells
were washed 2 × 5 minutes with PBS. For BrdU staining, cells were
denatured with 2 M HCl for 30 minutes at room temperature and
subsequently washed 3 × 5 minutes with PBS. PBS containing 1%
fetal bovine serum and 10% bovine serum albumin was used as block-
ing solution for 1 hour at room temperature. First, antibodies were
diluted in blocking solution and incubated at 4°C overnight. The
following antibodies were used: P-ATM 1:1000 (no. sc-4526; Cell
Signaling), γH2AX 1:1000 (no. 05-636; Upstate), 53BP1 1:500
(no. 4937; Cell Signaling), and BrdU 1:1000 (no. 555627; BD Biosci-
ences). Cells were washed 2 × 5 minutes in PBS. Secondary anti-
bodies were diluted at 1:10,000 in blocking solution and incubated
at 37°C for 1 hour. Cells were washed 2 × 5 minutes with PBS and
mounted with ProLong Gold Antifade reagent with 4′,6-diamidino-
2-phenylindole (no. P36931; Invitrogen). Images were acquired with
an inverse wide-field fluorescence microscope (DM IRBE; Leica,
Bensheim, Germany) equipped with a black and white camera
(ORKA-ER; Hamamatsu, Hamamatsu, Japan). Image processing with
Photoshop (Adobe Systems) was applied to whole images only. Images
used for comparison between different transductions were acquired
with the same instrument settings and exposure time and were pro-
cessed equally.
Flow Cytometry
Cell cycle distributionwas assessed by using a FACSCalibur (FACScan,
488-nm excitation laser; BD Biosciences) and WinMDI software.
Western Analysis
Cells were lysed for 30 minutes on ice in 1× RIPA buffer (Upstate)
containing 2 × HALT protease and phosphatase inhibitor cocktail
(Thermo Scientific, Rockford, IL). Cell extracts were denatured at
95°C for 5 minutes and homogenized by successive passing through
a 30-gauge syringe needle, and protein concentrations were deter-
mined using bicinchoninic acid protein assay (Pierce, Rockford, IL).
Figure W1. Efficient inhibition of REV3 expression after transduction with lentiviral-based particles. Cells were mock treated or trans-
duced with lentiviral-based particles containing either shSCR or shREV3 and/or lentiviral-based particles containing shP53. REV3 (A and
B) and P53 (C) expression were analyzed by quantitative real-time PCR 7 days after transduction. The averages of at least three inde-
pendent experiments are given for A549, IL45, p53-proficient HCT116, p53-deficient HCT116, SDM104, and AD293 cells, whereas rep-
resentative experiments are shown for Calu-3, MDA-MB-231, MCF-7, ZL55, and LP9-hTERT cells. Rev3 expression levels were
normalized to histone H3 expression levels. All Rev3 and p53 expression levels are reported as percentage compared with mock-treated
A549 (A and C) or p53-proficient HCT116 (B) cells, which was set as 100%. Shown are means ± SD.
Figure W2. REV3 silencing specifically reduces colony formation of
cancer cells. Cancer cells A549, IL45, MDA-MB-231, p53-proficient
HCT116, p53-deficient HCT116, and normal cells AD293 were either
mock treated or transduced with lentiviral-based particles contain-
ing shSCR or shREV3. Crystal violet staining was performed once
colonies were visible by eye. (A) MOI = 170. (B) MOI = 800. Experi-
ments were made in duplicate wells. See also related Figure 1.
Figure W3. Reduced colony formation after REV3 silencing is not
due to an siRNA off-target effect. IL45 mesothelioma cancer cells
and AD293 normal cells were either mock treated or transfected
with three different plasmids containing shRNA constructs target-
ing Rev3. Colonies were stained with crystal violet and counted
after 2 weeks. Experiment was made in duplicate wells.
Figure W4. REV3 depletion induces persistent DNA damage in MCF-7 breast cancer cells. Cells were mock treated or transduced with
lentiviral-based particles containing either shSCR or shREV3 and analyzed after 1 week. Cells were stained for γH2AX or BrdU and 53BP1
and quantified by immunofluorescence microscopy. Cells containing more than two 53BP1 foci per cell were considered as positive for
53BP1. At least two independent experiments were analyzed. *P < .05. **P < .01. Shown are means ± SD.
Figure W5. REV3 depletion induces DDR pathway specifically in
cancer cells. Cells were mock treated or transduced with lentiviral-
based particles containing either shSCR or shREV3. After 1 week,
whole-cell lysates were analyzed by Western analysis.
Figure W6. REV3 silencing induces senescence in p53-proficient cancer cells. Cancer cells A549, IL45, MDA-MB-231, p53-proficient
HCT116, and p53-deficient HCT116 and normal cells AD293 were mock treated or transduced with either lentiviral-based particles con-
taining shSCR or shREV3. Crystal violet assay (upper lines) or SA-β-galactosidase assay (bottom lines) was performed after 7 days.
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4.1. Abstract 
REV3, the catalytic subunit of translesion polymerase zeta (polζ), is commonly 
associated with DNA damage bypass and repair. Despite sharing accessory subunits 
with replicative polymerase δ, very little is known about the role of polζ in DNA 
replication. We previously demonstrated that inhibition of REV3 expression induces 
persistent DNA damage and growth arrest in cancer cells. To reveal determinants of this 
sensitivity and obtain insights into the cellular function of REV3, we performed whole-
genome silencing screens aimed at identification of synthetic lethal interactions with 
REV3 in A549 lung cancer cells. The top confirmed hit was RRM1, the large subunit of 
ribonucleotide reductase (RNR), a critical enzyme of de novo nucleotide synthesis. 
Treatment with the RNR-inhibitor hydroxyurea (HU) synergistically increased the fraction 
of REV3-deficient cells containing single stranded DNA (ssDNA) as indicated by an 
increase in replication protein A (RPA). However, this increase was not accompanied by 
accumulation of the DNA damage marker γH2AX suggesting a role of REV3 in tolerance 
of replication stress (RS). Consistent with a role of REV3 in DNA replication, increased 
RPA staining was confined to S-phase cells. Additionally, we found genes related to RS 
to be significantly enriched among the top hits of the synthetic lethality screen further 
corroborating the importance of REV3 for replication under conditions of RS.  
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4.2. Introduction 
Integrity and fidelity of the genomic material is constantly compromised in various ways 
but cells possess multiple mechanisms to cope with it [1]. If DNA damage cannot be 
removed completely it can be tolerated in order to continue replication without formation 
of lethal intermediates. Translesion synthesis (TLS) is a key DNA damage tolerance 
pathway that allows bypass of different types of lesions. Dependent on the nature of the 
lesion and recruited enzymes, this process can result in faithful or error-prone, thus 
mutagenic, DNA replication (reviewed in [2]). 
Polymerase zeta (polζ), with its catalytic subunit REV3L (hereafter REV3), plays a 
unique role in TLS. Even though it can bypass various DNA lesions by itself [3], it is 
thought to be mainly involved in the extension from a nucleotide inserted opposite the 
lesion by other TLS polymerases (TLS pols). REV3 is therefore able to contribute to 
mutagenesis in two ways: by introducing mismatches or by extending from a mismatch 
introduced by another polymerase. Besides, in contrast to other TLS pols, REV3 
belongs to B-family and its knockout is embryonic lethal in mice [4, 5]. Despite the 
development of conditional knockout mice models, [6, 7] the molecular basis for this 
developmental significance still remains elusive. 
Apart from its function in TLS, polζ is known to play a role in homologous recombination 
[8], non-homologous end-joining [9] and inter- and intrastrand crosslink repair [10, 11]. 
Additionally, yeast polζ is able to replicate undamaged DNA [12] and shares accessory 
subunits with polymerase δ [13, 14] emphasizing its tight relationship with normal DNA 
replication. 
Inhibition of REV3 expression in human cells leads to accumulation of DNA double 
strand breaks (DSB), activation of DNA damage response (DDR) and reduced fraction of 
S-phase cells [15], which results in increased formation of anaphase bridges and 
chromosomal breaks/gaps, expression of common fragile sites (CFS), genomic 
instability [16] and ultimately cell cycle arrest or senescence [15].  
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Cancer cells harbor multiple mutations in their genome, many of which affect DDR and 
lead to genomic instability but can be tolerated because of the redundant function of 
some of the DNA repair pathways [1]. Targeting the genes that carry out the function of 
the gene disturbed by a mutation is an attractive approach to cancer therapy [17]. In a 
more general sense there are pathways, disruption of which by itself can be tolerated 
but become lethal when combined with cancer-specific mutations. This so-called 
principle of synthetic lethality demonstrated its applicability for targeted cancer therapy 
of BRCA2-deficient breast cancer by PARP-inhibitors not only at the bench [18, 19] but 
also at the bedside [20]. Recent publications follow this example by discovering 
synthetic lethality between MSH2 and DNA polymerase β (POLB), MLH1 and 
polymerase γ (POLG)[21] as well as Chk1 and polymerase λ (POLL)[22], confirming that 
synthetic lethality between DDR genes is a common phenomenon. 
Loss-of-function genetic screening is a powerful approach for novel target gene 
discovery that can be employed for detection of synthetic lethal gene interactions in 
cancer cells (reviewed in [23, 24]). RNA interference technology was successfully used 
to identify vulnerabilities of cancers driven by certain oncogenes [25]. We took 
advantage of the whole-genome siRNA library to explore in an unbiased manner 
synthetic lethality in REV3-deficient cancer cells in order to gain an insight into cellular 
function of REV3. 
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4.3. Materials and Methods 
Cell culture, plasmid transfections, gene expression analysis 
The non-small cell lung cancer (NSCLC) cell line A549 was authenticated by DNA 
fingerprinting of short tandem repeat loci (Microsynth, Switzerland). All cell lines were 
cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) high glucose (Sigma) 
supplemented with 2mM L-glutamine, 10% fetal calf serum (FCS) and 1% (w/v) 
penicillin/streptomycin. Cells were grown at 37°C in humidified atmosphere containing 
5% CO2. 
Stable cell lines used for the siRNA screening were generated by transfection of A549 
cells with either shSCR or shREV3-4 plasmids. Plasmid transfections were performed 
using LipofectamineTM 2000 (Invitrogen) according to the manufacturer’s instructions. 
Subsequent selection of resistant clones was performed with 1ug/ml puromycin. 
Gene expression was assessed by quantitative real-time PCR (rtPCR) as described 
previously [15]. 
Reagents 
For siRNA transfections we used DharmaFECT 1 (DF) transfection reagent and siRNA 
duplexes acquired from Dharmacon (Thermo Fisher Scientific, USA). In the screen and 
the follow-up experiments siGENOME non-targeting control pool#2 and the PLK1 
SMARTpool siRNA were used as negative and positive control, respectively. For flow 
cytometry and colony formation experiments, REV3 expression was silenced with ON-
TARGETplus SMART pool REV3L (siREV3) while ON-TARGETplus non-targeting pool 
(siNT) was used as a negative control. 
Hydroxyurea (HU) was acquired from Applichem, Germany. 
CellTiter-Blue® Cell Viability Assay reagent was purchased from Promega, USA. 
Oligonucleotides used for cloning and primers for rtPCR were ordered from Microsynth, 
Switzerland. 
Sequences of shREV3-4 and shSCR were disclosed previously [15]. 
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shRRM1 oligo sequence: 
5’-GATCCCCGCACAGAAATAGTGGAGTATTCAAGAGA-
TACTCCACTATTTCTGTGCTTTTTA-3’ 
5’-AGCTTAAAAAGCACAGAAATAGTGGAGTATCTCTTG-
AATACTCCACTATTTCTGTGCGGG-3’ 
The following primers were used for detection of RRM1 mRNA levels by qPCR: 
Forward 5’- CCTGGGAACCATCAAATGCAGCAA-3’ 
Reverse 5’- GGGCCAGGGAAGCCAAATTACAAA-3’ 
Vector cloning and transfection 
The short hairpin RRM1 oligo was annealed and ligated into pSuperior.puro as 
described by the manufacturer (OligoEngine,Seattle, WA). The shRNA and H1 promoter 
fragments were subsequently transferred into the constitutive expressing lentiviral vector 
pLVTHM (Addgene, Cambridge, MA). 
Replication-deficient lentiviral particles were produced and titrated as described 
previously [15] 
 
Lentiviral transduction and colony forming assay 
Lentiviral transduction and subsequent colony forming assay were performed as 
described previously [15]. 
For siRNA transfection, lentiviral transduction and subsequent colony formation, the 
procedure was as follows. 25000 cells per well were seeded in 6 well plates and were 
transfected 24 hours later with 50nM siRNA (targeting REV3 or non-targeting control) 
using 2.5µl of DF per well. 24 hours after transfection the medium was exchanged. 
Another 24 hours later, cells were trypsinized, counted and 500 cells per well were 
seeded in 6 well plates for the subsequent shRRM1 lentiviral transduction and colony 
formation assay, which was performed as described previously [15]. 
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Genome-wide siRNA screening and follow –up experiments 
The equipment used for the screening was described previously [26]. One day before 
the transfection, either S1C6 or R1B6 cells (750 cells per well) was seeded in 272 
transparent flat-bottom 96 well plates (TPP, Switzerland) in 80µl of medium. Next day 
10µl of DF diluted 1:250 in DMEM was added to the siRNA library plates prepared in 
advance by dilution of the siGENOME stock library and addition of the negative and 
positive control siRNA. The resulting 20µl transfection mixes were transferred to the cell 
culture plates, resulting in a final siRNA concentration of 25nM. After transfection, cells 
were grown for 5 days before 20µl per well of CellTiter-Blue Reagent was added. The 
plates were subsequently incubated for 4 hours at 37°C and 50µl of 3% SDS solution 
was added to stop the reaction. Fluorescence of each well was determined with 
excitation/emission of 540/590nm. 
For the deconvolution of the siRNA pools, the experimental conditions were identical, i.e. 
25nM of siRNA and 0.04µl of DF per well in 96 well plates. For double transfections 
25nM of each siRNA and 0.08µl of DF were used. 
 
Data and statistical analysis 
For reading, pre-processing and normalization of the raw fluorescence data the 
cellHTS2 Bioconductor package was employed [27]. The data were per plate normalized 
to the negative control and log-transformed. To generate the differential viability list, 
genes were sorted by the absolute difference of the viability scores for two screened cell 
lines and Bayesian statistics for linear models in limma package [28] was used to 
calculate the P-value for each gene. For gene set enrichment analysis we employed 
ROMER from limma [29]. 
To assess statistical significance of treatment (siREV3, shREV3, shRRM1 and HU) 
effect interactions Analysis of Variance (ANOVA) was performed. 
For pairwise comparisons two-tailed Student’s t test was employed. 
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Flow cytometry 
For flow cytometry after 24 hours of HU treatment, 25000 cells per well were seeded in 6 
well plates and transfected as described above (50nM siRNA + 2.5µl DF). For flow 
cytometry after 72 hours of HU treatment, 5000 cells per well were seeded in 6 well 
plates and transfected with 20nM siRNA and 1µl of DF. 24 hours after transfection the 
medium was exchanged and another 24 hours later, cells were treated with 0.25µM of 
HU. After 24 or 72 hours, respectively, cells were labeled with 10 μM EdU for 60 min 
(according to the manufacturer’s instructions (C35002; Invitrogen)) harvested by 
trypsinization, and fixed for 20 min with ice-cold 70% Ethanol at room temperature. Cells 
were washed with 1% BSA/PBS, pH 7.4, permeabilized with 0.5% saponin/1% BSA/PBS 
for 10minutes , and stained in the fixation buffer with anti–γ-H2AX antibody (05-636, 
EMD Millipore) or anti-RPA32/RPA2 antibody (ab2175, Abcam) overnight at 4°C, 
followed by incubation with a secondary antibody (a31553, Invitrogen) for 30 min at 
room temperature. Subsequently, cells were treated with 20ug/ml RNase A and DNA 
was stained with 0.5 μg/ml propidium iodide (Sigma-Aldrich). Cell fluorescence was 
measured on an Attune flow cytometer (Applied Biosystems) and analyzed with the 
Attune cytometric software v1.2.5 (Applied Biosystems). 
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4.4. Results 
Characterization of cell lines used for the screening 
In order to define synthetic lethal gene interactions with REV3, we generated cell lines 
containing short hairpin targeting REV3 as well as control cell lines containing the vector 
with the scrambled short hairpin sequence. Translesion synthesis is a major pathway 
involved in bypass and repair of DNA crosslinks and it is known that reduction of REV3 
levels is associated with the increased sensitivity to DNA crosslinking agents [10, 
11].Thus we based selection of the cell lines used for the screening on their REV3 
expression levels and their cisplatin sensitivity as a functional readout. 
Compared to the parental cell line A549, the REV3 mRNA expression level in the control 
cell line S1C6 was identical whereas REV3 expression in the cell line R1B6 was 
decreased to 49% (Fig.1). The cisplatin sensitivity assessed by quantitation of cell 
viability 5 days after continuous drug treatment differed significantly for the two cell lines. 
The REV3 deficient cell line R1B6 was up to three times more sensitive than its 
proficient counterpart S1C6 (Fig.1) indicating that the decrease of REV3 mRNA 
expression is of functional relevance. 
 
Genome wide siRNA screening reveals a role of REV3 in tolerance of nucleotide 
deprivation 
First we optimized the general screening setup, i.e. number of seeded cells per well and 
incubation time after transfection, and established positive and negative controls. To find 
the most suitable conditions for the automated forward transfection of the selected cell 
lines we optimized siRNA and transfection reagent concentration to minimize toxicity of 
transfection and to maximize target gene knockdown assessed by rtPCR, reduction of 
enzymatic activity in a functional GAPDH knockdown assay and performance of positive 
control (data not shown). The optimized transfection conditions resulted in efficient gene 
knockdown and were also used for further experiments (Suppl.Fig.1). 
Whole genome silencing siRNA screens were carried out with cell viability as readout 
(Fig.2). In detail, R1B6 or S1C6 cells were seeded in 96 well plates and transfected with 
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the library containing pooled siRNA (4 siRNA per gene) targeting more than 20000 
human transcripts. Cell viability was assessed using CellTiter-Blue Cell Viability Assay 
and resulting values were normalized to non-targeting siRNA (siNT) control, log-
transformed and scored. The screens showed high correlation between replicates, i.e. 
Pearson correlation coefficient between replicates was 0.87 for S1C6 and 0.84 for R1B6 
(Suppl. Table 1). The positive (PLK1) and negative (non-targeting) controls performed 
well as evidenced by Z’ factors [30] generally exceeding 0.5.  
To identify genes whose silencing induced synthetic lethality specifically in REV3–
deficient cells, the gene list with the corresponding values of viability was sorted by the 
robust score of absolute difference in viability between S1C6 and R1B6 (Suppl. Table 2). 
To exclude low-confidence genes we applied a filter of P<0.05 (Suppl. Table 3). 
Validation of the screening results was performed using S1C6, R1B6 and the original 
lung cancer cells A549. For validation, we selected genes with the highest confidence 
scores (i.e. lowest p-values) and highest absolute value of the differential viability effect. 
First, we performed silencing of the selected genes by manual transfection with the 
pools from the library used for the screens (Suppl.Fig.2A). Positive control PLK1 had 
similar killing effect on the three cell lines with the residual viability in the range of 10-
15% indicating that the transfection efficiency was the same for the three cell lines. The 
REV3-deficient cell line R1B6 was in general more sensitive to gene silencing than the 
two control cell lines confirming the validity of the results obtained by the high throughput 
screen.  
We further deconvolved 15 selected genes by separately transfecting with the four 
individual siRNAs composing the pools. In total, 11 genes out of 15 had 2 or more 
siRNA with preferential killing of R1B6 when compared to S1C6 and A549 (Suppl. 
Fig.3). Silencing of RRM1, the large subunit of ribonucleotide reductase, showed the 
second strongest differential effect in the screen and a very robust profile in 
deconvolution process, i.e. all siRNA had more pronounced effect on REV3-deficient 
cells (Suppl. Fig.2B). Silencing of the small subunit of ribonucleotide reductase (RNR), 
RRM2, also scored in the top 2% (rank 292), suggesting that the inhibition of the 
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catalytic function of RNR is involved in the observed reduction of viability in a REV3-
deficient background rather than a subunit-specific effect. 
To assess whether alterations in nucleotide synthesis pathways in general are 
synergistic with REV3 silencing, we employed gene set enrichment analysis for linear 
models using rotation tests (ROMER) [29], which is particularly suitable for the analysis 
of experiments with a small number of replicates [31]. We tested a set of KEGG 
pathways related to nucleotide metabolism and found both purine and pyrimidine 
metabolisms as significantly enriched (Table 2).  
Since inhibition of RNR reduces concentration of deoxynucleotides and leads to 
induction of replication stress [32] we tested whether the reduction in viability upon 
silencing of REV3 in combination with RNR inhibition can be extended to the genes 
associated with the replication stress. To guarantee an unbiased analysis, we generated 
a gene set by search of the NCBI human gene database with the term 
“replication+stress” (Suppl. Table 4). The “replication+stress” gene set was significantly 
enriched among the genes that had high differential score in the screen (Table 2). 
REV3 is essential to tolerate the inhibition of ribonucleotide reductase in cancer 
cells  
To exclude a clonal effect, we investigated whether we could reproduce in the parental 
cell line A549 the reduction in colony formation observed in REV3-depleted cells after 
RRM1 silencing . For RRM1 silencing, we produced lentiviral particles carrying short 
hairpin targeting RRM1 mRNA (LV-shRRM1). Down-regulation of REV3 expression in 
combination with subsequent RRM1 silencing synergistically reduced cell growth of 
parental A549 cells (Fig.3A). 
We hypothesized that the reduction of cancer cell growth in a REV3-deficient 
background is dependent on the catalytic function of RNR. In this case a drug targeting 
the enzymatic activity of RNR should mimic the reduction of colony formation after 
RRM1 silencing in a REV3-deficient background. Hydroxyurea (HU) is a drug used in the 
treatment of myeloproliferative disorders that inhibits RNR by scavenging tyrosyl free 
radicals of the small subunit required for reduction of ribonucleotides to 
deoxyribonucleotides. We performed colony formation assays after siRNA transfection 
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(with siNT or siREV3) followed by continuous HU treatment (Fig.3 B,C). While the colony 
formation was reduced by REV3 silencing alone, its combination with the HU treatment 
caused more pronounced decrease in cell viability than expected by mere superposition 
of the individual effects, the interaction effect (HU:iREV3) being statistically significant. 
Down-regulation of REV3 expression enhances replication stress induced by 
inhibition of ribonucleotide reductase 
The synergy of REV3-depletion and inhibition the catalytic function of RNR taken 
together with the enrichment of other genes associated with replication stress in the 
screen results led us to a hypothesis that REV3 might be involved in the tolerance of 
nucleotide deprivation-induced replication stress in cancer cells. To test this hypothesis 
we performed a series of flow cytometry experiments to investigate changes of EdU 
incorporation,and determine the fraction of γH2AX and RPA positive cells as well as the 
cell cycle distribution after REV3 silencing for 48 hours and HU treatment for 24 hours. 
HU treatment and REV3 depletion both significantly reduced the median EdU 
incorporation (Fig.4). EdU incorporation was significantly decreased after siREV3 
transfection and subsequent HU treatment compared to HU-treated cells previously 
transfected with the non-targeting control siRNA (siNT). 
Replication protein A (RPA) is a protein that binds single-stranded DNA (ssDNA), 
detection of chromatin-bound RPA2 can be used to track the increase in cellular ssDNA 
[33], a characteristic feature of replication stress [34]. Down-regulation of REV3 
expression did not change significantly the fraction of RPA-positive cells, compared to 
control transfection. HU treatment significantly increased the number of RPA-positive 
cells, which was further increased by the control transfection and even more after REV3 
silencing. We found the synergy between HU treatment and REV3 silencing to be 
significant evidenced by the low p-value for the interaction effect HU:iREV3.  
An increased RPA signal can not only be due to enhanced replication stress but also 
due to increased end-resection during the process of DSB repair. To differentiate 
between these two causes we investigated whether observed increase in RPA staining 
is accompanied by changes in DNA damage induction. H2AX phosphorylation is a 
widely associated with various types of DNA damage including DSBs [35]. We took 
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advantage of that to rule out the induction of DSBs as the cause for RPA induction in our 
system. HU treatment was associated with a moderate but significant increase of the 
fraction of γH2AX positive cells. Unexpectedly, preceding siNT transfection increased 
γH2AX induction by HU treatment, while siREV3 transfection did not lead to a significant 
change compared to HU treated cells. Interestingly, comparison of siNT+HU and 
siREV3+HU revealed a significant decrease of H2AX phosphorylation by REV3 silencing 
upon HU treatment.  
In summary, the synergistic accumulation of ssDNA as indicated by the increased 
fraction of RPA-positive cells when combining siREV3 transfection with HU treatment 
without increase in γH2AX (or even with a decrease when compared to siNT+HU) leads 
us to the conclusion that REV3 depletion leads to aggravated replication stress induced 
by HU treatment. 
To further investigate in more details the role of REV3 in the tolerance of replication 
stress we analyzed the cell cycle distribution after inhibition of REV3 expression and HU 
treatment (Fig.5). We showed previously that siRNA-mediated REV3 silencing 
significantly decreased the fraction of cancer cells in S-phase whereas the fraction of 
cells in the G2-phase of the cell cycle was significantly increased [15]. This observation 
is in agreement with a suggested function of REV3 outside of S-phase [36]. As 
expected, HU treatment induced a pronounced S-phase accumulation. This 
accumulation was not further enhanced by additional REV3 silencing, but the HU:iREV3 
interaction was significant in all cell cycle phases reflecting that the cell cycle distribution 
of REV3-deficient cells was more perturbed by HU treatment than that of the controls. 
We also compared the fractions of RPA positive cells in different cell cycle phases 
(Fig.6). In S-phase, the fraction of RPA positive siREV3+HU treated cells was 
significantly higher than that of siNT+HU and HU treated cells, whereas the 
corresponding difference was not significant in G1- and G2-phases. This indicates that 
the synergistic RPA increase for the combination of siREV3 transfection and HU 
treatment (Fig.4) occurs mainly in the S-phase of the cell cycle. 
In summary, in REV3-deficient cells upon HU-treatment, a significant increase in the 
fraction of cells with positive RPA staining is confined to S-phase consistent with the role 
of polζ in DNA replication upon RS. 
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4.5. Discussion 
This study aimed to identify synthetic lethal gene interactions with REV3 in lung cancer 
cells. For screening, we used stable cell lines obtained from A549 by transfection with 
the vector carrying short hairpin against REV3 or the control vector. The 50% decrease 
in REV3 expression in the cell line R1B6 is of physiological relevance since it conferred 
cisplatin sensitivity  
Screening of a whole genome library allowed us to determine synthetic lethal 
interactions with REV3 in an unbiased way. Therefore a top position of a gene in the 
screen indicates that the viability of the tested REV3-deficient NSCLC cells is heavily 
dependent on this gene. Our analysis revealed that silencing of RRM1, the large subunit 
of RNR, had the second most pronounced effect in reduction of cell viability specifically 
in a REV3-deficient background. Additionally, RRM2, the small subunit of RNR, also 
ranked under the top genes in our screen (#292) further corroborating that inhibition of 
RNR is synthetic lethal with REV3 depletion. RRM2 is overexpressed in many tumor 
types. For example, it was shown that RRM2 is highly (~15x) overexpressed in NSCLC 
[37]. Moreover, RRM2 was suggested to act in cooperation with a variety of oncogenes 
to increase their transformation and tumorigenic potential [38]. It is well known that 
inhibition of RNR function affects proliferation of cancer cells to a greater extent than the 
normal cells which allows successful application of small molecule inhibitors targeting 
RNR in the clinics for cancer treatment (reviewed in [39]). All these data suggest that 
cancer cells are frequently addicted to RNR overexpression. Therefore, we further 
focused our analysis on the synthetic lethal interaction of REV3 with RNR.  
Downregulation of RRM1 expression and treatment with HU, a drug inhibiting small 
subunit RRM2 of RNR, in combination with transient siRNA based depletion of REV3 
resulted in the synergistic inhibition of cell proliferation. This indicates that the observed 
effects are not RNR-subunit specific and rather related to RNR catalytic function and 
nucleotide deprivation as a result of its inhibition. Inhibition of RNR catalytic activity 
leads to deprivation of deoxyribonucleotides, reduced replication rate and stalling of 
replication forks [40]. Higher concentrations of HU (~2mM) can induce complete cell 
cycle arrest which is often exploited for synchronization of cultured cells. The 
concentrations that we use (0.2-0.3mM) create nucleotide shortage thereby generating 
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conditions of mild replication stress but still allowing replication. Therefore we tested 
whether RS-related genes were overrepresented among the genes whose inhibition 
induced synthetic lethality in the REV3-deficient background and found this enrichment 
to be significant. We proceeded with detection of chromatin-bound RPA, an indication 
for replication associated ssDNA formation, and controlling levels of DNA damage 
measured by H2AX phosphorylation. Compared to individual treatments, combination of 
HU treatment with REV3 silencing synergistically increased the fraction of RPA positive 
cells, which was not accompanied by increased levels of γH2AX, suggesting that it was 
caused not by increase in DNA damage repair, but by induction of RS. Thus, under 
conditions of RS, silencing of REV3 impairs DNA replication but does not lead to 
increased DNA damage accumulation indicating that polζ is directly involved in DNA 
replication. This is further corroborated by our finding that the fraction of S-phase cells 
after siREV3+HU treatment is significantly higher than could be expected from a simple 
additive effect of HU treatment and REV3 silencing, which corroborates a significant role 
of REV3 in S-phase of HU-treated cells. Moreover, the significant increase in RPA 
positive cells was found only in S phase and not in G1 and G2 phases of the cell cycle. 
The role of REV3 in the tolerance of nucleotide depletion can be associated either with 
its function in DNA damage repair/tolerance or its direct involvement in DNA replication 
[12]. Even though Polζ is thought to be mainly involved in the first, recently it was shown 
that Polζ takes part in the replication of fragile sites [16]. We did not expect that the 
concentrations of HU that we used would strongly increase amount of DNA DSB since 
treatment of cells with 8 times higher HU concentration for the same time (24 hours) 
resulted only in a moderate induction of DSB as shown by pulse-field gel electrophoresis 
[40]. Also single stranded breaks were not detected by alkaline unwinding technique [41] 
after treatment with comparably low concentration of HU (0.1mM). Nevertheless, due to 
the high sensitivity of the flow cytometry method, we detected increased H2AX 
phosphorylation upon HU treatment that was further increased by preceding transfection 
with control siRNA. Lipid-mediated siRNA transfection is known to affect permeability of 
the cell membrane. For example, recommendation to use an antibiotic-free medium for 
transfection is given to avoid increased antibiotic uptake and associated cell toxicity 
(http://www.thermoscientificbio.com/uploadedFiles/Resources/basic-dharmafect-
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protocol.pdf). In analogy, we speculate that the increased H2AX phosphorylation 
detectable after control transfection and subsequent HU treatment is due to increased 
drug penetration and therefore the higher effective intracellular HU concentration even 
when cells were treated after removal of the transfection reagent.  
It was shown previously that mild RS can cause formation of 53BP1 nuclear bodies and 
increased H2AX phosphorylation specifically at common fragile sites when the cells 
carry unreplicated regions through mitosis [42]. HU treatment significantly reduced the 
replication rates of REV3-deficient cells compared to REV3-proficient cells therefore we 
assume that the fraction of cells undergoing mitosis was also reduced in REV3-deficient 
cells. Thus, we speculate that the decreased level of γH2AX in siREV3+HU treated cells 
compared to siNT+HU control can be attributed to the decreased replication rate, 
demonstrated by decreased EdU incorporation, upon REV3 silencing and thereby 
reduced level of HU-induced replication associated DNA damage. Consistently, it was 
previously reported that DNA damage induced H2AX phosphorylation is replication 
dependent and can be reduced by contact inhibition [35]. 
Nucleotide biosynthesis is commonly up-regulated to cope with increased metabolic 
requirements of cancer cells [43]. Therefore many oncogenes not only induce replication 
stress [44] [45, 46], but also activate nucleotide synthesis [47]. Thus, concentrations of 
the 4 dNTPs in tumor cells are on average 6-11 fold over normal cells [48]. But if the cell 
fails to adjust its metabolism, nucleotide deficiency promotes genomic instability [47] and 
also can lead to oncogene-induced senescence [49]. Interestingly, cells lacking REV3 
undergo senescence and accumulate persistent DNA DSBs at later time points [7, 15] 
possibly reflecting their inability to cope with RS [32]. Based on our present findings it is 
tempting to hypothesize that oncogene-induced RS could be the unifying feature 
responsible for the observed cancer cell specific growth arrest upon REV3 silencing 
described earlier by our group [15]. 
The function of Polζ in the replication under conditions of nucleotide deficiency 
associated replication stress might also help in understanding its role in embryogenesis. 
Rev3 knockout is embryonic lethal in mice causing depletion of hematopoietic 
compartment and embryonic stem cells [4]. A recent study showed that hematopoietic 
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tissue is highly prone to RS associated with nucleotide pool imbalance [50]. During 
hematopoiesis, a state similar to thymidine block occurs making this process strongly 
dependent on the activity of de novo nucleotide synthesis pathway. Besides, human 
embryonic stem cells are very sensitive to RS [51] and high levels of RS are observed 
upon stem cell induction [52]. Apparently, hematopoietic and embryonic stem cells 
overexpress REV3 in order to cope with excessive RS and suffer the most upon REV3 
depletion. 
In summary, our study identifies a novel function of human polζ in the tolerance of 
replication stress thereby broadening our understanding of its role in cell biology.   
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4.7. Figures and tables 
 
Rank Gene P-value 
Viability 
difference 
score* 
Gene name 
1 GPR27 1.7E-03 2.67 G protein-coupled receptor 27 
2 RRM1 1.6E-02 2.49 ribonucleotide reductase M1 
3 CFLAR 4.9E-05 2.24 CASP8 and FADD-like apoptosis regulator 
4 LMTK3 1.2E-02 2.19 lemur tyrosine kinase 3 
5 CCR6 4.6E-04 2.13 chemokine (C-C motif) receptor 6 
7 CACNA1A 2.3E-03 2.10 calcium channel, voltage-dependent, P/Q type, alpha 1A subunit 
8 COPZ1 9.4E-03 2.09 coatomer protein complex, subunit zeta 1 
9 CDY1 2.4E-02 2.09 chromodomain protein, Y-linked, 1   
10 CSAD 2.2E-02 2.08 cysteine sulfinic acid decarboxylase   
11 RASGRP2 8.6E-03 2.00 RAS guanyl releasing protein 2, CDC25L 
12 SERPINH1 1.9E-02 1.93 serpin peptidase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)    
… … … … … 
30 UBE2N 8.4E-04 1.63 ubiquitin-conjugating enzyme E2N (UBC13 homolog) 
292 RRM2 4.9E-03 0.85 ribonucleotide reductase M2 
 
Table 1. Highest ranking genes with a stronger effect on viability of REV3-deficient cells  
compared to control cells. 
*All the genes in the screen were scored based on the normalized viability of the cells 
after its silencing.  In the final list genes are sorted according to the difference of scores 
for control and REV3-deficient cell lines. Filter of P<0.05 is applied to exclude low-
confidence genes. Results are from four whole-genome silencing screens summarized 
as described in the material and methods section  
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Table 2. Selected gene sets whose silencing had stronger effect on the viability of 
REV3-deficient cells 
We tested whether nucleotide synthesis pathways and genes associated with replication 
stress are enriched among the genes whose silencing had stronger effect on the viability 
of REV3-deficient cells. The testing was performed by ROMER. *Replication stress gene 
list was generated by searching NCBI gene database with the term “replication+stress” 
(Table S4). 
  
 
Figure 1. Characterization of the cell lines used for the screening 
(A) REV3 mRNA level determined by rtPCR in the parental cell line A549, clone R1B6 
carrying short-hairpin targeting REV3 mRNA and the control cell line S1C6 carrying the 
scrambled control construct. (B) Sensitivity of the generated cell lines to continuous 
cisplatin treatment. Cell viability was determined after 5 days of cisplatin (CDDP) 
treatment.  
 
Gene set P-value 
Purine metabolism KEGG: hsa00230 0.0041 
Pyrimidine metabolism KEGG: hsa00240 <1E-5 
Replication stress [Homo sapiens]* 0.00034 
Figure 2. Schematic representation of the screening procedure. 24 hours after plating, 
cells are transfected with the siRNA from the Dharmacon library targeting >20 000 transcripts.
Cells are incubated for 5 days and CellTiter Blue viability assay is used to assess amount of 
cells in every well. Fluorescent signal is normalized and compared between two cell lines – 
S1C6 with normal and R1B6 with reduced REV3 expression – to find the genes whose 
silencing predominantly affects viability of REV3-deficient cells.  
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Figure 3. Inhibition of ribonucleotide reductase (RNR) function and REV3 silencing have 
synergistic effect on viability of cancer cells.
(A) Quantitation of the colony formation after REV3 silencing by siRNA and transduction of 
lentivirus carrying short hairpin targeting RRM1 mRNA.
(B) Image of a representative plate from a colony formation assay after REV3 silencing by 
LV-shREV3 and subsequent HU treatment. 
(C) Quantitation of the colony formation after REV3 silencing by LV-shREV3 and subsequent 
HU treatment.
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Figure 4. Effects of REV3 silencing and HU treatment on (A) EdU incorporation, (B) RPA2 
and (C) γH2AX levels determined by flow cytometry . The cells were seeded and transfected 
after 24 hours. 24 hours later the medium was exchanged and after 24 hours cells were 
treated with HU. After 24 hours of treatment, EdU was applied for 1 hour after which cells 
were harvested, fixed and stained. *P<0.05
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Figure 6. Effects of REV3 silencing and HU treatment on RPA levels in different cell 
cycle phases determined by flow cytometry: in (A) G1, in (B) S and (C) G2 -phases.
Figure 5. Effects of REV3 silencing and HU treatment on cell cycle distribution: percentages 
of (A) G1, (B) S and (C) G2 phase cells.
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4.8. Supplementary materials 
 
 S1C6-1 S1C6-2 R1B6-1 R1B6-2 
S1C6-1 1.00 0.87 0.81 0.76 
S1C6-2 0.87 1.00 0.77 0.75 
R1B6-1 0.81 0.77 1.00 0.84 
R1B6-2 0.76 0.75 0.84 1.00 
 
 
Supplementary Table 1. Pearson’s correlation values between the whole-genome 
silencing screens of the control (S1C6) and REV3-deficient (R1B6) cell lines.  
 
Supplementary Table 2 (available electronically only). Complete results of the silencing 
screens sorted by absolute difference of normalized viability scores between the control 
(S1C6) and REV3-deficient (R1B6) cell lines. 
 
Supplementary Table 3 (short version is included in the supplementary of the thesis). 
Results of the silencing screens (Suppl.Table 2.), filtered with the P<0.05 to exclude low-
confidence genes. 
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 Supplementary Table 4. Replication stress gene list, obtained by search of NCBI 
human gene database with the term “replication+stress”. 
ID Symbol Name 
7157 TP53 tumor protein p53 
1029 CDKN2A cyclin-dependent kinase inhibitor 2A 
4609 MYC v-myc myelocytomatosis viral oncogene homolog (avian) 
472 ATM ataxia telangiectasia mutated 
324 APC adenomatous polyposis coli 
3320 HSP90AA1 heat shock protein 90kDa alpha (cytosolic), class A member 1 
1111 CHEK1 checkpoint kinase 1 
545 ATR ataxia telangiectasia and Rad3 related 
983 CDK1 cyclin-dependent kinase 1 
2272 FHIT fragile histidine triad 
5591 PRKDC protein kinase, DNA-activated, catalytic polypeptide 
7486 WRN Werner syndrome, RecQ helicase-like 
898 CCNE1 cyclin E1 
641 BLM Bloom syndrome, RecQ helicase-like 
3014 H2AFX H2A histone family, member X 
1025 CDK9 cyclin-dependent kinase 9 
6117 RPA1 replication protein A1, 70kDa 
7158 TP53BP1 tumor protein p53 binding protein 1 
55294 FBXW7 F-box and WD repeat domain containing 7, E3 ubiquitin protein ligase 
2177 FANCD2 Fanconi anemia, complementation group D2 
83990 BRIP1 BRCA1 interacting protein C-terminal helicase 1 
7465 WEE1 WEE1 homolog (S. pombe) 
6118 RPA2 replication protein A2, 32kDa 
5976 UPF1 UPF1 regulator of nonsense transcripts homolog (yeast) 
11073 TOPBP1 topoisomerase (DNA) II binding protein 1 
64421 DCLRE1C DNA cross-link repair 1C 
5424 POLD1 polymerase (DNA directed), delta 1, catalytic subunit 
8317 CDC7 cell division cycle 7 
9025 RNF8 ring finger protein 8, E3 ubiquitin protein ligase 
571 BACH1 BTB and CNC homology 1, basic leucine zipper transcription factor 1 
79840 NHEJ1 nonhomologous end-joining factor 1 
5884 RAD17 RAD17 homolog (S. pombe) 
10769 PLK2 polo-like kinase 2 
64919 BCL11B B-cell CLL/lymphoma 11B (zinc finger protein) 
80198 MUS81 MUS81 endonuclease homolog (S. cerevisiae) 
25842 ASF1A ASF1 anti-silencing function 1 homolog A (S. cerevisiae) 
55723 ASF1B ASF1 anti-silencing function 1 homolog B (S. cerevisiae) 
10116 FEM1B fem-1 homolog b (C. elegans) 
8812 CCNK cyclin K 
79915 ATAD5 ATPase family, AAA domain containing 5 
80169 CTC1 CTS telomere maintenance complex component 1 
4796 TONSL tonsoku-like, DNA repair protein 
84893 FBXO18 F-box protein, helicase, 18 
79991 OBFC1 oligonucleotide/oligosaccharide-binding fold containing 1 
84083 ZRANB3 zinc finger, RAN-binding domain containing 3 
51550 CINP cyclin-dependent kinase 2 interacting protein 
92797 HELB helicase (DNA) B 
253714 MMS22L MMS22-like, DNA repair protein 
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Supplementary Figure 1. siRNA silencing results in a strong decrease of mRNA 
levels of (A) REV3 and (B) RRM1 48 hours after transfection assessed by rtPCR
Supplementary Figure 2. Effect  of manual transfection of (A) siRNA pools 
targeting the genes with the highest specificity for killing of REV3 deficient cells 
and (B) individual siRNA from RRM1 pool on viability of A549, S1C6 and R1B6.   
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Supplementary Figure 3. Deconvolution of the pools with the highest differential 
viability scores in the screens. The graphs show the cell survival after transfection of 
individual siRNA composing the pools.
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Supplementary Figure 4. Gating strategy for the flow cytometry experiments: (A) 
exclusion of debris, (B) exclusion of cell douplets, (C) γH2AX staining, (D) PI staining, 
(E) EdU staining, (F) cell cycle analysis.  
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5. Conclusions and perspective 
 
Sustained proliferative signaling is acknowledged to be one of the hallmarks of cancer 
which might be exploited for preferential targeting of cancer cells [1, 2]. In agreement 
with this, we show in the first part of this work that cancer cells whose proliferation is 
frequently stimulated by oncogenic signaling are more sensitive to downregulation of 
REV3 expression than untransformed cells [3]. In the second manuscript included in the 
thesis, we investigate synthetic lethal gene interactions with REV3 in cancer cells and 
demonstrated that REV3 is essential for tolerance of replication stress induced by 
hydroxyurea treatment. In addition to its conventional role in DNA damage repair and 
tolerance, recently it was suggested that REV3 is essential for overcoming cellular 
senescence in response to a potent proliferation stimulus [4], but the nature of this 
stimulus wasn’t clarified. Our finding suggests that replication stress can be a type of 
proliferation stimulus that sensitizes cells to REV3 silencing. 
For our work we used the artificially created cell lines: one with normal REV3 expression 
and another one with REV3 mRNA level reduced by 50%. We speculate that this level of 
downregulation is physiologically relevant since mutations leading to the complete 
inactivation of REV3 are not common in tumors. In detail, in the Catalogue of Somatic 
Mutations in Cancer (COSMIC) [5] only 1.7% of unique 7241 tumor samples have 
mutations in the Rev3l gene, 23.6% of which are synonymous substitutions not changing 
the protein sequence and other 65.9% are missense substitutions which should not 
affect catalytic function because of their positioning outside of N- and C-terminal 
domains. 
In a series of siRNA screens we found some of the genes that are known to be involved 
in parallel or complimentary to TLS pathways. For example, TLS and HR-mediated post-
replication repair (HR-PRR) are synthetic lethal in yeast in the presence of DNA 
damaging agents [6]. Yeast UBC13 is a ubiquitin ligase that is known to promote the 
switch from TLS to HR-PRR by PCNA polyubiquitination. We found in lung cancer cells 
that silencing of UBE2N, a human homologue of yeast UBC13, was synthetic lethal with 
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REV3 deficiency even in the absence of the exogenous DNA damage. Thus, our screen 
indeed identified synthetic lethal interactions of functional relevance. 
In our study we used only one agent inducing RS – hydroxyurea. Another RS inducing 
agent topoisomerase I inhibitor camptothecin was previously shown to have stronger 
effect on REV3 deficient cells [7] that doesn’t seem to be due to HR repair, because low 
concentrations of CPT used in the study don’t cause formation of DNA DSB [8]. As 
opposed to other RS inducing drugs, camptothecin not only doesn’t induce expression of 
fragile sites, but even stabilizes them [9]. This can be explained by a different 
mechanism involving blockage of DNA unwinding and thereby reducing amount of 
ssDNA and not increasing it like in case of other RS inducing drugs. Camptothecin 
treatment unlike other replication poisons induces G2 and not S-phase arrest [10] and 
upregulates RRM1 and RRM2 expression [11] likely causing the delay of late replication 
state onset. 
Nucleotide concentrations are tightly regulated throughout the cell cycle and perturbation 
of this regulation leads to increased mutation rates [12]. One of the key components of 
this regulation is the regulation of RNR activity. In yeast, upregulation of RNR activity 
increases replication fork speed, indicating that nucleotide pools are limiting for normal 
replication [13]. Both in yeast and mammalian cells the nucleotide pools are expanded 
upon entry in the S-phase. In mammalian cells, exit from S phase is associated with 
decrease of dN pools, most notably of deoxycytidine changing 3-fold [14, 15]. Because 
nucleotide concentrations in the nucleus are higher than in the cytoplasm, the absolute 
changes of nuclear nucleotide pools during the cell cycle are more pronounced [16] 
perhaps making them limiting for late replication. Thus, in addition to the role of Polζ in 
replication after HU generated nucleotide deprivation, we speculate that Polζ might also 
be involved in the late replication. 
In this context, the recently discovered role of Polζ in the stability of fragile sites can be 
viewed as a particular case of late replication since fragile sites are known to be 
replicated late during the cell cycle and their stability is compromised by RS inducing 
agents (aphidicolin, hydroxyurea, low folate medium). In detail, common fragile sites 
(CFS) are replicated in late S phase and their replication is even further delayed by 
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aphidicolin, causing the replication of CFS to persist in G2 phase [17]. In our study, upon 
REV3 silencing in the absence of HU treatment, an increase in the fraction of cells in the 
G2-phase was the most prominent effect (1.5 fold) suggesting that REV3 plays the most 
important role in this cell cycle phase, which is in agreement with the recently reported 
enrichment of REV3 on the chromatin in G2/M and its role in fragile site maintenance 
[18]. However, HU treatment increased S-phase fraction of REV3 depleted cells more 
than that of the cells without REV3 silencing, which suggests its increased role in S-
phase upon nucleotide deprivation. Thus, we speculate that under our experimental 
conditions, the HU treatment induces in A549 cells the early onset of the “late 
replication” in S-phase by creating conditions of nucleotide shortage more typical for G2-
phase. 
 
Polymerase 
Km values, µM 
dCTP-G dTTP-A dATP-T dGTP-C 
Yeast polζ 0.14 [30] - 0.39 [31] 0.11[30] 
Yeast polδ 1.4 [32] 6.6 [32] 2.1 [32] 2.5 [32] 
Yeast polη 0.43 [33] 1.3 [33] 1.7 [33] 5.0 [33] 
 
Table 5.1. Steady-state kinetic parameters Km of yeast polymerases ζ, δ and η. 
Late replicating regions were shown to be particularly prone to mutagenesis in both 
yeast [19] and humans [20], indicating a likely conservation of the mechanism underlying 
this phenomenon. In yeast, comparison of available catalytic parameters Km of 
polymerases ζ, δ and η (Table 5.1) suggests that in the conditions of nucleotide 
shortage (dN<<Km) Polζ can bind nucleotides with the highest affinity because its Km 
values for incorporation of 3 nucleotides are 5-20 times lower than those of Polδ. This is 
due to Polζ lysine residue K1061 that binds triphosphate group of nucleotides, 
increasing the binding affinity, but decreasing replication fidelity [21, 22]. This error-
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prone nature of Polζ suggests that it can contribute to the late replication mutagenesis 
by participating in this process as suggested above. 
Our data suggest that reduction of the nucleotide pools represents a mechanism that 
could control the replicative polymerase switch in the late S and G2 phases and/or RS 
induction. Possible mediators in this non-TLS polymerase switch include REV1 and 
Spartan. In yeast, REV1 dependent recruitment of Polζ to DNA was shown to be 
independent from Rad6-Rad18-mediated PCNA ubiquitination [23] that is required for 
initiation of TLS. This recruitment is controlled by phosphorylation of ATR-homolog 
Mec1, which is one of the main players in RS response [24]. Besides, Rev1 is highly 
expressed during G2/M phase rather than S phase and its association with Polζ is 
highest in G2 phase [25]. Another possible player in RS-induced Polζ recruitment is 
Spartan (DVC1, C1orf124), a ubiquitin-binding p97 adaptor protein that accumulates at 
sites of RS independently from RAD18-mediated PCNA monoubiquitylation [26]. 
Spartan is a substrate of cycle-regulated anaphase-promoting complex (APC), it 
prevents the binding of Polζ and REV1 to POLD2, an accessory subunit of Polδ, thereby 
suppressing TLS [27]. Additionally, it was shown that exchange of Polδ and Polζ is 
redox-dependent since both of the polymerases have iron-sulfur clusters sensitive to 
oxidation [28]. This might represent an additional level of control for the choice of the 
replicative polymerase because redox state of the cell and the nucleus is known to be 
cell cycle dependent [29]. Which of these or other mechanisms control the REV3 
function in replication is unclear and could represent an interesting topic for the future 
investigation. 
Like it is often the case in scientific research, our study raises even more questions than 
gives the answers and I will try to address some of them and give my view of possible 
directions for the future research on the topic. Even though our flow cytometry data 
indicate the participation of REV3 in replication under conditions of replication stress, the 
direct evidence of that is still missing. There are several experiments that could further 
clarify this issue. The most suitable for that is the method of DNA fiber spreading 
analysis that is used to assess progression of individual replication forks. Reduction of 
the average speed of replication fork caused by depletion of REV3 upon replication 
stress could prove its direct involvement in the DNA replication. 
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Unfortunately the direct biochemical detection of human REV3 is complicated by the 
large size and very low abundance of this protein as well as inferior quality of 
commercially available antibodies. Therefore immunofluorescent detection would require 
prior development of a working antibody. Once available, antibodies could be used in a 
wide range of experiments such as protein coimmunoprecipitation (IP) followed by either 
targeted detection of protein of interest using Western blotting or unbiased mass-
spectrometry. These experiments would allow finding the direct interaction partners of 
REV3 in different conditions, e.g. normal versus replication stress.  
Another interesting question is how REV3 is recruited to the replication fork and what is 
inducing the polymerase switch in the conditions of replication stress. The switch can be 
carried out in a PCNA monoubiquitination-dependent manner similar to how it is made in 
translesion synthesis. Alternatively, PCNA-ubiquitination might not be strictly required for 
it and REV3 recruitment can be mediated by other proteins like REV1 and Spartan as 
discussed above. Determination of PCNA ubiquitination status under conditions of 
replication stress would be helpful for finding an answer to this question. 
To investigate whether REV3 is involved in the tolerance of oncogene-induced 
replication stress, isogenic cell lines that differ in oncogene expression could be used. 
Especially interesting would be to investigate how the nature of the oncogene influences 
extent of involvement of REV3 in DNA replication. Thus, both c-myc and Cyclin E are 
strong inducers of replication stress, but c-myc activation additionally upregulates the 
rate of nucleotide synthesis likely alleviating nucleotide deficiency caused by oncogenic 
stress. Comparison of oncogenes of these two types (like c-myc and Cyclin E) and role 
of REV3 upon their activation could provide a clue about whether nucleotide shortage is 
essential for the recruitment of REV3 upon oncogene-induced replication stress. This is 
another possible direction of the future research and an important issue for 
understanding the function of REV3 in replication stress tolerance. 
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34 24332 XM_372048 0 LOC389672 -13.241 0.00058 1.6 254 D08 27671 -0.5998 25112 -0.565 9649 -2.0353 7250 -2.3334
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8. Supplemetary Table. Screening results: genes with P value less than 0.05 sorted by the difference of normalized viability (delta).
Included are only 500 genes with the strongest synthetic lethal effect (highest delta) and all significant synthetic rescue genes (lowest delta).
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A. Synthetic lethal genes
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41 1270 NM_012152 23566 EDG7 -8.52883 0.00237 1.56 14 B10 26485 -0.3743 33095 0.02478 10077 -1.8475 11694 -1.616
42 2684 NM_001063 7018 TF -5.29569 0.0104 1.53 28 H08 20149 -0.7356 21883 -0.6337 5993 -2.5738 9957 -1.8466
44 4580 NM_001776 953 ENTPD1 -11.1029 0.00102 1.52 48 F08 22449 -0.6995 17134 -0.9665 6528 -2.4571 7523 -2.2441
45 15437 NM_020882 57642 KIAA1510 -4.80806 0.01386 1.52 161 G05 30215 -0.4417 26683 -0.4795 12926 -1.5743 6699 -2.3775
46 4763 NM_000937 5430 POLR2A -4.91556 0.01299 1.52 50 E11 8667 -2.0926 13338 -1.382 3528 -3.4205 4056 -3.0842
48 4471 NM_003329 7295 TXN -33.5783 2.78E-05 1.5 47 E07 32510 -0.0999 30283 -0.1836 11718 -1.6474 11541 -1.6411
49 5550 NM_018438 26270 FBXO6 -3.07078 0.04837 1.5 58 G06 31800 -0.3004 29045 -0.3211 16857 -1.1871 6772 -2.4383
50 1290 NM_017986 55065 FLJ10060 -3.40139 0.03693 1.5 14 D06 32926 -0.0603 32083 -0.02 8429 -2.1051 18207 -0.9773
51 16762 NM_030651 80863 C6ORF31 -5.46438 0.00946 1.49 175 E10 32154 -0.3198 31191 -0.1851 14459 -1.4044 8697 -2.0875
52 5204 NM_006421 10565 BIG1 -11.8309 0.00083 1.49 55 B08 19208 -0.9811 17900 -0.9759 7441 -2.3082 5690 -2.6205
53 15423 NM_020861 57621 ZBTB2 -7.43645 0.00366 1.48 161 F03 23716 -0.7911 25807 -0.5277 10138 -1.9248 6805 -2.3549
54 4605 NM_004462 2222 FDFT1 -5.83648 0.00775 1.47 48 H09 15056 -1.2759 14198 -1.2377 4338 -3.0467 6720 -2.4069
56 16746 XM_290811 80816 KIAA1713 -5.74798 0.00811 1.45 175 D06 32220 -0.3169 30905 -0.1984 14604 -1.39 9116 -2.0196
60 6620 NM_000832 2902 GRIN1 -4.27151 0.01957 1.42 69 H08 26509 -0.6047 28254 -0.3771 13376 -1.5019 7163 -2.3192
61 6200 NM_014207 921 CD5 -4.23608 0.02005 1.42 65 E08 27300 -0.5623 31278 -0.2602 14213 -1.4297 7640 -2.2292
64 6227 NM_001318 1444 CSHL1 -3.85696 0.02615 1.39 65 G11 15690 -1.3614 26629 -0.4923 8537 -2.1651 6438 -2.4761
65 2764 NM_001153 307 ANXA4 -6.81487 0.0048 1.39 29 G04 33981 -0.1003 28336 -0.2535 10088 -1.8151 14648 -1.3209
66 19479 NM_014261 148022 TRIF -3.34139 0.03873 1.37 203 H03 23427 -0.7735 23489 -0.613 13154 -1.5468 5914 -2.5845
67 9306 NM_001679 483 ATP1B3 -4.27153 0.01957 1.36 97 H06 26807 -0.5962 17477 -1.0891 10724 -1.8769 6333 -2.5193
70 13684 NM_016564 51286 BM88 -3.3516 0.03842 1.33 143 E04 34298 -0.1448 31768 -0.2003 19537 -0.9948 8984 -2.0059
71 10180 NM_021974 5435 POLR2F -5.15747 0.01125 1.32 107 A04 21413 -0.9452 23646 -0.6137 10747 -1.8222 7182 -2.3855
75 9453 NM_016451 1315 COPB -6.05762 0.00691 1.31 99 D09 18805 -1.1431 13796 -1.4212 7342 -2.3584 5124 -2.8333
76 2859 NM_018489 55870 ASH1L -3.66637 0.0301 1.31 30 G03 15697 -1.1712 19219 -0.7891 5595 -2.7075 9703 -1.8771
78 2745 NM_016265 51711 ZNF325 -5.46898 0.00944 1.29 29 E09 19968 -0.8673 23587 -0.5181 7580 -2.2275 10958 -1.7396
80 19803 NM_197964 154791 HSPC268 -7.09941 0.00423 1.28 207 C03 26773 -0.5778 25471 -0.4726 13142 -1.5816 8886 -2.024
81 3502 NM_005649 6940 ZNF354A -12.9747 0.00062 1.27 37 D10 32500 -0.2182 31789 -0.0924 14946 -1.3282 12236 -1.5319
82 23124 XM_047083 0 LOC92755 -5.22651 0.01082 1.27 241 G12 19559 -1.1112 21422 -0.799 10244 -1.9593 6604 -2.4932
83 15976 NM_023016 65124 C2ORF26 -4.58047 0.01599 1.26 167 D04 34933 -0.2197 31752 -0.2298 17654 -1.1365 9702 -1.8389
84 4451 NM_024080 79054 TRPM8 -5.6848 0.00839 1.26 47 C11 28174 -0.3064 26936 -0.3526 10029 -1.8719 14515 -1.3103
86 142 NM_024110 79092 CARD14 -4.38345 0.01817 1.26 2 D10 24987 -0.5383 21564 -0.6542 13939 -1.4946 7798 -2.2182
87 19206 NM_080622 140701 C20ORF135 -3.26488 0.04119 1.26 201 A06 32973 -0.2925 30899 -0.249 18602 -1.0381 8738 -2.0233
88 3488 NM_003412 7545 ZIC1 -5.69806 0.00833 1.26 37 C08 23995 -0.6559 31627 -0.0998 11791 -1.6703 11663 -1.6011
89 23512 XM_371488 0 LOC388939 -3.80605 0.02714 1.26 245 H04 37409 -0.1901 30052 -0.2923 18325 -1.0794 9824 -1.9159
92 20242 XM_116971 196993 LOC196993 -5.99522 0.00714 1.25 211 G10 33023 -0.3048 29103 -0.2844 15503 -1.2801 9895 -1.8082
94 18475 NM_018593 117247 SLC16A10 -19.4232 0.00017 1.24 193 D07 40140 0.00163 33150 -0.133 15056 -1.3287 14613 -1.2791
95 3663 NM_021251 11132 CAPN10 -9.91634 0.00147 1.24 39 B03 29405 -0.2845 30984 -0.1324 11931 -1.5794 14283 -1.3095
96 13823 NM_016202 51157 ZNF580 -4.24964 0.01986 1.23 144 H11 21546 -0.8135 25491 -0.4991 13157 -1.5554 7813 -2.2259
100 7772 NM_020348 26507 CNNM1 -5.85646 0.00766 1.21 81 H08 30116 -0.3985 30788 -0.2276 15706 -1.2793 11021 -1.7767
102 10182 NM_006233 5438 POLR2I -3.79512 0.02736 1.21 107 A06 33888 -0.2829 27524 -0.3946 17191 -1.1445 9720 -1.949
95
103 2755 NM_003427 7629 ZNF76 -7.46438 0.00362 1.21 29 F07 25479 -0.5157 28814 -0.2294 10736 -1.7253 13529 -1.4355
107 3715 NM_004390 1512 CTSH -9.7223 0.00156 1.21 39 F07 34381 -0.059 33880 -0.0035 13613 -1.3891 16678 -1.0858
109 3483 NM_014569 23660 ZFP95 -3.63809 0.03075 1.2 37 C03 16563 -1.1907 26603 -0.3493 9530 -1.9774 9085 -1.9615
110 3594 NM_000687 191 AHCY -8.34814 0.00254 1.2 38 D06 27358 -0.45 31166 -0.1007 12675 -1.5136 13136 -1.4305
111 24033 XM_379501 0 LOC401367 -3.80278 0.02721 1.2 251 C09 38151 -0.1387 30250 -0.295 18982 -1.0189 10541 -1.8055
116 20445 NM_078483 206358 SLC36A1 -4.2596 0.01973 1.19 213 H09 22190 -0.8891 22489 -0.4376 12787 -1.5754 7915 -2.1222
118 12575 NM_015305 23357 KIAA0759 -4.51727 0.01665 1.18 131 H11 19229 -0.941 28780 -0.2826 11840 -1.7478 9925 -1.8306
119 3911 NM_001535 3275 HRMT1L1 -3.6387 0.03074 1.18 41 F11 14452 -1.3851 23607 -0.5595 8455 -2.1477 7847 -2.1512
120 21792 NM_198504 344838 PAQR9 -3.90084 0.02534 1.18 227 H12 23283 -0.8716 28939 -0.383 13592 -1.5064 8757 -2.0999
121 13623 NM_016305 51188 SS18L2 -3.46051 0.03525 1.17 142 H03 36309 0.01159 33923 -0.1231 22225 -0.7988 11572 -1.6507
124 10503 NM_002951 6185 RPN2 -4.27767 0.01949 1.15 110 D03 30137 -0.4445 28198 -0.3297 16460 -1.2 10190 -1.8754
126 13217 NM_020847 27327 TNRC6 -4.96676 0.01259 1.15 138 F05 30640 -0.3109 26995 -0.4568 16478 -1.2461 10391 -1.8141
129 12810 NM_014033 25840 DKFZP586A0522 -4.23025 0.02013 1.13 134 D06 28897 -0.3672 32024 -0.1473 18570 -1.0636 10761 -1.7058
132 16915 NM_031309 83482 SCRT1 -4.61942 0.01559 1.12 177 B07 29889 -0.3776 31961 -0.1822 17975 -1.1071 11184 -1.6916
133 2012 NM_001762 908 CCT6A -10.3758 0.00127 1.12 21 H08 22722 -0.6896 23621 -0.5465 10006 -1.8446 11510 -1.6224
135 18508 NM_178858 118980 SFXN2 -5.20677 0.01094 1.11 193 G04 38189 -0.0703 31505 -0.2065 19037 -0.9902 12399 -1.5161
136 18692 NM_145255 124995 MRPL10 -4.27088 0.01958 1.11 195 F08 33051 -0.2984 26047 -0.4786 17118 -1.1825 10290 -1.8213
139 16371 NM_024763 79819 FLJ23129 -3.06811 0.04847 1.11 171 E03 27854 -0.4867 31886 -0.1675 19083 -1.0031 10045 -1.8699
140 18753 NM_130807 126308 MOBKL2A -4.90361 0.01308 1.11 196 C09 22598 -0.8529 18855 -0.9209 11789 -1.7097 7500 -2.2794
144 24186 XM_380120 0 LOC402537 -3.91333 0.02511 1.1 252 H06 31330 -0.4228 28217 -0.3955 17864 -1.1518 10135 -1.8681
145 18956 NM_144639 131669 FLJ31300 -5.53304 0.00911 1.09 198 D08 38162 -0.1108 32336 -0.1169 19804 -0.9574 12991 -1.4581
146 1330 NM_002068 2769 GNA15 -4.3137 0.01903 1.09 14 G10 23858 -0.525 28815 -0.175 11080 -1.7106 15922 -1.1708
149 4479 NM_021009 7316 UBC -8.39703 0.00249 1.09 47 F03 2603 -3.7425 3008 -3.5152 1292 -4.8284 1484 -4.6003
151 2371 NM_017534 4620 MYH2 -8.45971 0.00244 1.07 25 F07 20353 -0.7325 24256 -0.4358 12188 -1.6022 10721 -1.708
153 475 NM_002419 4296 MAP3K11 -4.25692 0.01977 1.07 5 H07 21259 -0.7783 27470 -0.2804 14381 -1.3977 10478 -1.7973
155 16015 NM_024031 78994 MGC3121 -3.09888 0.04724 1.06 167 G07 29102 -0.4832 26344 -0.4992 17890 -1.1174 8710 -1.9946
159 654 NM_002645 5286 PIK3C2A -4.96451 0.01261 1.06 7 G06 22457 -0.675 23919 -0.45 14500 -1.3731 10200 -1.8635
162 22289 NM_207477 400931 FLJ27365 -3.74662 0.02836 1.05 233 B05 36937 -0.2164 35649 -0.0467 21664 -0.8337 12876 -1.5262
164 2084 NM_014325 23603 CORO1C -3.36723 0.03794 1.04 22 F08 23616 -0.6312 32442 -0.1017 11068 -1.7003 16523 -1.1153
166 13126 NM_014402 27089 QP-C -5.01909 0.01221 1.04 137 F10 28886 -0.3988 30791 -0.2608 18157 -1.1156 11955 -1.6221
168 3324 NM_004348 860 RUNX2 -3.5497 0.0329 1.04 35 E12 33741 -0.1429 29141 -0.2553 20887 -0.8682 11884 -1.6048
169 406 NM_005544 3667 IRS1 -7.95342 0.00296 1.04 5 B10 26144 -0.4799 26487 -0.333 15414 -1.2976 12122 -1.587
172 22980 XM_210826 0 LOC286404 -4.38408 0.01816 1.03 240 C12 38710 -0.1192 34113 -0.1111 21896 -0.8441 13649 -1.4392
173 13299 NM_014167 29080 HSPC128 -5.99143 0.00715 1.02 139 E03 27292 -0.4409 30217 -0.2969 17246 -1.1884 12190 -1.5939
177 3491 NM_006006 7704 ZBTB16 -3.79363 0.02739 1.01 37 C11 19983 -0.9199 27922 -0.2795 13284 -1.4983 10686 -1.7273
182 5287 NM_005489 10044 SH2D3C -5.63525 0.00862 1 56 A07 29159 -0.4177 28601 -0.2763 12632 -1.5547 15882 -1.1314
183 19064 NM_174959 136306 LOC136306 -3.50527 0.03404 0.99 199 E08 23483 -0.8004 17254 -1.0453 12731 -1.5763 7635 -2.2557
190 15814 NM_022489 64423 FLJ22056 -12.2164 0.00075 0.98 165 F10 36568 -0.1654 32994 -0.1716 18846 -1.0503 14393 -1.2396
193 844 NM_014264 10733 PLK4 -3.16682 0.04464 0.97 9 G04 30634 -0.2921 28237 -0.2155 20930 -0.8369 11703 -1.617
96
198 14736 NM_017842 55652 FLJ20489 -3.30231 0.03997 0.97 154 D12 26564 -0.5278 27930 -0.3879 18997 -1.059 10063 -1.7934
202 5375 NM_001783 973 CD79A -3.44028 0.03581 0.96 56 H11 37277 -0.0634 32531 -0.0906 14131 -1.3929 21686 -0.682
204 15611 NM_021817 60484 HAPLN2 -5.58957 0.00883 0.96 163 E11 31899 -0.3546 31680 -0.2343 18680 -1.0459 12851 -1.4619
205 1507 NM_000865 3354 HTR1E -3.35092 0.03844 0.96 16 F07 25055 -0.3984 28182 -0.1802 19794 -0.8983 11798 -1.5917
207 3184 NM_004739 9219 MTA2 -5.05503 0.01195 0.95 34 B04 25080 -0.6343 31149 -0.1595 15270 -1.3254 14080 -1.3769
208 19205 NM_080621 140700 C20ORF136 -10.2378 0.00133 0.95 201 A05 35160 -0.1999 33863 -0.1168 19021 -1.006 15298 -1.2154
209 10740 NM_004610 6953 TCP10 -4.10325 0.02196 0.95 112 G12 30153 -0.4148 27859 -0.3448 18497 -1.0382 12004 -1.6229
210 3604 NM_012067 22977 AKR7A3 -11.8407 0.00083 0.95 38 E04 32316 -0.2098 32866 -0.0241 17525 -1.0462 16656 -1.088
212 5220 NM_001493 2664 GDI1 -3.8431 0.02642 0.94 55 C12 40748 0.1039 32235 -0.1272 23279 -0.6628 14812 -1.2402
215 2442 NM_018903 56137 PCDHA12 -3.44046 0.03581 0.94 26 D06 23248 -0.5101 20584 -0.7082 15986 -1.2142 9703 -1.8799
216 3130 NM_015995 51621 KLF13 -4.06053 0.02262 0.94 33 E10 34511 -0.0601 31862 -0.0878 22654 -0.7186 14657 -1.3048
218 16121 NM_024322 79172 MGC11266 -3.07974 0.048 0.93 168 H05 28099 -0.5167 28879 -0.3387 19538 -0.9849 10370 -1.7369
221 4592 NM_004100 2070 EYA4 -5.29861 0.01038 0.93 48 G08 24628 -0.5659 27697 -0.2737 12572 -1.5116 15720 -1.1808
222 4460 NM_004623 7268 TTC4 -6.80386 0.00483 0.93 47 D08 31272 -0.1559 31460 -0.1286 15561 -1.2382 19302 -0.8991
223 3959 NM_024075 79042 LENG5 -3.07564 0.04817 0.93 42 B11 27502 -0.4827 24058 -0.5512 18194 -1.0607 9957 -1.8257
225 5324 NM_001376 1778 DNCH1 -13.6657 0.00052 0.92 56 D08 29857 -0.3836 25728 -0.429 15527 -1.257 13138 -1.405
226 2423 NM_006194 5083 PAX9 -6.73487 0.00498 0.92 26 B11 19601 -0.7563 23660 -0.5072 13694 -1.4375 11200 -1.6729
227 2492 NM_000296 5310 PKD1 -7.16407 0.00411 0.92 26 H08 22199 -0.5767 27665 -0.2816 13906 -1.4153 14612 -1.2892
228 3572 NM_000666 95 ACY1 -5.05904 0.01192 0.92 38 B08 28819 -0.375 31912 -0.0666 14571 -1.3125 18062 -0.9711
230 1266 NM_005226 1903 EDG3 -9.28695 0.00181 0.92 14 B06 26818 -0.3563 28549 -0.1884 14938 -1.2796 16656 -1.1057
231 4147 NM_005622 6296 SAH -3.05612 0.04897 0.92 44 B07 17351 -1.1042 27141 -0.3643 12634 -1.552 10677 -1.7555
232 18478 NM_054114 117289 TAGAP -4.28267 0.01943 0.92 193 D10 31675 -0.3401 30247 -0.2653 19544 -0.9523 12609 -1.4919
235 19391 NM_152908 146802 FLJ31196 -3.51124 0.03389 0.91 202 H11 23287 -0.8255 27162 -0.414 15765 -1.2743 10360 -1.7944
236 13111 NM_014388 27042 MGC29875 -9.48086 0.0017 0.91 137 E07 38238 0.0058 34389 -0.1014 21713 -0.8576 17575 -1.0662
240 3976 NM_002372 4124 MAN2A1 -4.0068 0.02349 0.91 42 D04 33401 -0.2024 34079 -0.0488 22484 -0.7553 14244 -1.3091
241 1192 NM_001716 643 BLR1 -3.81406 0.02698 0.91 13 D04 25724 -0.3989 26749 -0.3408 11728 -1.5755 17992 -0.9749
242 3927 NM_000203 3425 IDUA -3.24991 0.0417 0.9 41 H03 18013 -1.0673 20808 -0.7416 13303 -1.4938 7999 -2.1235
244 3598 NM_003739 8644 AKR1C3 -7.48847 0.00358 0.9 38 D10 19820 -0.915 21686 -0.624 11074 -1.7084 11373 -1.6384
247 568 NM_025233 80347 COASY -9.36483 0.00176 0.9 6 H04 28036 -0.3009 31386 -0.0834 16728 -1.1377 17234 -1.0507
248 9452 NM_004371 1314 COPA -3.87917 0.02573 0.9 99 D08 6092 -2.7692 5239 -2.8181 3565 -3.4006 2300 -3.989
257 908 NM_003318 7272 TTK -3.25604 0.04149 0.89 10 D08 23891 -0.5862 28836 -0.251 18720 -1.0057 11739 -1.6197
258 1409 NM_005281 2827 GPR3 -6.44518 0.00571 0.89 15 F05 24765 -0.5297 28380 -0.1887 15685 -1.2214 14679 -1.2843
262 19543 NM_152496 149175 FLJ31434 -3.29394 0.04024 0.89 204 E07 34272 -0.2588 29777 -0.2698 21808 -0.81 12987 -1.4979
265 1383 NM_018949 2837 GPR14 -3.49464 0.03433 0.89 15 D03 23810 -0.5864 32495 0.00662 17677 -1.0489 14478 -1.3042
269 5956 NM_014387 27040 LAT -10.0413 0.00141 0.88 63 A04 32245 -0.3111 31585 -0.2056 18710 -1.0503 14532 -1.2338
270 1984 NM_018429 55814 BDP1 -3.18092 0.04412 0.88 21 F04 23745 -0.6261 29344 -0.2335 11827 -1.6033 17507 -1.0174
272 17505 NM_032810 84896 ATAD1 -27.9684 5.06E-05 0.88 183 C09 36459 -0.1024 34042 -0.0873 20058 -0.9787 18458 -0.9668
273 2804 NM_032595 84687 PPP1R9B -4.02074 0.02326 0.88 30 B08 27859 -0.3436 32692 -0.0227 15005 -1.2842 19996 -0.8339
274 1975 NM_005872 10286 BCAS2 -11.9779 0.0008 0.88 21 E07 36106 -0.0215 34683 0.00769 18387 -0.9667 20370 -0.7989
97
275 15512 NM_021177 57819 LSM2 -3.48863 0.03449 0.87 162 E08 21637 -0.9243 24713 -0.5944 15220 -1.3604 9558 -1.9056
277 2205 NM_021170 57801 HES4 -6.68468 0.0051 0.87 23 H09 13697 -1.3815 15390 -1.1318 9147 -2.0238 7683 -2.2313
280 3828 NM_001680 486 FXYD2 -4.7131 0.0147 0.87 40 G12 17445 -1.0947 20123 -0.749 9491 -1.9431 11245 -1.6328
281 5304 NM_001101 60 ACTB -11.6782 0.00087 0.86 56 B12 34060 -0.1936 29037 -0.2545 16495 -1.1697 17302 -1.0078
282 3825 NM_000150 2528 FUT6 -10.1676 0.00136 0.86 40 G09 35265 -0.0793 31428 -0.1058 20166 -0.8558 16755 -1.0575
283 20319 NM_144994 200539 ANKRD23 -4.01876 0.02329 0.86 212 F03 32101 -0.3243 28010 -0.3286 21170 -0.9174 12801 -1.4627
287 1269 NM_003775 8698 EDG6 -3.68767 0.02963 0.86 14 B09 26034 -0.3991 29774 -0.1278 13857 -1.388 19743 -0.8604
289 1678 NM_002831 5777 PTPN6 -7.53513 0.00351 0.86 18 D10 21382 -0.6952 23637 -0.5105 14767 -1.3555 12151 -1.568
290 5226 NM_015071 23092 ARHGAP26 -3.67456 0.02992 0.86 55 D06 35995 -0.075 32202 -0.1287 23268 -0.6634 14677 -1.2534
292 4144 NM_001034 6241 RRM2 -6.78081 0.00488 0.85 44 B04 8053 -2.2116 7999 -2.1269 5056 -2.8732 3991 -3.1752
293 2891 NM_005187 863 CBFA2T3 -5.7016 0.00832 0.85 31 A11 17990 -0.9899 21192 -0.6301 11171 -1.7195 11775 -1.6098
300 20595 NM_145115 221785 ZNF498 -4.61298 0.01566 0.85 215 E03 37987 -0.071 32674 0.11219 24766 -0.6143 16492 -1.0419
304 19233 NM_080827 140870 WFDC6 -5.20067 0.01098 0.85 201 C09 31153 -0.3745 27060 -0.4404 18428 -1.0517 12946 -1.4562
305 12174 NM_007242 11269 DDX19 -5.66003 0.0085 0.85 127 G06 28852 -0.5495 32414 -0.2195 16030 -1.3202 17187 -1.1416
306 18862 NM_144628 128637 C20ORF140 -3.27342 0.04091 0.84 197 D10 38282 -0.097 34360 -0.0656 25192 -0.5974 15318 -1.2528
307 1947 NM_001157 311 ANXA11 -6.21497 0.00639 0.84 21 C03 31212 -0.2316 30523 -0.1766 15486 -1.2145 19255 -0.8801
311 19139 NM_148178 138716 C9ORF23 -3.36384 0.03804 0.84 200 C11 36815 -0.128 33373 -0.0745 24708 -0.6242 15666 -1.2567
312 3320 NM_000538 5994 RFXAP -15.7958 0.00033 0.84 35 E08 31957 -0.2213 30697 -0.1803 19226 -0.9878 16963 -1.0914
314 1470 NM_020400 57121 GPR92 -9.77043 0.00154 0.83 16 C06 27581 -0.2598 26571 -0.2652 18531 -0.9934 15506 -1.1975
315 2650 NM_152860 121340 SP7 -5.3267 0.01022 0.83 28 E10 17546 -0.9352 22996 -0.5622 11425 -1.643 12492 -1.5194
317 3707 NM_001908 1508 CTSB -10.9675 0.00106 0.83 39 E11 37975 0.08446 34282 0.01351 21929 -0.7012 19443 -0.8645
321 17717 NM_033085 89885 FATE -4.69845 0.01484 0.83 185 E05 25533 -0.647 31010 -0.2503 14928 -1.3788 16073 -1.1761
322 5958 NM_002309 3976 LIF -5.15891 0.01125 0.83 63 A06 21525 -0.8942 22140 -0.7182 14154 -1.4529 9700 -1.817
326 2800 NM_003024 6453 ITSN1 -10.0395 0.00141 0.83 30 B04 32762 -0.1097 34913 0.0721 20865 -0.8086 19340 -0.882
328 3119 NM_001572 3665 IRF7 -4.04351 0.02289 0.82 33 D11 36165 0.00747 31880 -0.087 24441 -0.6091 16705 -1.1162
329 15526 NM_021196 57835 SLC4A5 -3.69803 0.0294 0.82 162 F10 33707 -0.2847 30578 -0.2871 22041 -0.8262 13653 -1.3911
330 3671 NM_001266 1066 CES1 -12.8052 0.00065 0.82 39 B11 28362 -0.3366 28016 -0.2777 15607 -1.1919 16975 -1.0604
331 20283 NM_182532 199964 LOC199964 -3.13965 0.04566 0.82 212 C03 37968 -0.0821 34349 -0.0343 27387 -0.546 15270 -1.2083
332 12129 NM_007177 11170 TU3A -18.0985 0.00021 0.82 127 C09 42163 -0.0022 37698 -0.0016 23343 -0.778 20838 -0.8637
333 20529 NM_194247 220988 HNRNPA3 -3.74812 0.02832 0.82 214 G09 33838 -0.2744 23706 -0.3331 21146 -0.845 13134 -1.3944
335 11532 NM_014792 9834 KIAA0125 -6.26202 0.00624 0.81 121 A12 34801 -0.2563 32994 -0.1617 21411 -0.8681 16783 -1.178
339 60 NM_016248 11215 AKAP11 -4.39041 0.01808 0.81 1 E12 14848 -1.3048 14136 -1.3441 10449 -1.9012 7006 -2.3653
347 21527 XM_370995 333929 SNAI3 -4.40112 0.01796 0.8 225 B11 34659 -0.2871 31109 -0.2851 20941 -0.8592 14876 -1.3209
354 1695 NM_003702 8601 RGS20 -3.26393 0.04123 0.8 18 F03 10663 -1.699 14797 -1.1862 9029 -2.0652 6733 -2.4198
356 5296 NM_003254 7076 TIMP1 -4.29297 0.01929 0.8 56 B04 35790 -0.1221 33614 -0.0433 23662 -0.6492 16088 -1.1128
359 2622 NM_003017 6428 SFRS3 -5.24009 0.01073 0.8 28 C06 12347 -1.4422 15813 -1.1024 8011 -2.1551 9068 -1.9815
363 2564 NM_002916 5984 RFC4 -16.8733 0.00026 0.79 27 F08 21614 -0.6203 22207 -0.5377 14081 -1.3512 13062 -1.3902
367 15676 NM_022091 63921 DJ467N11.1 -3.92313 0.02493 0.79 164 C04 34895 -0.2361 28322 -0.3935 21634 -0.8608 13624 -1.3447
368 18096 XM_057296 116064 LOC116064 -3.31009 0.03972 0.79 189 D12 15841 -1.2755 21928 -0.7558 12577 -1.6486 9497 -1.9584
98
369 14598 NM_197958 55323 FLJ11196 -3.39591 0.03709 0.79 153 A06 35505 -0.1168 33881 -0.0928 25888 -0.598 15055 -1.1869
370 4930 NM_004574 5414 PNUTL2 -3.13129 0.04598 0.79 52 C10 34045 -0.1213 32529 -0.1011 25166 -0.5789 14928 -1.2186
371 3736 NM_016216 51163 DBR1 -9.35615 0.00177 0.79 39 H04 30284 -0.242 26374 -0.3648 15844 -1.1701 17566 -1.011
373 2063 NM_003663 8545 CGGBP1 -4.01101 0.02342 0.79 22 D11 32042 -0.191 33476 -0.0565 16213 -1.1495 22477 -0.6714
375 1704 NM_000327 6094 ROM1 -5.59594 0.0088 0.79 18 F12 19673 -0.8154 24292 -0.471 13701 -1.4636 13709 -1.394
376 1935 NM_016453 51517 NCKIPSD -3.79816 0.0273 0.79 21 B03 29060 -0.3347 29217 -0.2397 14291 -1.3303 20147 -0.8147
379 3869 NM_012203 9380 GRHPR -3.07613 0.04815 0.78 41 C05 25053 -0.5914 28705 -0.2774 19606 -0.9343 12312 -1.5013
384 3844 NM_001482 2628 GATM -5.39212 0.00985 0.78 41 A04 25190 -0.5835 27659 -0.331 17378 -1.1083 13490 -1.3695
385 15507 NM_172231 57794 SF4 -3.35535 0.0383 0.78 162 E03 37532 -0.1297 34342 -0.1197 25607 -0.6099 15574 -1.2012
386 1240 NM_001841 1269 CNR2 -3.12298 0.04629 0.78 13 H04 16646 -1.0268 25602 -0.4041 11905 -1.5539 13088 -1.434
388 13036 NM_014356 26238 C6ORF123 -3.99032 0.02377 0.78 136 G04 37111 0.0868 34057 -0.0841 27166 -0.5445 17827 -1.0071
389 5019 NM_006325 5901 RAN -3.83962 0.02648 0.78 53 C03 7874 -2.2857 10020 -1.823 5663 -2.7208 4523 -2.9421
393 703 NM_017431 53632 PRKAG3 -4.31244 0.01904 0.77 8 C07 14111 -1.2484 14641 -1.0907 8453 -2.153 11678 -1.7294
394 5298 NM_000362 7078 TIMP3 -8.2275 0.00266 0.77 56 B06 36065 -0.1111 32774 -0.0798 22013 -0.7534 17661 -0.9782
402 2395 NM_004148 4814 NINJ1 -3.78743 0.02751 0.76 25 H07 19454 -0.7976 21933 -0.581 15889 -1.2196 10932 -1.6799
403 3647 NM_000709 593 BCKDHA -3.46016 0.03526 0.76 38 H11 18833 -0.9887 18916 -0.8211 13724 -1.3989 9288 -1.9306
415 896 NM_022445 27010 TPK1 -4.07589 0.02238 0.75 10 C08 21109 -0.7648 26806 -0.3563 16372 -1.199 13477 -1.4205
419 19359 XM_375359 146227 BEAN -10.0959 0.00139 0.75 202 F03 29652 -0.4769 29268 -0.3063 17486 -1.1248 16161 -1.1529
425 526 NM_006343 10461 MERTK -4.36439 0.0184 0.74 6 D10 35834 0.05315 33317 0.00272 25972 -0.503 18733 -0.9304
429 12004 NM_032102 10929 SRP46 -4.03741 0.02299 0.74 126 A04 40694 -0.0615 36649 -0.0343 26943 -0.5591 18334 -1.024
433 4461 NM_003320 7275 TUB -11.6822 0.00087 0.74 47 D09 31060 -0.1657 30222 -0.1865 20467 -0.8428 18214 -0.9828
434 3664 NM_012114 23581 CASP14 -6.71935 0.00502 0.74 39 B04 34814 -0.0409 34472 0.02149 19404 -0.8777 23113 -0.6151
436 17484 NM_032786 84872 FLJ14451 -4.68074 0.015 0.74 183 A12 24520 -0.6747 29779 -0.2803 16855 -1.2297 15725 -1.198
437 4528 NM_001889 1429 CRYZ -3.2387 0.04208 0.74 48 B04 32898 -0.1482 29551 -0.1802 23456 -0.6118 15642 -1.188
441 5370 NM_004244 9332 CD163 -8.72588 0.00221 0.73 56 H06 25639 -0.6033 26112 -0.4077 15463 -1.2629 14971 -1.2166
443 4470 NM_003323 7288 TULP2 -5.737 0.00816 0.73 47 E06 20425 -0.7704 25028 -0.4586 14126 -1.3778 14455 -1.3163
445 2865 NM_007348 22926 ATF6 -7.09682 0.00423 0.73 30 G09 31757 -0.1546 32980 -0.0101 19365 -0.9162 21793 -0.7097
446 16296 NM_024675 79728 FLJ21816 -3.29847 0.04009 0.73 170 F12 27565 -0.5068 30166 -0.2348 21295 -0.855 14222 -1.3467
454 16311 NM_024688 79741 C10ORF68 -7.90711 0.00302 0.72 170 H03 30857 -0.3441 32016 -0.149 18962 -1.0224 19143 -0.918
456 198 NM_004766 9276 COPB2 -5.90822 0.00746 0.72 3 A06 10083 -1.8246 9244 -1.8822 7367 -2.427 5588 -2.7251
458 8470 NM_006353 10473 HMGN4 -3.31176 0.03966 0.72 89 B10 27692 -0.5482 29447 -0.3085 20386 -0.901 14329 -1.3998
459 2863 NM_001675 468 ATF4 -5.74754 0.00812 0.72 30 G07 29145 -0.2784 30429 -0.1262 17521 -1.0606 20644 -0.7879
460 5322 NM_005552 3831 KNS2 -6.47795 0.00562 0.72 56 D06 33317 -0.2254 32311 -0.1004 21880 -0.7622 17316 -1.0067
464 4371 NM_004607 6902 TBCA -3.91418 0.02509 0.72 46 E03 22389 -0.7062 28032 -0.2546 15603 -1.2497 16102 -1.1461
466 19833 NM_182525 157376 FLJ32770 -4.90429 0.01307 0.72 207 E09 34659 -0.2053 29369 -0.2672 23022 -0.7728 16464 -1.1343
471 1973 NM_004742 9223 BAIAP1 -3.89046 0.02553 0.71 21 E05 33612 -0.1247 35091 0.02456 18178 -0.9832 24302 -0.5442
475 18935 NM_182501 130916 MGC61716 -3.36537 0.038 0.71 198 B11 37878 -0.1215 31332 -0.1624 25619 -0.5859 16416 -1.1205
476 3620 NM_017584 55586 ALDRL6 -4.37275 0.01829 0.71 38 F08 24427 -0.6135 27980 -0.2563 15277 -1.2443 17154 -1.0455
482 3607 NM_000693 220 ALDH1A3 -4.04741 0.02283 0.7 38 E07 27860 -0.4238 31571 -0.0821 20509 -0.8194 16571 -1.0954
99
485 9220 NM_001088 15 AANAT -3.1044 0.04702 0.7 97 A04 22826 -0.8281 26157 -0.5073 17970 -1.1322 11894 -1.61
486 669 NM_006875 11040 PIM2 -5.23323 0.01077 0.7 7 H09 20906 -0.7783 21926 -0.5755 15831 -1.2464 12999 -1.5136
488 4480 NM_006398 10537 UBD -3.51272 0.03385 0.7 47 F04 33869 -0.0408 33849 -0.023 18510 -0.9878 25785 -0.4813
489 16316 NM_021819 79748 LMAN1L -4.28829 0.01935 0.7 170 H08 33224 -0.2374 33451 -0.0857 24173 -0.6721 17401 -1.0557
491 2289 NM_031918 83855 KLF16 -3.32619 0.03921 0.7 24 G09 18377 -0.9692 22388 -0.5321 15624 -1.298 12078 -1.6065
500 1320 NM_004122 2693 GHSR -7.70726 0.00327 0.7 14 F12 30976 -0.1484 30016 -0.1161 18915 -0.939 21722 -0.7226
501 12128 NM_007086 11169 WDHD1 -3.52599 0.0335 0.7 127 C08 36194 -0.2224 35909 -0.0717 26293 -0.6063 17876 -1.0848
506 6056 NM_016224 51429 SNX9 -7.95444 0.00296 0.7 64 A08 32296 -0.3206 33538 -0.1154 20789 -0.8914 18373 -0.9378
508 175 NM_025197 80279 CDK5RAP3 -4.77257 0.01417 0.7 2 G07 21595 -0.7488 24253 -0.4847 17257 -1.1865 13377 -1.4396
510 19114 NM_205545 137797 UNQ430 -7.27382 0.00392 0.7 200 A10 30764 -0.3871 30674 -0.1961 20119 -0.9207 18046 -1.0527
512 18681 NM_178860 124925 SEZ6 -9.20612 0.00186 0.69 195 E09 33935 -0.2603 30979 -0.2285 21544 -0.8507 17878 -1.0243
521 19155 NM_144657 139324 FLJ30678 -4.36112 0.01844 0.69 200 E03 27251 -0.562 24548 -0.5175 18617 -1.0326 13907 -1.4286
522 21359 NM_198281 285513 LOC285513 -4.38577 0.01814 0.69 223 D11 35851 -0.2099 31332 -0.2367 23192 -0.7162 16991 -1.1113
525 195 NM_004073 1263 PLK3 -4.13325 0.02151 0.69 3 A03 16310 -1.1308 19301 -0.8201 13791 -1.5224 10580 -1.8042
531 3936 XM_290331 2679 GGT2 -5.13942 0.01137 0.69 41 H12 31555 -0.2585 31616 -0.1381 22602 -0.7291 16953 -1.0398
538 3536 NM_003752 8663 EIF3S8 -6.22717 0.00635 0.68 37 G08 10118 -1.9017 10802 -1.6496 7064 -2.4094 6239 -2.5037
539 19493 NM_138813 148229 ATP8B3 -7.83902 0.0031 0.68 204 A05 34699 -0.241 31087 -0.2077 21928 -0.8021 18240 -1.0079
544 520 NM_002376 4140 MARK3 -6.02923 0.00701 0.68 6 D04 30446 -0.1819 24184 -0.4595 18504 -0.9921 17757 -1.0076
552 18480 NM_080864 117579 RLN3 -4.49347 0.01691 0.67 193 D12 40207 0.00403 35747 -0.0242 26794 -0.4971 19362 -0.8731
553 1588 NM_000911 4985 OPRD1 -5.28454 0.01046 0.67 17 E04 38007 0.1627 35939 0.09242 28126 -0.3914 22386 -0.7009
554 1616 NM_012369 26211 OR2F1 -3.10354 0.04705 0.67 17 G08 14674 -1.2103 18581 -0.8593 13079 -1.4961 9612 -1.9206
560 2192 NM_002092 2926 GRSF1 -7.50644 0.00355 0.67 23 G08 27914 -0.3544 30499 -0.145 19997 -0.8954 18732 -0.9455
562 4397 NM_006288 7070 THY1 -4.39083 0.01808 0.67 46 G05 31901 -0.1954 32299 -0.0502 24213 -0.6158 18182 -0.9708
563 928 NM_003390 7465 WEE1 -4.53968 0.01641 0.67 10 F04 10784 -1.7338 13301 -1.3674 7926 -2.2456 7880 -2.1947
565 1235 NM_000740 1131 CHRM3 -4.5704 0.01609 0.67 13 G11 22266 -0.6072 28447 -0.252 16854 -1.0524 16002 -1.144
569 4506 NM_022553 6293 VPS52 -3.45046 0.03553 0.67 47 H06 25838 -0.4312 29428 -0.2249 21480 -0.7731 15488 -1.2167
572 15201 NM_018226 57140 RNPEPL1 -3.58421 0.03204 0.67 159 C09 40559 0.04058 36975 0.00064 28816 -0.4112 19179 -0.8793
575 4553 NM_004401 1676 DFFA -6.85824 0.00471 0.66 48 D05 37225 0.03008 35489 0.08398 25486 -0.4921 21617 -0.7213
576 13197 NM_014471 27290 SPINK4 -4.01356 0.02338 0.66 138 D09 27157 -0.485 29854 -0.3116 21352 -0.8723 15354 -1.2508
578 3672 NM_016280 51716 CES4 -6.82034 0.00479 0.66 39 B12 27356 -0.3887 27001 -0.3309 16204 -1.1377 18863 -0.9082
581 18491 NM_145202 118471 PRAP1 -7.2007 0.00405 0.66 193 E11 26084 -0.6202 26167 -0.4743 17328 -1.1259 14463 -1.2939
585 2591 NM_002968 6299 SALL1 -4.13876 0.02143 0.66 27 H11 12861 -1.3693 16484 -0.9676 10127 -1.8267 9619 -1.8316
594 2443 NM_018904 56136 PCDHA13 -3.35062 0.03845 0.66 26 D07 34808 0.07219 32925 -0.0305 28247 -0.393 19426 -0.8784
597 23944 XM_371843 0 LOC389425 -3.29288 0.04027 0.65 250 D04 19518 -1.1056 16298 -1.197 13119 -1.5561 8989 -2.0483
598 13896 NM_016310 51728 POLR3K -5.75421 0.00809 0.65 145 F12 31497 -0.2531 32027 -0.2034 23395 -0.7415 17392 -1.0161
602 12730 NM_012322 23658 LSM5 -3.89554 0.02543 0.65 133 E10 26365 -0.4672 25566 -0.4663 20694 -0.9047 14162 -1.3234
603 4520 NM_000754 1312 COMT -6.14853 0.0066 0.65 48 A08 29681 -0.2967 27891 -0.2636 17248 -1.0554 20480 -0.7992
607 898 NM_021643 28951 TRIB2 -3.09008 0.04759 0.65 10 C10 27339 -0.3917 32357 -0.0848 23658 -0.6679 16831 -1.0999
612 2313 NM_012090 23499 MACF1 -8.0764 0.00282 0.64 25 A09 32571 -0.0541 32413 -0.0176 21667 -0.7721 23319 -0.5869
100
616 4545 NM_014881 9937 DCLRE1A -12.5465 0.00069 0.64 48 C09 36881 0.01668 35229 0.07337 23003 -0.64 24316 -0.5515
617 3643 NM_007255 11285 B4GALT7 -6.55035 0.00543 0.64 38 H07 30059 -0.3142 30908 -0.1127 20929 -0.7901 18756 -0.9167
622 3708 NM_001814 1075 CTSC -4.2611 0.01971 0.64 39 E12 24415 -0.5528 27531 -0.3029 18772 -0.9255 15345 -1.206
623 5171 NM_006225 5333 PLCD1 -3.73767 0.02854 0.64 54 G11 40617 0.11862 34885 0.02004 29625 -0.3583 20117 -0.7765
625 2848 NM_014795 9839 ZFHX1B -17.9567 0.00022 0.64 30 F04 38271 0.11455 34854 0.06966 24965 -0.5498 24539 -0.5385
626 424 NM_025164 23387 KIAA0999 -4.34372 0.01865 0.63 5 D04 37167 0.02761 30541 -0.1275 26446 -0.5188 20194 -0.8507
627 1683 NM_000322 5961 RDS -5.22352 0.01083 0.63 18 E03 19210 -0.8497 22836 -0.5602 15373 -1.2975 13836 -1.3807
632 20502 NM_153451 220064 ORAOV1 -3.07634 0.04814 0.63 214 E06 37567 -0.1236 30735 0.04152 28257 -0.4268 18225 -0.9218
646 18499 NM_144587 118663 C10ORF87 -12.1647 0.00076 0.63 193 F07 37815 -0.0845 34279 -0.0847 23964 -0.6581 20874 -0.7646
650 2664 NM_006372 10492 SYNCRIP -3.66496 0.03014 0.62 28 F12 26649 -0.3322 28740 -0.2405 16421 -1.1197 22038 -0.7004
661 332 NM_024619 79672 FN3KRP -4.467 0.0172 0.62 4 D08 37087 0.03254 31408 -0.0861 27276 -0.4827 21417 -0.8081
662 3675 NM_016044 51011 CGI-105 -4.97994 0.01249 0.62 39 C03 34475 -0.055 33630 -0.0142 20414 -0.8045 25045 -0.4992
666 10649 NM_004175 6634 SNRPD3 -4.172 0.02094 0.62 111 H05 16830 -1.3044 14237 -1.3395 8022 -1.7538 8649 -2.1226
668 4484 NM_003969 9040 UBE2M -5.08703 0.01173 0.62 47 F08 33993 -0.0355 32536 -0.0801 20767 -0.8218 25017 -0.5249
669 1232 NM_001407 1951 CELSR3 -5.20058 0.01098 0.62 13 G08 22517 -0.591 27461 -0.3029 16431 -1.089 17253 -1.0354
674 20442 XM_291062 205717 KIAA2018 -3.75824 0.02811 0.61 213 H06 39894 -0.0429 31781 0.06137 28815 -0.4033 19811 -0.7985
675 3150 NM_002357 4084 MAD -5.45235 0.00952 0.61 33 G06 33440 -0.1056 27123 -0.3201 22381 -0.7361 19276 -0.9096
676 9222 NM_001606 20 ABCA2 -5.52225 0.00916 0.61 97 A06 34905 -0.2153 35160 -0.0806 25296 -0.6388 19802 -0.8746
677 2541 NM_002874 5887 RAD23B -5.67122 0.00845 0.61 27 D09 31020 -0.0991 30655 -0.0725 24312 -0.5633 19317 -0.8257
679 3190 XM_034274 4603 MYBL1 -7.78991 0.00316 0.61 34 B10 29577 -0.3964 29872 -0.2199 20653 -0.8898 19023 -0.9428
680 388 NM_000875 3480 IGF1R -5.28422 0.01046 0.61 5 A04 29448 -0.3082 30943 -0.1087 20060 -0.9175 22186 -0.715
683 19015 NM_153216 134187 FLJ25680 -3.79427 0.02738 0.61 199 A07 33305 -0.2963 31369 -0.1828 24137 -0.6534 17736 -1.0397
688 3774 NM_001406 1949 EFNB3 -4.4026 0.01794 0.6 40 C06 30367 -0.295 32334 -0.0648 19395 -0.9121 22111 -0.6573
689 3833 NM_000817 2571 GAD1 -3.0574 0.04891 0.6 40 H05 30775 -0.2757 29989 -0.1734 17345 -1.0733 23270 -0.5836
691 24096 XM_379508 0 LOC401386 -3.75126 0.02826 0.6 251 H12 33610 -0.3215 27724 -0.4208 22446 -0.777 16396 -1.1681
696 18502 NM_178832 118812 C10ORF83 -5.5072 0.00924 0.6 193 F10 35938 -0.1579 31900 -0.1885 20202 -0.9045 22775 -0.6389
697 16920 NM_031426 83543 C9ORF58 -7.93756 0.00298 0.6 177 B12 31494 -0.3022 33237 -0.1257 22013 -0.8147 20622 -0.8088
698 324 NM_152649 197259 FLJ34389 -6.34386 0.006 0.6 4 C12 36374 0.00453 32259 -0.0475 26808 -0.5077 22607 -0.7301
703 5189 NM_001092 29 ABR -3.84483 0.02638 0.59 55 A05 30178 -0.3293 29828 -0.2392 22844 -0.69 16688 -1.0682
704 2363 NM_005823 10232 MSLN -4.11376 0.0218 0.59 25 E11 20421 -0.7276 24738 -0.4074 17533 -1.0775 14759 -1.2468
706 2073 NM_015282 23332 CLASP1 -10.3408 0.00128 0.59 22 E09 32499 -0.1705 31971 -0.1228 22411 -0.6825 20594 -0.7976
708 5208 NM_014697 9722 CAPON -6.4831 0.00561 0.59 55 B12 33565 -0.1759 31076 -0.1801 23331 -0.6595 19012 -0.8801
711 9316 NM_001686 506 ATP5B -7.448 0.00364 0.59 98 A04 29193 -0.4913 27319 -0.4132 19908 -0.9581 16700 -1.1289
712 2819 NM_001756 866 SERPINA6 -7.42665 0.00367 0.59 30 C11 27428 -0.366 28786 -0.2063 19220 -0.9271 20089 -0.8272
716 3004 NM_005250 2300 FOXL1 -3.42275 0.03631 0.59 32 C04 30521 -0.1802 32701 0.0113 26362 -0.4791 19335 -0.8694
718 9036 NM_003169 6829 SUPT5H -3.32291 0.03931 0.59 95 A12 34381 -0.2182 33520 -0.0826 26798 -0.5264 18899 -0.9533
719 7048 NM_000268 4771 NF2 -4.38797 0.01811 0.59 74 D04 36550 -0.0965 34573 -0.0787 27098 -0.5095 19174 -0.8443
721 19954 NM_173527 161253 FLJ38964 -3.80219 0.02722 0.59 208 G10 31826 -0.3363 28386 -0.3134 23120 -0.7196 16775 -1.1085
730 4293 NM_014272 11173 ADAMTS7 -7.25094 0.00396 0.59 45 F09 27159 -0.4374 27919 -0.2636 20173 -0.8958 18101 -0.9769
101
734 2103 NM_004392 1602 DACH1 -5.31902 0.01026 0.58 22 H03 32168 -0.1853 33038 -0.0755 20133 -0.8371 23775 -0.5904
735 22336 NM_203453 403313 LOC403313 -7.57216 0.00346 0.58 233 F04 42119 -0.027 37222 0.01558 27287 -0.5007 23197 -0.677
745 3845 NM_000157 2629 GBA -4.94556 0.01275 0.58 41 A05 25019 -0.5934 27609 -0.3336 19014 -0.9785 16174 -1.1077
748 3690 NM_001871 1360 CPB1 -9.17883 0.00188 0.58 39 D06 34432 -0.0568 34807 0.03544 22854 -0.6416 24434 -0.5349
753 4548 NM_006773 8886 DDX18 -5.79332 0.00792 0.58 48 C12 31173 -0.2259 27692 -0.2739 18615 -0.9453 21827 -0.7073
758 4025 NM_012343 23530 NNT -3.11932 0.04644 0.57 42 H05 28494 -0.4316 27458 -0.3605 22715 -0.7405 15355 -1.2008
767 17898 NM_144581 112849 C14ORF149 -6.82264 0.00479 0.57 187 D06 33642 -0.2185 32427 -0.1731 24419 -0.6704 20202 -0.8654
768 4401 NM_012461 26277 TINF2 -3.47708 0.0348 0.57 46 G09 14958 -1.2881 15814 -1.0805 12438 -1.5768 9318 -1.9352
781 18892 NM_174898 129530 LOC129530 -3.08322 0.04786 0.57 197 G04 30690 -0.4159 28994 -0.3105 23384 -0.7048 16345 -1.1592
785 4591 NM_001990 2140 EYA3 -7.68257 0.0033 0.57 48 G07 33058 -0.1412 28191 -0.2482 22152 -0.6943 20054 -0.8295
793 3259 NM_002584 5081 PAX7 -6.62393 0.00525 0.57 34 H07 38594 -0.0125 34622 -0.007 27574 -0.4728 22870 -0.6771
794 514 NM_004635 7867 MAPKAPK3 -10.2288 0.00133 0.57 6 C10 32276 -0.0977 33272 0.00077 24605 -0.581 22811 -0.6463
796 22710 XM_117266 0 LOC200726 -3.26103 0.04132 0.56 237 E06 40978 -0.0633 36173 -0.0417 29969 -0.3989 20669 -0.8351
799 5327 NM_021223 58498 MYL7 -9.56319 0.00165 0.56 56 D11 34209 -0.1873 29116 -0.2506 22435 -0.726 19454 -0.8387
801 3748 NM_001360 1717 DHCR7 -3.70697 0.0292 0.56 40 A04 32047 -0.2173 33224 -0.0256 20268 -0.8486 24331 -0.5193
808 12291 NM_014972 22980 KIAA1049 -3.11422 0.04663 0.56 129 A03 34177 -0.1289 33183 -0.0886 28615 -0.4413 19346 -0.892
811 1254 NM_006564 10663 CXCR6 -3.78189 0.02763 0.56 14 A06 27954 -0.2965 30219 -0.1064 19200 -0.9175 23643 -0.6004
812 16080 NM_024104 79086 MGC2747 -14.3581 0.00045 0.56 168 D12 34915 -0.2034 31909 -0.1947 23378 -0.726 20032 -0.787
814 4450 NM_014555 29850 TRPM5 -6.01699 0.00706 0.56 47 C10 35744 0.03696 33137 -0.0537 23119 -0.667 26125 -0.4624
817 1390 NM_024980 80045 GPR157 -5.42135 0.00969 0.55 15 D10 31143 -0.1991 30502 -0.0847 24374 -0.5854 20418 -0.8082
819 19699 NM_153044 150291 FLJ35155 -3.65295 0.03041 0.55 205 B07 40310 -0.0202 34724 -0.0437 29338 -0.3963 20994 -0.7769
824 19386 XM_378712 146713 LOC146713 -7.1078 0.00421 0.55 202 H06 36794 -0.1655 33423 -0.1147 25066 -0.6053 20901 -0.7818
825 15383 NM_020817 57577 KIAA1407 -10.3294 0.00129 0.55 161 B11 39945 -0.0389 36162 -0.041 26536 -0.5366 22193 -0.6495
827 1942 NM_014391 27063 ANKRD1 -4.50623 0.01677 0.55 21 B10 27778 -0.3998 29231 -0.239 17954 -1.0011 21180 -0.7426
832 4113 NM_000309 5498 PPOX -3.82096 0.02685 0.55 43 G09 26204 -0.4644 28038 -0.3364 21977 -0.7824 16803 -1.1202
839 17759 NM_033199 90226 UCN2 -14.3224 0.00045 0.55 185 H11 37515 -0.0918 35054 -0.0735 25551 -0.6034 22985 -0.6601
841 4476 NM_018955 7314 UBB -4.47703 0.01709 0.55 47 E12 1844 -4.2398 2051 -4.0677 1294 -4.8262 1509 -4.5762
842 1672 NM_000958 5734 PTGER4 -4.38541 0.01814 0.55 18 D04 32204 -0.1043 33239 -0.0186 27475 -0.4598 21304 -0.758
849 3694 NM_000098 1376 CPT2 -3.15309 0.04515 0.55 39 D10 34863 -0.0389 30542 -0.1531 19756 -0.8518 26264 -0.4307
851 1171 NM_000025 155 ADRB3 -3.42782 0.03617 0.54 13 B07 27937 -0.2798 31895 -0.087 18690 -0.9032 24103 -0.553
854 12102 NM_007056 11129 SFRS16 -5.73054 0.00819 0.54 127 A06 37300 -0.179 35914 -0.0715 23468 -0.7702 25599 -0.5668
862 19902 NM_144967 158763 FLJ30058 -3.45277 0.03547 0.54 208 C06 36017 -0.1578 30152 -0.2263 26198 -0.5393 19015 -0.9276
864 2619 NM_005066 6421 SFPQ -3.61057 0.0314 0.54 28 C03 16402 -1.0324 21146 -0.6832 14202 -1.3291 12946 -1.4679
865 20537 XM_167709 221061 C10ORF38 -3.09558 0.04737 0.54 214 H05 34699 -0.2382 27155 -0.1371 26603 -0.5138 17960 -0.9429
866 23884 XM_371736 0 LOC389286 -4.33619 0.01874 0.54 249 G04 37954 -0.1295 33554 -0.1597 27933 -0.5308 20714 -0.8391
869 3377 NM_005643 6882 TAF11 -3.74412 0.02841 0.54 36 B05 39045 0.05472 36803 0.10789 30345 -0.2798 23207 -0.637
870 1954 NM_014278 22824 APG-1 -5.88225 0.00756 0.54 21 C10 32309 -0.1818 29621 -0.2199 23220 -0.6301 19690 -0.8478
872 1313 NM_031866 8325 FZD8 -3.89121 0.02551 0.54 14 F05 33646 -0.0291 33526 0.04345 22346 -0.6986 27906 -0.3612
875 19966 NM_130901 161725 C15ORF16 -10.6889 0.00115 0.54 208 H10 34920 -0.2024 32621 -0.1127 23945 -0.6691 21995 -0.7176
102
878 1977 NM_000633 596 BCL2 -6.46525 0.00566 0.53 21 E09 29095 -0.3329 27183 -0.3438 21008 -0.7745 18077 -0.9712
882 550 NM_001932 4356 MPP3 -7.37904 0.00375 0.53 6 F10 32804 -0.0743 33673 0.01805 26185 -0.4912 23045 -0.6315
883 13132 NM_014407 27094 KCNMB3 -3.06632 0.04855 0.53 137 G04 30973 -0.2982 33547 -0.1371 26935 -0.5467 18985 -0.9548
895 3899 NM_017902 55662 HIF1AN -3.23282 0.04228 0.53 41 E11 34795 -0.1175 32188 -0.1122 27666 -0.4375 19349 -0.8491
896 24527 XM_378219 0 LOC399737 -4.21095 0.02039 0.53 256 D11 36494 -0.1951 32239 -0.2014 26031 -0.5706 19896 -0.8826
898 2128 NM_001941 1825 DSC3 -5.81439 0.00784 0.53 23 B04 32709 -0.1257 30465 -0.1466 25317 -0.5551 21106 -0.7734
899 16099 NM_024123 79136 LY6G6E -3.07118 0.04835 0.53 168 F07 36868 -0.1249 34302 -0.0904 28912 -0.4195 19151 -0.8519
901 6128 NM_001138 181 AGRP -4.79501 0.01398 0.53 64 G08 34217 -0.2373 29663 -0.2925 24407 -0.6599 18532 -0.9253
902 1709 NM_002980 6344 SCTR -3.09207 0.04751 0.53 18 G05 28041 -0.304 32123 -0.0679 26114 -0.5331 19419 -0.8916
905 2428 NM_020418 57060 PCBP4 -5.02666 0.01215 0.53 26 C04 36300 0.13275 34027 0.017 29371 -0.3367 24127 -0.5657
910 5182 NM_004264 9412 SURB7 -8.25911 0.00263 0.52 54 H10 32743 -0.1923 28614 -0.2658 23498 -0.6926 19586 -0.8151
913 15846 NM_032461 64649 SPANXB1 -3.1712 0.04448 0.52 166 A06 32423 -0.3229 34420 -0.0937 26285 -0.5584 18811 -0.9056
933 15262 NM_020657 57343 ZNF304 -3.18325 0.04404 0.52 159 H10 26940 -0.5497 25753 -0.5212 21272 -0.8491 14751 -1.258
954 859 NM_015690 27148 STK36 -3.25937 0.04138 0.51 9 H07 24303 -0.6261 25611 -0.3563 20612 -0.859 16203 -1.1476
967 2873 NM_023005 9031 BAZ1B -5.5026 0.00926 0.51 30 H05 24180 -0.5479 26299 -0.3367 18425 -0.988 18914 -0.9141
969 7571 NM_006409 10552 ARPC1A -3.43642 0.03592 0.51 79 G11 25148 -0.6314 28450 -0.3217 20380 -0.8828 17794 -1.0874
971 5188 NM_000308 5476 PPGB -5.99708 0.00713 0.51 55 A04 39906 0.07377 35519 0.01273 28553 -0.3681 23713 -0.5613
972 899 NM_016388 50852 TRIM -3.05973 0.04882 0.51 10 C11 28695 -0.3219 33399 -0.0391 25957 -0.5341 20126 -0.842
976 7049 NM_005008 4809 NHP2L1 -4.20237 0.02051 0.51 74 D05 7248 -2.4307 8298 -2.1375 5687 -2.7619 4883 -2.8176
981 18500 NM_153336 118672 C10ORF89 -4.12548 0.02162 0.5 193 F08 32190 -0.3168 32418 -0.1653 20596 -0.8766 23174 -0.6138
982 2165 NM_001457 2317 FLNB -3.13642 0.04578 0.5 23 E05 33601 -0.0869 34616 0.03768 29472 -0.3358 21901 -0.72
983 15575 NM_021242 58526 MIG12 -5.38278 0.0099 0.5 163 B11 35686 -0.1928 32023 -0.2187 25508 -0.5965 20031 -0.8216
991 18561 NM_175054 121504 HIST4H4 -3.71849 0.02895 0.5 194 C09 34715 -0.2393 30416 -0.2191 26506 -0.5619 19463 -0.8973
998 552 NM_006039 9902 MRC2 -6.69003 0.00509 0.5 6 F12 26267 -0.3949 28507 -0.2222 20844 -0.8204 20576 -0.795
1011 2519 NM_004705 5612 PRKRIR -4.23884 0.02001 0.5 27 B11 25226 -0.3974 29181 -0.1436 22161 -0.6969 19164 -0.8372
1013 3414 NM_000458 6928 TCF2 -3.81022 0.02706 0.5 36 E06 33017 -0.1872 29886 -0.1925 25622 -0.5239 20043 -0.8485
1018 196 NM_006314 10256 CNKSR1 -10.0308 0.00142 0.49 3 A04 16281 -1.1333 15955 -1.0948 13411 -1.5627 11739 -1.6542
1023 13176 NM_014447 27236 ARFIP1 -3.24442 0.04189 0.49 138 B12 35847 -0.0844 35841 -0.0479 30266 -0.369 21750 -0.7484
1024 7320 NM_001316 1434 CSE1L -3.39844 0.03701 0.49 77 B12 23189 -0.791 25727 -0.4956 18393 -1.0302 16229 -1.2415
1025 510 NM_012324 23542 MAPK8IP2 -4.37284 0.01829 0.49 6 C06 25763 -0.4229 27619 -0.2679 22307 -0.7225 18440 -0.9531
1028 1583 NM_001708 611 OPN1SW -4.14987 0.02126 0.49 17 D11 13282 -1.3541 16024 -1.0729 11649 -1.6631 10839 -1.7473
1029 496 NM_002745 5594 MAPK1 -4.30413 0.01915 0.49 6 B04 31878 -0.1156 31425 -0.0816 22190 -0.7301 26134 -0.4501
1031 12167 NM_007230 11253 MAN1B1 -4.37073 0.01832 0.49 127 F11 39674 -0.09 35625 -0.0832 29523 -0.4391 23080 -0.7162
1032 435 NM_144624 127933 KIS -3.22854 0.04243 0.49 5 E03 34702 -0.0714 33543 0.00774 30040 -0.335 22307 -0.7072
1042 18364 NM_172347 93107 KCNG4 -3.70623 0.02922 0.49 192 C04 34328 -0.1894 36058 -0.0792 28333 -0.4669 21303 -0.7754
1046 3581 NM_138430 113622 ADPRHL1 -3.26584 0.04116 0.49 38 C05 34550 -0.1133 33927 0.02172 22186 -0.706 27630 -0.3578
1047 13211 NM_014487 27309 ZNF330 -4.63171 0.01547 0.49 138 E11 34631 -0.1342 32994 -0.1673 27463 -0.5092 21510 -0.7644
1053 17946 NM_052880 113791 MGC17330 -3.70252 0.0293 0.48 187 H06 28335 -0.4662 31237 -0.227 23597 -0.7198 19175 -0.9407
1057 24463 XM_373471 0 LOC387706 -3.61323 0.03134 0.48 255 G07 41269 -0.0178 33906 -0.1157 29287 -0.3901 22522 -0.709
103
1058 3802 NM_016594 51303 FKBP11 -5.69263 0.00836 0.48 40 E10 37286 0.00113 30894 -0.1305 23678 -0.6242 25175 -0.4701
1066 7080 NM_003380 7431 VIM -5.51175 0.00922 0.48 74 F12 32707 -0.2567 33993 -0.1031 23223 -0.7321 22877 -0.5896
1069 615 NM_018216 55229 PANK4 -6.76301 0.00492 0.48 7 D03 29756 -0.269 29275 -0.1585 24217 -0.6331 21995 -0.7549
1072 10183 NM_006234 5439 POLR2J -3.25355 0.04158 0.48 107 A07 31881 -0.371 26639 -0.4417 23324 -0.7043 17914 -1.0669
1076 2662 NM_003174 6840 SVIL -3.69992 0.02936 0.48 28 F10 25834 -0.377 31175 -0.1232 20102 -0.8279 23149 -0.6294
1079 17471 NM_032762 84848 MGC16121 -15.2321 0.00037 0.48 182 H11 36899 -0.0893 34344 -0.0801 27082 -0.5704 25353 -0.554
1080 17976 NM_052891 114771 PGLYRP3 -3.86769 0.02595 0.48 188 B12 36977 -0.0883 34151 -0.0798 29262 -0.408 22097 -0.7143
1096 6516 NM_002007 2249 FGF4 -3.36586 0.03798 0.47 68 G12 34990 -0.2342 33998 -0.107 27363 -0.4791 20245 -0.8062
1100 24141 XM_380098 0 LOC402475 -3.62967 0.03095 0.47 252 D09 38586 -0.1223 31334 -0.2444 27976 -0.5047 21189 -0.8041
1108 3699 NM_001888 1428 CRYM -3.757 0.02814 0.47 39 E03 31505 -0.185 30619 -0.1495 20611 -0.7907 25342 -0.4822
1110 1223 NM_006641 10803 CCR9 -5.44078 0.00958 0.47 13 F11 35856 0.08019 34588 0.02995 24486 -0.5135 28460 -0.3133
1115 3573 NM_000022 100 ADA -3.64874 0.03051 0.47 38 B09 33532 -0.1565 32299 -0.0492 27056 -0.4197 21502 -0.7195
1120 16036 NM_024051 79017 C7ORF24 -3.44404 0.03571 0.47 168 A04 28757 -0.4833 29418 -0.312 23509 -0.718 17174 -1.0091
1123 3822 NM_002569 5045 FURIN -9.8483 0.0015 0.46 40 G06 39536 0.08567 34559 0.03122 26832 -0.4438 26999 -0.3692
1126 2071 NM_001280 1153 CIRBP -14.8568 0.0004 0.46 22 E07 37479 0.03516 35896 0.04421 26657 -0.4322 26810 -0.4171
1129 19553 NM_182517 149466 MGC52423 -3.73151 0.02867 0.46 204 F05 39536 -0.0527 35335 -0.0229 30046 -0.3477 23294 -0.655
1130 24220 XM_379935 0 LOC402601 -13.6855 0.00052 0.46 253 C04 40551 -0.0329 35848 -0.0468 27427 -0.4858 25857 -0.521
1132 7884 NM_199336 151313 DKFZP434N062 -5.85489 0.00767 0.46 83 A12 36801 -0.1493 34696 -0.0649 24243 -0.6539 26864 -0.4868
1136 19120 NM_144651 137902 FLJ25471 -13.0045 0.00061 0.46 200 B04 41364 0.04005 36253 0.04496 27998 -0.4439 28429 -0.397
1138 4356 NM_001230 843 CASP10 -3.91287 0.02512 0.46 46 C12 26284 -0.4748 27772 -0.268 19375 -0.9374 21481 -0.7302
1139 5334 NM_000257 4625 MYH7 -3.87478 0.02582 0.46 56 E06 34307 -0.1832 32782 -0.0795 27069 -0.4551 20947 -0.732
1141 3738 NM_016286 51181 DCXR -3.70859 0.02917 0.46 39 H06 31396 -0.19 31801 -0.0949 21179 -0.7514 25790 -0.457
1147 5242 NM_007066 11142 PKIG -6.44555 0.00571 0.46 55 E10 31619 -0.262 32254 -0.1264 22660 -0.7016 22975 -0.6069
1149 13235 NM_031890 27439 CECR6 -3.34638 0.03858 0.46 138 G11 35730 -0.0892 33979 -0.1248 29705 -0.3959 21916 -0.7375
1153 24274 XM_379541 0 LOC401441 -6.46398 0.00566 0.46 253 G10 39894 -0.0565 34239 -0.113 27796 -0.4665 24128 -0.6208
1158 19257 NM_152427 142913 CFLP1 -4.18036 0.02082 0.46 201 E09 35620 -0.1811 33656 -0.1257 27402 -0.4793 21222 -0.7432
1159 3340 NM_003077 6603 SMARCD2 -4.05867 0.02265 0.46 35 G04 37209 -0.0017 32586 -0.0941 29413 -0.3744 23244 -0.6369
1160 4948 NM_000673 131 ADH7 -3.12194 0.04634 0.46 52 E04 25973 -0.5117 27104 -0.3643 22708 -0.7272 16620 -1.0637
1166 19396 XM_375404 146850 C17ORF38 -3.60649 0.0315 0.46 203 A04 34831 -0.2013 31216 -0.2027 27170 -0.5003 20171 -0.8144
1167 3574 NM_014237 8749 ADAM18 -4.55626 0.01624 0.46 38 B10 32320 -0.2096 28716 -0.2189 24760 -0.5476 20458 -0.7914
1178 2616 NM_006802 10946 SF3A3 -3.2817 0.04064 0.45 28 B12 13789 -1.2828 15353 -1.145 10062 -1.8263 12581 -1.5092
1185 2483 NM_004426 1911 PHC1 -3.19156 0.04374 0.45 26 G11 33626 0.02235 32799 -0.036 30448 -0.2847 22989 -0.6354
1188 572 NM_002498 4752 NEK3 -3.2631 0.04125 0.45 6 H08 23223 -0.5726 27987 -0.2488 21123 -0.8012 18797 -0.9255
1189 13759 NM_016257 51440 HPCAL4 -6.7014 0.00506 0.45 144 C07 34930 -0.1164 34203 -0.075 27845 -0.4739 23738 -0.6227
1200 1966 NM_021813 60468 BACH2 -6.54661 0.00544 0.45 21 D10 33806 -0.1164 30754 -0.1658 22637 -0.6667 24774 -0.5165
1204 19734 NM_178495 150771 MARLIN1 -3.41898 0.03642 0.45 205 E06 33332 -0.2945 31937 -0.1644 21721 -0.83 24935 -0.5287
1208 22376 NM_004698 9129 PRPF3 -4.17726 0.02087 0.45 234 A08 31200 -0.4563 32083 -0.2098 24079 -0.7344 20963 -0.8296
1209 2843 NM_004219 9232 PTTG1 -3.88229 0.02568 0.45 30 E11 28467 -0.3124 32112 -0.0485 22749 -0.6839 23938 -0.5743
1213 19271 NM_175733 143425 LOC143425 -6.95668 0.00451 0.45 201 F11 38475 -0.0699 33754 -0.1215 27467 -0.4759 23243 -0.6119
104
1214 1419 NM_001508 2863 GPR39 -3.61678 0.03125 0.45 15 G03 27735 -0.3663 30999 -0.0614 23459 -0.6406 22263 -0.6834
1215 18879 NM_152906 128989 DKFZP761P1121 -3.36343 0.03806 0.45 197 F03 36147 -0.1798 27423 -0.3909 25058 -0.6051 20084 -0.862
1216 519 NM_004954 2011 MARK2 -4.53994 0.01641 0.45 6 D03 32760 -0.0762 28375 -0.2289 22759 -0.6935 25112 -0.5076
1217 5355 NM_003357 7356 SCGB1A1 -4.34434 0.01864 0.45 56 G03 38887 -0.0024 32685 -0.0838 28690 -0.3712 22796 -0.61
1218 14096 NM_018364 54665 FLJ11220 -3.50047 0.03417 0.45 147 G08 38106 0.07616 35451 -0.0445 32642 -0.2842 23658 -0.5784
1226 294 NM_139021 225689 ERK8 -3.94159 0.02461 0.45 4 A06 36821 0.02216 34286 0.04043 31501 -0.275 25554 -0.5534
1227 23783 XM_374095 0 LOC389242 -6.30578 0.00611 0.44 248 F11 41071 -0.0437 35368 -0.0428 30717 -0.4066 24804 -0.5698
1246 19572 NM_053041 149951 COMMD7 -3.60201 0.03161 0.44 204 G12 36609 -0.1637 33062 -0.1188 28348 -0.4316 22084 -0.732
1248 23992 XM_374163 0 LOC389372 -8.01359 0.00289 0.44 250 H04 37000 -0.1829 32370 -0.207 23879 -0.692 24915 -0.5775
1250 15188 NM_020404 57124 CD164L1 -4.97916 0.0125 0.44 159 B08 33191 -0.2486 31816 -0.2162 25877 -0.5664 20605 -0.7758
1251 12191 NM_007272 11330 CTRC -3.09771 0.04728 0.44 127 H11 32692 -0.3693 31401 -0.2653 26656 -0.5865 19965 -0.9254
1257 3696 NM_021151 54677 CROT -3.12845 0.04608 0.44 39 D12 22485 -0.6716 21578 -0.6544 18766 -0.9259 14622 -1.2756
1259 2062 NM_005507 1072 CFL1 -4.18864 0.02071 0.44 22 D10 28933 -0.3382 32703 -0.0902 23407 -0.6197 22281 -0.684
1264 18492 NM_145806 118472 ZNF511 -3.56076 0.03262 0.44 193 E12 36137 -0.1499 33183 -0.1316 28155 -0.4256 21385 -0.7297
1265 502 NM_002746 5595 MAPK3 -3.60784 0.03147 0.44 6 B10 23868 -0.5331 28006 -0.2478 21429 -0.7804 19497 -0.8727
1276 2685 NM_022037 7072 TIA1 -6.99886 0.00442 0.43 28 H09 28138 -0.2538 29848 -0.1859 21772 -0.7127 23747 -0.5927
1278 8026 NM_004450 2079 ERH -3.73843 0.02853 0.43 84 E10 36818 -0.138 31658 -0.1928 27964 -0.4576 22745 -0.7385
1281 20695 NM_153248 253150 MGC14276 -3.57668 0.03222 0.43 216 E07 36511 -0.1754 32545 0.01099 28910 -0.3968 22654 -0.6313
1284 17339 NM_032112 84545 MRPL43 -3.10559 0.04697 0.43 181 E11 36923 -0.091 35427 -0.0318 30806 -0.3216 23201 -0.664
1285 10668 NM_006943 6666 SOX12 -3.14441 0.04548 0.43 112 A12 34313 -0.2283 29905 -0.2425 26946 -0.4954 20683 -0.8379
1286 536 NM_152619 166614 MGC45428 -4.23427 0.02007 0.43 6 E08 25695 -0.4267 26174 -0.3454 22668 -0.6993 18679 -0.9346
1287 570 NM_024800 79858 NEK11 -6.61803 0.00526 0.43 6 H06 21828 -0.662 23152 -0.5224 17819 -1.0466 17860 -0.9993
1292 2549 NM_007182 11186 RASSF1 -3.60986 0.03142 0.43 27 E05 34359 0.04839 33439 0.05287 30596 -0.2316 23769 -0.5265
1301 20170 NM_153183 170685 NUDT10 -5.76744 0.00803 0.43 211 A10 38801 -0.0722 36016 0.0231 28930 -0.38 24084 -0.5249
1309 15 NM_032630 51550 CINP -3.37553 0.03769 0.43 1 B03 40064 0.12728 36593 0.02807 33982 -0.1998 25557 -0.4982
1310 3111 NM_004516 3609 ILF3 -11.4873 0.00092 0.43 33 D03 24780 -0.538 23225 -0.544 19425 -0.9405 18175 -0.9945
1311 3264 NM_002636 5252 PHF1 -7.37042 0.00376 0.43 34 H12 23526 -0.7266 22153 -0.6512 18293 -1.0649 16297 -1.1659
1322 4455 NM_139073 130560 SPATA3 -5.57195 0.00892 0.42 47 D03 23558 -0.5645 26307 -0.3866 19577 -0.907 19404 -0.8915
1325 391 NM_054111 117283 IHPK3 -4.02265 0.02323 0.42 5 A07 30324 -0.2659 28389 -0.2329 25978 -0.5446 20910 -0.8005
1326 1338 NM_000172 2779 GNAT1 -11.1549 0.00101 0.42 14 H06 33363 -0.0413 31158 -0.0622 26588 -0.4478 25317 -0.5017
1328 1762 NM_003382 7434 VIPR2 -4.91311 0.013 0.42 19 C10 33628 -0.0218 31449 -0.0742 28595 -0.3708 24437 -0.5701
1330 7416 NM_000349 6770 STAR -6.0684 0.00687 0.42 78 B12 33560 -0.2208 32447 -0.1627 25907 -0.5393 23213 -0.6887
1331 23604 XM_379145 0 LOC401020 -7.05962 0.0043 0.42 246 G12 39055 -0.1182 33960 -0.1278 28089 -0.4791 24408 -0.6105
1332 1281 NM_004767 9283 GPR37L1 -3.21318 0.04297 0.42 14 C09 33600 -0.0311 35494 0.12574 25333 -0.5176 30550 -0.2306
1333 19414 XM_378680 147080 LOC147080 -4.08168 0.02229 0.42 203 B10 39104 -0.0344 35838 -0.0035 30898 -0.3148 23965 -0.5657
1336 13380 NM_013349 29937 SPUF -5.18851 0.01105 0.42 140 C12 34855 -0.0824 34963 -0.0779 29154 -0.4049 24304 -0.5977
1339 2343 NM_018848 8195 MKKS -3.16631 0.04466 0.42 25 D03 24608 -0.4586 29645 -0.1464 23299 -0.6673 20402 -0.7797
1340 5506 NM_013367 29945 ANAPC4 -4.52872 0.01652 0.42 58 C10 36081 -0.1182 36080 -0.0082 29377 -0.3857 24521 -0.5819
1341 7348 NM_004975 3745 KCNB1 -3.10449 0.04702 0.42 77 E04 38970 -0.0421 34362 -0.0781 30249 -0.3125 24471 -0.649
105
1344 3642 NM_001497 2683 B4GALT1 -6.45095 0.0057 0.42 38 H06 28367 -0.3978 27666 -0.2726 20864 -0.7946 21549 -0.7164
1347 23328 XM_372749 390975 LOC390975 -4.62237 0.01557 0.42 243 H12 38589 -0.1105 33056 -0.1529 28477 -0.4438 23372 -0.6588
1352 2361 NM_002441 4439 MSH5 -6.85853 0.00471 0.42 25 E09 28459 -0.2488 30200 -0.1196 24016 -0.6236 23392 -0.5824
1353 3682 NM_001303 1352 COX10 -3.43919 0.03584 0.42 39 C10 25188 -0.5079 25085 -0.4371 17364 -1.038 21133 -0.7443
1354 24163 XM_379986 0 LOC402633 -3.18488 0.04398 0.42 252 F07 41324 -0.0234 36616 -0.0196 32777 -0.2762 24346 -0.6038
1355 4467 NM_016437 27175 TUBG2 -3.32891 0.03912 0.42 47 E03 34447 -0.0164 32512 -0.0811 29529 -0.314 23431 -0.6194
1369 20491 NM_152716 219988 FLJ36874 -3.54664 0.03297 0.42 214 D07 37422 -0.1292 33364 0.15993 28991 -0.3898 25983 -0.4101
1373 15005 NM_019606 56257 FLJ20257 -3.35578 0.03829 0.41 157 C05 33356 -0.2399 32100 -0.1986 27650 -0.4819 20304 -0.7862
1374 2535 NM_021168 57799 RAB40C -5.87438 0.00759 0.41 27 D03 33939 0.03065 34989 0.11824 29768 -0.2712 25791 -0.4087
1382 24215 XM_374526 0 LOC392793 -3.83824 0.02651 0.41 253 B11 37311 -0.1531 30233 -0.2926 26721 -0.5234 22090 -0.7481
1385 22811 XM_293570 0 LOC344741 -8.19434 0.00269 0.41 238 E11 39552 -0.1031 34931 -0.0882 29668 -0.4572 25183 -0.5587
1389 7487 NM_012111 10598 AHSA1 -5.84693 0.0077 0.41 78 H11 36674 -0.0927 34443 -0.0766 28226 -0.4156 25072 -0.5776
1402 19291 NM_175058 144100 LOC144100 -4.63278 0.01546 0.41 201 H07 35325 -0.1931 34535 -0.0885 27811 -0.4579 22744 -0.6432
1409 1267 NM_004720 9170 EDG4 -4.63363 0.01546 0.41 14 B07 33419 -0.0389 34183 0.07145 25957 -0.4825 29085 -0.3015
1410 403 NM_001569 3654 IRAK1 -4.49091 0.01693 0.41 5 B07 31658 -0.2038 30797 -0.1155 27405 -0.4674 22915 -0.6684
1414 18802 NM_182752 127262 LOC127262 -11.9681 0.0008 0.41 196 G10 37223 -0.1329 33417 -0.0952 26771 -0.5265 25448 -0.5169
1419 12430 NM_015141 23171 KIAA0089 -3.46108 0.03524 0.41 130 D10 39135 0.04451 35829 -0.0178 32893 -0.2512 24707 -0.5353
1420 24175 XM_379848 0 LOC402521 -3.15374 0.04513 0.41 252 G07 32974 -0.3491 32896 -0.1742 27425 -0.5334 21216 -0.8023
1428 4433 NM_033285 94241 TP53INP1 -7.23479 0.00399 0.4 47 B05 32253 -0.1113 32998 -0.0597 27136 -0.4359 24680 -0.5445
1429 2615 NM_005877 10291 SF3A1 -6.82142 0.00479 0.4 28 B11 12822 -1.3877 14187 -1.259 10692 -1.7387 10890 -1.7174
1431 2528 NM_002859 5829 PXN -9.78421 0.00153 0.4 27 C08 34542 0.05605 32921 0.03034 28621 -0.3279 26044 -0.3947
1434 2061 NM_004365 1070 CETN3 -6.19827 0.00644 0.4 22 D09 35294 -0.0515 33208 -0.0681 27436 -0.3906 24663 -0.5375
1436 4601 NM_015002 23014 FBXO21 -4.76813 0.01421 0.4 48 H05 34919 -0.0622 32327 -0.0507 27943 -0.3593 24146 -0.5617
1440 12897 XM_032397 25974 DKFZP564I122 -3.21853 0.04278 0.4 135 C09 33209 -0.1454 33749 -0.0659 30415 -0.358 22688 -0.6587
1441 2638 NM_005496 10051 SMC4L1 -3.20319 0.04332 0.4 28 D10 30277 -0.1481 30339 -0.1624 27014 -0.4015 21840 -0.7134
1444 2419 NM_019619 56288 PARD3 -4.55636 0.01623 0.4 26 B07 29931 -0.1456 29423 -0.1927 26823 -0.4676 22376 -0.6744
1445 2291 NM_000425 3897 L1CAM -7.16568 0.00411 0.4 24 G11 34157 -0.0749 32556 0.00815 29288 -0.3914 26390 -0.4789
1448 7235 NM_003060 6584 SLC22A5 -3.11029 0.04679 0.4 76 C11 36012 -0.1356 31251 -0.215 28029 -0.4207 22836 -0.732
1455 5176 NM_080744 136853 SRCRB4D -4.1457 0.02132 0.4 54 H04 35039 -0.0945 33051 -0.0579 29579 -0.3606 22852 -0.5926
1456 5347 NM_006654 10818 FRS2 -4.74933 0.01438 0.4 56 F07 31778 -0.2936 32494 -0.0922 24581 -0.5942 23079 -0.5922
1457 3126 NM_002229 3726 JUNB -3.13984 0.04565 0.4 33 E06 39282 0.12674 33621 -0.0103 32479 -0.1989 25873 -0.485
1466 7188 XM_029962 57582 KCNT1 -5.34913 0.01009 0.4 75 G12 31187 -0.3412 29270 -0.3006 24592 -0.6349 20079 -0.8046
1471 24272 XM_378044 0 LOC402354 -3.14131 0.04559 0.4 253 G08 34581 -0.2627 29748 -0.3159 26562 -0.532 20686 -0.8429
1475 2523 NM_004697 9128 PRPF4 -4.98585 0.01245 0.4 27 C03 26307 -0.3369 29079 -0.1487 23173 -0.6325 21852 -0.6478
1482 24372 XM_378064 0 LOC402367 -3.82688 0.02673 0.4 254 G12 39861 -0.0732 29623 -0.3267 26294 -0.589 24035 -0.6043
1483 1423 NM_005305 2866 GPR42 -4.84949 0.01352 0.4 15 G07 31316 -0.1911 31491 -0.0387 26754 -0.451 24055 -0.5718
1491 2817 NM_000541 6295 SAG -4.44844 0.01741 0.39 30 C09 29205 -0.2755 31631 -0.0703 24170 -0.5965 24549 -0.5379
1493 2399 NM_002516 4858 NOVA2 -4.6249 0.01554 0.39 25 H11 34795 0.04118 32523 -0.0127 30443 -0.2815 25143 -0.4783
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19877 16506 NM_024922 79984 FLJ21736 3.1258 0.04619 -0.1 172 H06 38138 -0.0543 34928 -0.0683 39809 0.03726 37813 0.03391
19888 3063 NM_000522 3209 HOXA13 3.16973 0.04453 -0.1 32 H03 33948 -0.0267 31503 -0.0425 38469 0.06614 36877 0.06209
19912 15175 NM_020367 57097 PARP11 3.13981 0.04565 -0.1 159 A07 37343 -0.0786 34626 -0.0941 38395 0.00284 36133 0.0345
19921 16320 NM_024701 79754 ASB13 3.25259 0.04161 -0.11 170 H12 35076 -0.1592 31085 -0.1916 36663 -0.0712 34599 -0.0641
19943 82 NM_020639 54101 ANKRD3 3.10322 0.04707 -0.11 1 G10 31406 -0.224 30949 -0.2136 36875 -0.0819 32967 -0.1309
19964 14988 NM_018897 56171 DNAH7 3.54834 0.03293 -0.12 157 A12 35639 -0.1444 33579 -0.1336 37642 -0.0369 35029 0.00059
19966 473 XM_042066 4214 MAP3K1 3.44267 0.03575 -0.12 5 H05 28835 -0.3386 26772 -0.3175 33341 -0.1846 31125 -0.2266
20001 1164 NM_000681 150 ADRA2A 3.58347 0.03206 -0.14 13 A12 31591 -0.1025 31826 -0.0901 36997 0.08195 35734 0.01507
20006 3659 NM_130767 134526 CACH-1 3.91047 0.02516 -0.15 39 A11 29888 -0.261 29408 -0.2077 33337 -0.0969 33569 -0.0766
20009 9312 NM_000705 496 ATP4B 3.15498 0.04508 -0.15 97 H12 35298 -0.1992 31429 -0.2424 38550 -0.031 33580 -0.1127
20010 15192 NM_020408 57128 C6ORF149 4.10137 0.02199 -0.15 159 B12 33503 -0.2352 32526 -0.1843 36647 -0.0644 33951 -0.0554
20011 3138 NM_006562 10660 LBX1 3.62652 0.03102 -0.15 33 F06 29831 -0.2703 28190 -0.2645 35224 -0.0818 32564 -0.1532
20016 16222 NM_024589 79641 FLJ22386 3.41518 0.03653 -0.15 169 H10 22293 -0.8347 14835 -0.9169 23221 -0.7281 22161 -0.7205
20026 15264 NM_020155 56834 C11ORF4 3.38126 0.03752 -0.15 159 H12 36410 -0.1151 32344 -0.1924 38854 0.01999 34807 -0.0194
20031 15180 NM_020378 57106 KLP1 3.17601 0.0443 -0.16 159 A12 33085 -0.2533 33134 -0.1576 37383 -0.0357 33792 -0.0621
20035 4236 NM_003358 7357 UGCG 3.59249 0.03184 -0.16 45 A12 31622 -0.2179 30080 -0.156 36131 -0.0549 35623 -0.0001
20045 15948 NM_032478 64978 MRPL38 4.04009 0.02295 -0.17 167 A12 33664 -0.2731 32408 -0.2003 36854 -0.0747 33342 -0.058
20052 9408 NM_001803 1043 CDW52 3.32333 0.0393 -0.18 98 H12 29461 -0.4781 24569 -0.5662 31351 -0.3029 28093 -0.3786
20061 4679 NM_002426 4321 MMP12 3.7641 0.02799 -0.19 49 F11 26820 -0.418 26072 -0.444 33038 -0.1851 28520 -0.2886
20064 90 NM_031916 83853 ASP 4.47302 0.01713 -0.2 1 H06 33368 -0.1366 31100 -0.2066 39170 0.00517 37380 0.05032
20065 2016 NM_001773 947 CD34 4.17455 0.02091 -0.2 21 H12 33188 -0.143 29496 -0.226 36946 0.03999 35261 -0.0072
20068 17561 NM_032648 84734 MGC10820 4.88665 0.01321 -0.21 183 H05 30997 -0.3365 29711 -0.2836 37512 -0.0755 32974 -0.1297
20070 14506 NM_018188 55210 ATAD3A 3.21911 0.04276 -0.21 152 A10 28627 -0.384 30097 -0.2818 37383 -0.0689 31223 -0.1762
20072 1944 NM_007193 11199 ANXA10 5.23897 0.01074 -0.21 21 B12 30574 -0.2614 27643 -0.3196 34533 -0.0574 33164 -0.0957
20073 91 NM_138293 472 ATM 5.7533 0.00809 -0.22 1 H07 29157 -0.3312 29550 -0.2803 36372 -0.1018 34166 -0.0794
20077 10571 NM_006278 6484 SIAT4C 3.70046 0.02935 -0.23 111 A11 29763 -0.4819 25653 -0.49 23665 -0.193 30004 -0.328
20081 13920 NM_138284 53342 IL17D 7.11055 0.00421 -0.24 145 H12 31194 -0.2671 29787 -0.308 38004 -0.0416 34119 -0.044
20085 183 NM_003948 8999 CDKL2 4.69091 0.01491 -0.25 2 H03 29061 -0.3204 27601 -0.2981 36323 -0.1128 36242 -0.0017
20087 95 NM_000706 552 AVPR1A 4.14803 0.02129 -0.25 1 H11 29279 -0.3252 31442 -0.1908 39246 0.00797 35718 -0.0153
20088 192 NM_005192 1033 CDKN3 3.3023 0.03997 -0.26 2 H12 26424 -0.4576 27497 -0.3035 37251 -0.0764 32166 -0.1738
20089 3477 NM_003403 7528 YY1 4.28212 0.01943 -0.26 37 B09 29433 -0.3612 28964 -0.2267 36497 -0.0402 34765 -0.0254
20093 17656 NM_033401 85445 CNTNAP4 3.11073 0.04677 -0.28 184 H04 26989 -0.5326 28506 -0.3291 36458 -0.1233 32170 -0.1872
20095 2235 NM_004134 3313 HSPA9B 3.03709 0.04976 -0.28 24 C03 17897 -1.0074 18706 -0.7913 25407 -0.5965 23513 -0.6454
20101 2884 NM_001208 690 BTF3L1 5.91575 0.00743 -0.3 31 A04 24139 -0.5658 21256 -0.6258 30987 -0.2476 28485 -0.3353
20102 4620 NM_002053 2633 GBP1 3.17475 0.04435 -0.31 49 A12 22097 -0.6975 25823 -0.4578 31233 -0.2662 28995 -0.2647
20110 1347 NM_018841 55970 GNG12 5.32998 0.0102 -0.39 15 A03 24437 -0.5489 24845 -0.3806 34467 -0.0855 34069 -0.0696
20112 96 NM_000707 553 AVPR1B 9.59179 0.00163 -0.41 1 H12 22186 -0.7254 22712 -0.66 32624 -0.2586 29300 -0.301
20115 4126 NM_002798 5694 PSMB6 3.19936 0.04346 -0.53 43 H10 14342 -1.334 16221 -1.126 26387 -0.5186 19837 -0.8808
B. Synthetic rescue genes
107
